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Our Mission
To protect and enhance public and animal health 
through the regulation of medicines, medical devices 
and healthcare products.
Our strategIc gOaLs and BaLanced scOrecard
STAKEHOLDERS 
Enhance healthcare product safety and patient outcomes by effective risk management 
and market surveillance.
Deliver clear, relevant and timely communications to patients, consumers and 
healthcare professionals.
PROCESSES 
Improve service delivery within a high quality, risk-based regulatory framework.
ORGANISATIONAL DEVELOPMENT 
Improve service delivery within a high quality, risk-based regulatory framework.
Influence legislation and policy development at European and international levels for 
the benefit of public and animal health.
HUMAN RESOURCES DEVELOPMENT 
Build future capabilities to meet evolving regulatory requirements, and scientific and 
technological advances.
FINANCIALS/VALUE FOR MONEY 
Build future capabilities to meet evolving regulatory requirements, and scientific and 
technological advances.
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CHAIRMAN’S 
STATEMENT
The Irish Medicines Board (IMB) delivered on an 
extensive and challenging programme of work 
in 2013 and it is my pleasure, as Chairman, to 
present its annual report. 
The IMB remains on target with the implementation 
of the five year strategic plan for 2011-2015 which 
sets out five high level strategic objectives and a 
clear roadmap to achieve these goals within the 
timeframe. This report outlines in detail the high level 
of activity and achievement by the IMB during year 
three of the plan as it remained focused on its core 
remit to protect human and animal health.
In 2013, the Board approved a new brand identity 
to accompany a name change for the IMB. Our new 
name, effective from mid-2014, is more reflective of 
the organisation’s expanded and broader role since 
first established in 1996. Over the last 17 years, the 
IMB’s regulatory remit has grown incrementally to 
include other health products as well as a number 
of health related functions. In addition to human 
and veterinary medicines, and clinical trials for 
human medicines, we now have a role in regulating 
a range of areas including medical devices, blood 
and blood components, tissues and cells, human 
organs intended for transplantation as well as 
cosmetic products. Our new name, the Health 
Products Regulatory Authority (HPRA), more clearly 
reflects the wider scope of our work, functions and 
responsibilities across the health products sector. 
Health products can be life-saving and can improve 
the health and the quality of our lives. The IMB plays 
a unique and important role in national healthcare 
policy to safeguard human and animal health in 
relation to these products. Our fundamental aim, as 
always, is based on the need to make sure that health 
products used in Ireland or exported abroad, are as 
safe as possible and do what they are intended to do.
Our responsibility to regulate and monitor medicines, 
medical devices and healthcare products demands 
excellence across all areas of our operations with a 
clear focus by our staff to ensure the needs and best 
interests of our citizens and our animal population 
are at the forefront of our deliberations, actions and 
processes. At all times, the IMB’s actions and decisions 
are influenced by the latest and best available clinical 
and scientific data at national and EU level. As a 
state agency in the current economic environment, 
we must, and indeed do, continually re-evaluate 
our processes and structures to ensure they deliver 
best efficiencies. At the same time we must have 
the flexibility to meet future requirements from a 
changing regulatory landscape across an industry 
where innovation and progression is a key driver. 
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The information presented throughout this report 
outlines the depth and breadth of our work 
programme across all departments and product 
areas. This impressive level of activity was achieved in 
a year in which the IMB also successfully hosted and 
managed some 22 high level EU meetings as part of 
Ireland’s Presidency of the Council of the European 
Union. In addition, during 2013 the IMB commenced 
its new role for the establishment, maintenance 
and publication of a list for interchangeable 
medicines which supports increased levels of generic 
substitution. The first list was published in August 
2013. A significant level of stakeholder engagement 
and communications was undertaken to support 
this national health policy initiative and we worked 
closely with our colleagues in the Department 
of Health and the HSE in its effective initial 
implementation and ongoing work programme. 
Also during 2013, a key focus for the organisation 
was to highlight our concerns about the risk to public 
health from the purchasing of prescription medicines 
via the internet. Medicines sourced online are of 
dubious origin, may be falsified and could pose a 
health risk to those who use them. The increase in 
illegal medicines detentions as well as our successful 
court prosecutions in this area, and the subsequent 
publicity relating to these, continue to highlight 
this crucial message to the general public and other 
stakeholders. This will continue to be a constant area 
of vigilance for the IMB and, in time, the HPRA. 
All our regulatory actions are grounded in legislative 
requirements and the application of scientific and 
regulatory expertise. The IMB and our partners at a 
European level review adverse reaction and clinical 
data on an ongoing basis to ensure that people 
continue to have access to products where the 
benefit of using that product outweighs the inherent 
risk. During the past 12 months there was, as in 
previous years, an intense focus and time investment 
on monitoring the safety of these products in use 
on the Irish market which is outlined further in this 
report. It is important to note the active role the IMB 
plays at EU level where new legislation is developed. 
Our experts continue to be active contributors in 
this area with an objective of ensuring that a strong 
patient centric regulatory system for human and 
veterinary products is maintained and enhanced.
The pharmaceutical, medical device and life 
sciences sector in Ireland is export driven and 
a major contributor to our economy. The IMB’s 
robust regulatory role contributes to the continued 
success of this sector by ensuring compliance with 
good manufacturing practices and adherence to 
legal requirements. A strong national regulator is a 
significant asset to Ireland’s reputation as a major 
world player in this specialist sector. 
The IMB has earned an enviable reputation 
internationally as a highly effective and strong 
regulatory agency. Its standing is a reflection of the 
quality of its organisational structure and policies. It 
is also due to the excellence of the work carried out 
by everyone at the IMB and I wish to thank the Chief 
Executive, management and all the staff for their 
continued professionalism throughout 2013.
I would like to thank my fellow Board members 
for their continued support and valuable expert 
guidance during the past year. I would also like to 
express my appreciation to those members who chair 
IMB advisory committees and sub-committees. The 
contribution of these committees is of immense value 
to the IMB and I wish to thank all members for their 
active participation and commitment.
On behalf of the Board, I thank the Minister for 
Health and the Minister for Agriculture, Food and the 
Marine as well as their executives and staff for their 
continued support of the IMB and its activities.
Michael D. Hayes
Chairman
BOARD MEMBERS
The Board of the IMB is appointed by the Minister for 
Health in accordance with the powers conferred by 
subsection 2 of section 7 of the Irish Medicines Board 
Act, 1995. There were nine Board members up to 31 
December 2013.
* Term ended 31 December 2013
Mr. Michael D. Hayes 
(Chairman)
Engineering Consultant
Professor Caitriona O’Driscoll
Professor of Pharmaceutics, 
University College Cork
Mr. Noel O’Donoghue
Veterinary Surgeon
Mr. Brendan McLaughlin*
Farmer and Elected Board 
Director in the Management 
Committee of ICSA
Ms. Anne Horan
Chief Executive, Ryan Academy 
for Entrepreneurship, Dublin  
City University
Mr. Wilfred Higgins*
Former Principal Engineering 
Advisor, Health Service Executive
Professor Mary Horgan 
Associate Professor of Medicine, 
University College Cork
Dr. Elizabeth Keane* 
Adjunct Professor of 
Epidemiology and Public Health, 
University College Cork
Mr. Pat Brangan*
Former Senior Veterinary 
Inspector, Department of 
Agriculture, Food and the Marine
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Mr. Pat O’Mahony
Chief  Executive
Mr. John Lynch 
Director of  Compliance
Dr. Gabriel Beechinor
Director of  Veterinary Sciences
Dr. J.M. Morris 
Director of  Scientific Affairs
Ms. Suzanne McDonald 
Director of Information 
Technology and Change 
Management
Dr. Lorraine Nolan 
Director of Human Products 
Authorisation and Registration 
Ms. Rita Purcell
Director of Finance  
and Corporate Affairs 
Dr. Joan Gilvarry 
Director of Human Products  
Monitoring
Ms. Frances Lynch
Director of  Human Resources
MANAGEMENT COMMITTEE
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CHIEF 
EXECUTIVE’S 
REPORT
I am pleased to introduce the 2013 annual 
report of the Irish Medicines Board (IMB). This 
is a significant report as it is the last full-year 
review that will be submitted in the name of the 
IMB. From July next year, our organisation will 
become known as the Health Products Regulatory 
Authority (HPRA).
Established in 1996, the IMB name has served us 
well. However, over the last 18 years our regulatory 
remit has expanded to include other health products 
as well as a number of health related functions. Our 
new name will better reflect the wider scope of our 
work, functions and responsibilities across the health 
product sector, something that is evident from the 
significant level of activity outlined in this report.
STRATegIC PlAn 2011 – 2015  
The layout of the annual report for 2013 is structured 
to ensure that the main chapters are closely aligned 
with the IMB’s five high-level strategic goals.
These goals are to:
1. Enhance healthcare product safety and patient 
outcomes by effective risk management and 
market surveillance.
2. Deliver clear, relevant and timely 
communications to patients, consumers and 
healthcare professionals.
3. Improve service delivery within a high quality, 
risk-based regulatory framework.
4. Influence legislation and policy development at 
European and international levels for the benefit 
of public and animal health.
5. Build future capabilities to meet evolving 
regulatory requirements, and scientific and 
technological advances.
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AuTHoRISATIon, RegISTRATIon And 
lICenSIng ACTIvITIeS   
Our pre market activities are a core regulatory 
function of the IMB. We are committed to providing 
an efficient authorisation system to help ensure 
patients have timely access to appropriate 
treatments. The activities of note during 2013 
included the following:
•	 There	were	102	clinical	trials	for	human	
medicines approved to commence in Ireland 
representing a significant annual increase of over 
30%. While the IMB received 10 applications for 
clinical investigations of a medical device, the 
number of clinical investigations ongoing in 
Ireland remains lower than expected.
•	 In	respect	of	human	medicines,	the	IMB	assessed	
198 new national applications (including parallel 
product authorisations), 51 applications via 
mutual recognition procedures (MRP) and 280 via 
decentralised procedures (DCP). 
•	 As	part	of	our	active	contribution	to	the	
European human medicines licensing system 
during 2013, we acted as reference (lead) 
Member State for the assessment of 12 of the 
MRP and DCP procedures. The IMB was also 
allocated as rapporteur or co-rapporteur for 15 
new marketing authorisation applications by the 
European Medicines Agency (EMA). Based on 
2013 allocations, the IMB is ranked as fifth in the 
EU for rapporteurships for centrally authorised 
human products. We acted as lead in 38 scientific 
advice procedures for medicines proposed for 
the treatment of a broad range of conditions.
•	 We	assessed	and	approved	a	total	188	
applications for new veterinary medicines, 
representing an increase of 24% compared with 
2012. In Europe, we issued 50 new marketing 
authorisations as the reference Member State 
while the IMB acted as the rapporteur or 
co-rapporteur for 7 centralised procedures 
(including extension applications to new target 
species).
•	 Over	the	course	of	2013,	the	IMB	issued	17,749	
variations to marketing authorisations for human 
products authorised through the national or 
MR procedures. Of note, at a European level, we 
acted as rapporteur for two paediatric Article 45 
procedures, one paediatric Article 46 procedure 
and 13 procedures relating to Paediatric 
Investigational Plans (PIPs). The IMB approved 
1,364 variations to veterinary authorisations 
granted through the national, MR or centralised 
procedures.
•	 A	total	of	334	notifications	of	medical	devices	
to the medical device register were received. In 
addition, 26 organisations registered with the 
IMB as Irish based manufacturers of medical 
devices.
•	 There	were	a	total	of	113	manufacturers’	licences	
in place at year end for human and veterinary 
medicines.
•	 There	were	four	blood	establishments	and	23	
tissue establishments authorised at year end.
SAFeTy And CoMPlIAnCe MonIToRIng 
Monitoring the safety of medicines, medical 
devices and other healthcare products that have 
been licensed or registered for use in Ireland is 
a core public health function of the IMB. We also 
monitor quality issues relating to how a product is 
manufactured, packaged, labelled, distributed or 
stored. Our regulatory decisions are always based on 
the best available information regarding benefit  
and risk. 
•	 A	key	part	of	our	monitoring	efforts	is	the	
operation of a national pharmacovigilance 
scheme for adverse reactions, or side effects, 
associated with the use of human medicines. 
During the year under review, the IMB received a 
total of 2,835 valid new adverse reaction reports. 
This figure is consistent with the reporting rates 
seen in 2011 and 2012.
•	 The	IMB	continued	to	contribute	to	work-sharing	
for signal detection within the EU during 2013. 
We acted as the human medicine lead for the 
detection and management of signals for 58 
active substances. We also retained responsibility 
for assessing any signals arising as a result of 
signal detection for 21 centrally authorised active 
substances (or combination of active substances) 
incorporating 34 authorised products for which 
IMB is rapporteur.  In addition, the IMB acted 
as concerned Member State in 15 EU safety-
related referrals and provided the lead on the 
assessment of two significant safety referral 
procedures at the EMA.
•	 Periodic	safety	update	reports	(PSURs)	are	
vigilance reports submitted by marketing 
authorisation holders which are intended to 
provide an evaluation of the benefit-risk balance 
of a medicine. For human medicines, the IMB 
evaluated PSURs relating to 2,500 medicinal 
products, a figure which includes PSURs 
submitted as national, mutual recognition, 
centralised, EU single-assessment and PSUR 
work-sharing procedures.
•	 The	IMB	received	272	national	reports	of	
suspected adverse events to veterinary 
medicines in 2013 which compares with the 244 
reports received the previous year. We completed 
the evaluation of 1,072 PSURs for veterinary 
medicines representing year-on-year increase of 
approximately 25%.
•	 Post-market	surveillance	and	vigilance	is	
important in ensuring the safety of those who 
use medical devices. A total of 2,268 medical 
device vigilance reports were received and 
assessed. A slight increase on 2012, this figure 
continues the upward trend in the number of 
vigilance cases received annually.
•	 Systems	were	put	in	place	for	reporting	of	serious	
adverse events and reactions relating to human 
organs intended for transplantation.
Another key function of the IMB is to monitor and 
inspect industry compliance with legislation, policies 
and procedures. We are committed to ensuring that 
all healthcare products manufactured, processed 
or distributed in Ireland meet essential quality 
standards.
•	 313	inspections	and	audits	were	performed	
in 2013 compared to 315 in 2012 and 300 
in 2011. The 2013 figure included 115 Good 
Manufacturing Practice (GMP) inspections,  
126 Good Distribution Practice (GDP) inspections, 
17 Good Clinical Practice (GCP) inspections,  
19 medical device audits and 29 inspections 
covering blood, tissues and organs.
•	 We	sent	275	medicinal	and	other	product	
samples for analytical testing. These included  
156 samples sent to governmental laboratories 
in Ireland.
•	 During	2013,	a	total	of	774	quality	defects	were	
reported to, or identified by, the IMB. This was a 
slight increase on the numbers reported for 2012.
•	 It	may	be	necessary	in	certain	cases	to	withdraw,	
or recall, products from the Irish market in order 
to protect public health. In 2013, 109 medicine 
recalls occurred. Of these, 107 related to human 
medicines and two to veterinary medicines.
•	 The	IMB	initiated	nine	prosecutions	in	the	District	
Courts during the course of 2013 as a result 
of illegal activity involving the manufacture, 
supply and/or sale of medicines. The number of 
dosage units detained as part of our enforcement 
programme during 2013 was 919,965. This 
represents an annual increase of 20%.
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legISlATIve And RegulAToRy 
develoPMenTS
As evidenced by the planned introduction of our new 
name in 2014, the remit and role of our organisation 
continues to change and expand due to changes in 
our operating environment. These include changes to 
national and European legislation and the addition of 
further competencies.
Presidency of the Council of European Union
A significant event in 2013 for the IMB was Ireland’s 
Presidency of the Council of European Union. We 
had the honour of hosting 22 informal meetings of 
our regulatory peers from across the member states, 
EMA and European Commission in the various areas 
we regulate. Essential progress was made in respect 
of a number of important regulatory issues during 
the six months of the Presidency and, from an IMB 
perspective, we were very pleased with the positive 
feedback received from participants.
Among the highlights from the Irish Presidency was 
the first joint meeting of the CHMP, CMDh and PRAC 
with a view to enhancing understanding of their 
respective roles and how they must collaborate to the 
benefit of patients.  The Irish Presidency also included 
the first ever combined meeting of both the Heads 
of Medicines Agencies (HMA) and the Competent 
Authorities for Medical Devices (CAMD). 
The IMB also provided a high level of support to the 
Department of Health as it chaired the European 
Council’s Working Party on Pharmaceuticals and 
Medical Devices. This working party had a substantial 
work programme during the Irish Presidency with 
two proposals for medical devices Regulations, the 
Regulation on clinical trials of medicinal products and 
the transparency legislation before the Council. 
Benchmarking of European Medicines Agencies 
The aim of the Benchmarking of European 
Medicines Agencies (BEMA) programme is to provide 
assurance to the heads of the EU medicines agency 
network with respect to the quality of the systems 
and practices in place in agencies for regulating 
medicines. I serve as co-chair of the BEMA steering 
group while the IMB provides the secretariat for 
the group and is responsible for visit logistics. We 
continued to lead the steering group throughout 
2013 as assessment visits were undertaken in this the 
third benchmarking cycle. 
The IMB’s own benchmarking assessment visit took 
place in October 2013 when three assessors from the 
Austrian, Greek and UK agencies interviewed senior 
staff, reviewed evidence and rated the ‘maturity’ of 
the IMB’s management and scientific quality systems. 
Several proposed ‘best practices’ were accepted by 
the assessors related to our project management 
office, leadership development programme and 
our contribution to the European network. The 
assessors also nominated a further best practice in 
the close link between our strategic and business 
planning objectives and the objectives in staff’s 
individual performance development plan. As is to 
be expected, some ‘opportunities for improvement’ 
were highlighted and identified as actions to 
enhance the quality of our services. Overall, we were 
extremely pleased with the outcome of the IMB’s 
assessment which reflected well on our progress and 
achievements in recent years. The assessors noted 
our strong dedication to quality in general and to the 
BEMA programme in particular.
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Health (Pricing and Supply of Medical Goods)  
Act 2013 
A significant regulatory development during 2013 
was the commencement of the Health (Pricing 
and Supply of Medical Goods) Act. Under this 
Act, the IMB is responsible for the establishment, 
consultation, publication and maintenance of a 
list of interchangeable medicinal products which 
will be grouped together under their respective 
active substance, strength and pharmaceutical 
form(s). The purpose of the legislation is to provide 
for substitution of medicines that are considered 
interchangeable so that a pharmacist can dispense a 
less expensive medicine than the one prescribed. 
Throughout 2013, the IMB worked closely with the 
Department of Health and HSE in the implementation 
of this legislation. Between August and December, 
we published 11 active substances to the 
interchangeable list which is maintained on the IMB 
website. In each case, the IMB consulted with the 
relevant marketing authorisation holders prior to 
adding a medicine or a group of medicines to the list. 
The IMB also supported the various communications 
initiatives introduced to raise awareness and 
understanding of generic and interchangeable 
medicines.
 
Ongoing Implementation of EU 
Pharmacovigilance Legislation
The new pharmacovigilance legislation is resulting in 
more systematic risk management planning, greater 
coordination of real time signal management, and 
faster assessment and decision-making. During 
2013, the IMB continued its work with stakeholders 
including the EMA, other national regulators and 
industry to support the phased implementation of 
further elements of the legislation.
This included the publication by the EMA of the 
initial list of medicines that are subject to additional 
monitoring. The introduction of the symbol for these 
products (an inverted black triangle) is an important 
deliverable of the new pharmacovigilance legislation. 
Explanatory information was published on the IMB 
website and in relevant health publications while we 
also developed a national guideline for marketing 
authorisation holders. 
Falsified Medicines Directive
The falsified medicines Directive aims to strengthen 
the protection of patients and consumers by 
preventing falsified (including counterfeit) medicines 
entering the legal supply chain. During 2013, as part 
of the continued implementation of the provisions of 
the falsified medicines Directive, the IMB established 
a registration scheme for manufacturers, importers 
and distributors of active substances and for brokers 
of medicines.   
 
European Commission’s Joint Plan for Immediate 
Actions on Medical Devices
In February 2012, the European ‘joint plan of 
immediate actions’ was published with the objective 
of reinforcing the existing regulatory system for 
medical devices in advance of the proposed revision 
to the medical devices legislation. The plan outlined 
actions for Member States and the Commission in 
the areas of functioning of notified bodies, market 
surveillance, coordination, communication and 
transparency. 
During 2013, in advance of the legislative proposal 
being finalised, the IMB focussed on the adoption of 
the joint plan. 
•	 The	performance	of	notified	bodies	for	
medical devices and their oversight which 
is highlighted in the joint plan was subject 
to significant attention and development at 
European level during 2013. The IMB helped 
establish a subgroup of the European Notified 
Body Operations Group (NBOG) to plan a joint 
assessment scheme, to develop common criteria, 
documents and guidance, and to coordinate 
the joint assessments. During 2013, 21 of the 23 
countries responsible for class III notified bodies 
were subject to joint assessment while the 
remaining two will be completed in 2014.  
The IMB directly participated as experts in 
five joint assessments of EU notified bodies in 
2013. This included the first mandatory joint 
assessment and further contributions are 
planned for 2014. The IMB was also subject to a 
successful joint assessment in their surveillance 
audit of the National Standards Authority of 
Ireland (NSAI) in December 2013. 
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•	 At	EU	level,	the	joint	plan	has	also	resulted	in	a	
review of activities conducted by Member States 
in the area of market surveillance. To ensure we 
fully contribute to these developments, the IMB 
has set out a re-development proposal for its 
market surveillance activities to include greater 
emphasis on proactive and reactive surveillance 
across the product life-cycle. 
 
Cosmetics Regulation
The new Cosmetic Products Regulation, EU 
Regulation 1223/2009, came into effect in July 
2013. In November, the European Union (Cosmetic 
Products) Regulations 2013 (S.I. No. 440 of 2013) 
came into force. The national regulations gave full 
effect to the EU Regulation, designated the IMB as 
competent authority and allocated powers to the  
IMB and HSE. 
Participation in the European and International 
Regulatory Systems
The products regulated by the IMB are part of an 
ever-changing and developing international industry. 
Healthcare products manufactured here are used 
around the world while products manufactured 
elsewhere are used by Irish patients and consumers. 
As a result, the IMB is committed to playing its part 
in the global regulatory network to ensure that we 
represent and protect the interests of Irish patients 
and consumers.
Our participation and contribution to the 
European medicines regulatory system continues 
to be significant. IMB scientific and technical staff 
are members of a broad range of committees 
and working parties at the EMA, the European 
Commission, the HMA and via other platforms. The 
IMB also worked closely with relevant international 
organisations as necessary. 
Significant contributions and achievements from an 
IMB perspective during 2013 include the following:
•	 The	IMB	attended	the	7th	International	Summit	
of Heads of Medicines Regulatory Agencies. 
Significant progress was made in respect of 
adopting formalised procedures for international 
co-operation across a number of regulatory 
areas with agreement on the formation of the 
International Coalition of Medicines Regulatory 
Authorities (ICMRA) with the selection of Health 
Canada as chair with the IMB and PMDA Japan as 
vice Chairs. Seven priority projects were agreed 
including the development of terms of reference 
and rules of procedure which the IMB will lead. 
Additional projects involve communications, 
rapid sharing of information, mapping, 
inspections, generic medicines and capacity 
building.  
•	 During	2013,	the	IMB	was	invited	to	join	the	
management committee of the International 
Medical Device Regulators Forum (IMDRF). This 
forum seeks to promote the harmonisation of 
medical device regulation across the globe.
•	 The	Irish	PRAC	delegate	continued	to	fulfil	the	
role of Vice-Chair of this important EMA public 
health committee. Our Pharmacovigilance and 
Risk Management Lead also acted as Regulatory 
Chair for the ICH Implementation Working Group 
on the new E2C R2 guideline on Periodic Benefit 
Risk Evaluation Reports.
•	 As	in	previous	years,	IMB	experts	contributed	
to initiatives to facilitate the transition from 
implementation to operation of the new EU 
pharmacovigilance legislation. This included 
participation in a three year pharmacovigilance 
project entitled SCOPE (Strengthening 
Collaborations for Operating Pharmacovigilance 
in Europe). The IMB will also lead the impact 
assessment topic in a work package on risk 
communications. 
•	 The	IMB	Pharmacovigilance	Manager	for	human	
medicines continued to represent the World 
Health Organization WHO) as a member of the 
Board of the Uppsala Monitoring Centre (UMC) 
and WHO Collaborating Centre for International 
Drug Monitoring during 2013. 
•	 Negotiation	on	the	two	proposed	regulations	
on medical devices and in-vitro diagnostics 
continued in 2013 during and after the Irish 
Presidency of the European Council. The 
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IMB continued its active contribution to the 
working groups and subgroups focused on the 
development of the expected new regulatory 
system and we will continue to support the 
Department of Health in this regard as required.
•	 As	in	previous	years,	the	IMB	also	continued	
to engage actively in discussions on how to 
optimise resourcing of the network for medical 
device regulation in Europe. These discussions 
included significant dialogue with the medical 
device industry associations on possible fee-
based funding models.
STAkeHoldeR engAgeMenT And 
CoMMunICATIonS
As set out in our five year strategic plan, the IMB 
is committed to expanding and improving our 
communications activities and to ensuring that 
all our stakeholders have timely access to relevant 
safety and regulatory information. As well as our 
regular meetings and ongoing publication of safety 
and regulatory updates, newsletters and guidance 
documents, a number of significant communications 
initiatives were implemented during 2013. 
Consultative Panel on the Legal Classification  
of Medicines
Established in 2011, the Consultative Panel on the 
Legal Classification of Medicines concluded its work 
in 2013. The Panel was independently chaired and 
consisted of external representatives drawn from 
a wide range of interested stakeholders including 
patients, healthcare professionals, the Department 
of Health and relevant government agencies. The 
focus of the panel was to review policies relating 
to the legal classification of human medicines 
and to develop recommendations to address 
current unmet needs in the availability of non-
prescription medicines. The IMB is currently working 
to develop processes to address the issues and 
recommendations identified and this is an area of 
priority focus for 2014.
Events
•	 As	outlined	earlier,	the	Irish	Presidency	was	a	
considerable area of focus for the IMB in the first 
half of 2013. We hosted a total of 22 meetings 
during this period with approximately 1000 
delegates visiting Ireland for IMB organised 
events. The number of delegates attending each 
meeting varied with the largest events taking 
place in Dublin Castle and the Convention Centre 
Dublin. The logistics for all these meetings were 
organised and managed in-house by an IMB 
team. This included online registrations, venue 
management, onsite support and networking 
events.
•	 The	IMB,	in	association	with	the	Irish	Presidency	
of the Council of the European Union and 
with the support of the King’s Centre for Risk 
Management and the Nickel Institute, hosted the 
European Risk Summit in Trinity College Dublin 
on 11 and 12 June 2013. This successful and 
well-received event discussed the advantages 
of evidence and risk-based rulemaking as well 
as the challenges of formulating European 
directives / regulations and, by extension, 
national legislation on hazard classifications. 
Approximately 100 Irish and international 
experts comprising policy-makers, regulators, 
governing bodies, industry and academia from a 
range of industries attended the summit. It also 
presented an opportunity to foster dialogue and 
collaboration among the relevant stakeholder 
community to address the challenges in this area.
•	 IMB	information	days	and	seminars	provide	
regulatory guidance and updates to a range of 
stakeholders. The events enable all attendees to 
submit questions, seek clarifications and network 
with colleagues. A webinar event outlining 
the IMB’s approach to the development of the 
interchangeable list of medicinal products was 
held in February. The topics covered included 
an overview of the approach to stakeholder 
consultation and publication of the lists. A 
veterinary information day was held on 24 
October. The programme was focused on 
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updating stakeholders on recent changes in the 
regulatory framework for veterinary medicines in 
advance of publication of the EU Commission’s 
proposed new legislation in this area. An 
information day on the new Common European 
Submission Platform (CESP) took place on 20 
November. This joint DIA/IMB event provided the 
latest information on the CESP system which is 
designed to enable the simultaneous delivery 
of applications to the various EU regulatory 
agencies.
•	 2013	was	the	fourth	year	of	the	IMB’s	
involvement at the BT Young Scientist and 
Technology Exhibition in the RDS. Thousands 
of students as well as teachers, parents and 
members of the general public from all over 
Ireland again visited the IMB’s exhibition stand 
which was focused on the important issue of 
medicines and medical devices safety.
Research
The IMB published a series of research results during 
2013 focused on consumer attitudes in respect of a 
number of medicines topics. These included:
•	 Sources	of	information	and	advice	on	medicines.
•	 The	use	of	the	internet	as	a	source	of	medicines	
information and possible supply.
•	 Awareness	of	and	attitudes	towards	generic	
medicine.
Among the key findings were: 
•	 Two	thirds	of	people	(63%)	state	that	they	always	
read the product information when taking a 
prescription medicine.
•	 One	in	two	people	always	seek	advice	from	a	
healthcare professional before taking a new over 
the counter medicine.
•	 Almost	4	out	of	10	people	(37%)	using	online	
channels for information are attempting to 
diagnose health symptoms (self-diagnosis).
•	 Actual	purchase	of	medicines	online	is	low	with	
2% of all adults claiming to have done so which, 
nevertheless, equates to approximately 60,000 
people. 
•	 Nine	out	of	ten	consumers	(92%)	who	had	
personally used generic medicines said that they 
had a positive experience overall. 
Brand Identity
It has been decided by the Board of the IMB to 
change the name of the organisation to better 
reflect the range of products and processes we 
now regulate. The new name to the replace the 
Irish Medicines Board is the Healthcare Products 
Regulatory Authority (HPRA). It is anticipated that 
our new name will become operational in mid 2014. 
We will also be launching a new corporate website at 
that time. In preparation for the adoption of the new 
name, the IMB initiated a project to develop a new 
brand identity incorporating a logo and a style guide. 
The latter document provides clear direction on the 
application of the new brand across all platforms and 
publications. This project was completed during 2013.
Media Relations
We continued to progress our proactive media 
communications programme to highlight important 
safety messages and to build awareness of the role 
of the IMB. In total, we issued 32 press releases 
concerning safety and regulatory issues and 
responded to 449 queries from different media 
sources during the year.
Website 
The IMB website continued to be updated with news, 
safety information and regulatory documents while 
further changes and improvements were made in 
response to stakeholder feedback. Almost 225,000 
unique visitors accessed the website during the past 
twelve months representing an annual increase 
of 32%. Development of a new and more modern 
corporate website began in 2013 and this project 
will be completed during the first six months of 2014 
coinciding with the launch of the Health Products 
Regulatory Authority.
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develoPIng oRgAnISATIonAl 
CAPABIlITy
As an organisation the IMB must respond to changes 
in our operating environment to ensure we remain 
an effective and progressive regulatory body. We are 
committed to ensuring that we have the requisite 
structures, systems and supports in place to deliver 
on our public and animal health mission. 
Information Technology and Change 
Management
Technology is recognised as a key component in 
supporting regulatory activities at both national 
and international levels. Throughout 2013, the 
IMB continued to contribute to, and actively lead, 
a number of key technology projects at a national 
and European level. This includes the ongoing 
development and management of the Common 
Electronic Submission Portal (CESP) on behalf of the 
wider EU regulatory community. In 2013, the CESP 
portal activity levels grew substantially, handling 
over 100,000 submissions on behalf of 20 European 
regulatory organisations and the pharmaceutical 
industry.
The IMB is also actively engaged at national level 
through its involvement with the National Health 
Data Standards Committee and works with other 
relevant agencies including the HSE, NSAI and HIQA. 
In addition, the IMB contributed to the development 
of the eHealth Strategy for Ireland and contributed 
technological support to the introduction of 
interchangeable medicines in co-operation with 
Department of Health and the HSE.    
IMB technologies are also strategically positioned to 
support the effective and efficient operation of the 
organisation.  During 2013, there was a strong focus 
on developing the key requirements for our new 
workflow technology solutions. Work also began on 
the implementation of a new HR solution and the 
development of the new hpra.ie website.
 
 
 
The IMB is committed to continuous improvement 
across all areas of our organisation. As part of our 
commitment to change management, it was decided 
to adopt a project management office model for all 
relevant activities. The Project Management Office 
came into full operation in 2013. It ensures that 
all organisational projects are fully aligned with 
corporate strategy and provides management with 
the necessary information to support the planning 
process.
Staff Developments
It is vitally important that the IMB has the human 
resources in place to deliver on our core regulatory 
functions for the benefit of all our stakeholders. 
During 2013, we continued to develop and adapt our 
work practices to enable us to manage our human 
resources with the flexibility necessary to respond to 
changing and challenging external factors.
Chief among these external issues was the 
introduction of the Haddington Road Agreement 
(HRA) which applied to all public sector bodies with 
effect from July 2013. The terms of this agreement 
included a further reduction to the salaries of staff 
as well as the deferral of payment of increments 
during the course of the agreement and extended 
working hours. Such demands on public sector 
workers clearly impact them in a number of ways and 
not just financially. In the IMB, our human resources 
colleagues provided extensive assistance and 
support around the introduction of the agreement. 
I commend the professionalism of all our staff 
across the IMB who were delivering the extensive 
programme of work outlined in this report while 
implementing the terms of HRA.
Another significant focus of activity during 2013 was 
completion of a business requirements phase for 
the replacement of the human resources IT system. 
The detailed planning and preparatory work being 
carried out at this stage will help ensure we deliver 
a greatly enhanced system by June 2014. This will 
result in greater efficiencies for the human resources 
department and will provide managers and staff with 
improved access to personnel and training records.
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The organisation’s first leadership development 
programme concluded in 2013 with all core 
objectives successfully achieved. The programme 
supports the development of managers within the 
IMB by helping to identify and evaluate the skills 
they have or need to have in order to become more 
effective managers and leaders. I am very pleased 
that following a review of the pilot programme 
during 2013, the commencement of a second 
programme was recommended and approved. The 
application and selection process for the second 
programme was concluded by the end of 2013 and it 
will commence in January 2014 with 10 participants.
Extension to the IMB Offices
Kevin O’Malley House, which accommodates the 
offices of the IMB, was extended upward by two 
floors during the course of 2012 and 2013 with the 
certificate of practical completion being granted 
on 12 July 2013. The extension of two new floors 
has ensured that all IMB staff can be housed in one 
building which reduces rental costs and will result in 
practical efficiencies over time. This was a complex 
build due to our requirement that the building 
remained fully in use throughout the duration of the 
project. I am pleased to confirm that the addition of 
the two new floors was completed on time and under 
budget.
Financial Performance
The IMB is largely self-funded by a system of fees 
which are approved annually by the Minister 
for Health, following a public consultation. This 
approach is in line with the typical funding model of 
healthcare products regulation worldwide. The IMB is 
committed to the highest standards of independence 
and governance so as to ensure quality of service 
combined with value for money. We continued in 
2013 to successfully manage the affairs of the IMB in 
line with our statutory obligation that income at least 
meets costs.
THe FuTuRe
As ever we can say that the immediate and medium 
term future will be interesting and challenging. 
A major event for 2014 will be the rebranding of IMB 
to the HPRA. This will serve as a real visible indicator 
of the broad range of health products now regulated 
by the organisation. It will provide an opportunity 
to revitalise the organisation and by various means, 
including a new website, enhance our abilities to 
communicate directly with patients and consumers. 
Staff recruitment and retention will be a challenge 
over the near and mid term and this will receive 
particular attention. 
Our core work remains the protection and 
enhancement of public and animal health and we will 
continue to focus all our efforts to this end. 
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AUTHORISATION, REGISTRATION 
AND LICENSING ACTIVITIES  
The authorisation and registration of health products is 
a core public health function of the IMB. These are the 
regulatory actions which are carried out before a health 
product can be marketed and supplied in Ireland. The 
IMB is committed to the timely approval of new product 
applications in particular, following a positive assessment of 
their safety, quality and effectiveness.
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The IMB is responsible for the authorisation of 
medicines and clinical trials and for the registration 
of certain medical devices. We also licence 
manufacturers and wholesalers of human medicines, 
manufacturers of veterinary medicines as well as 
blood and tissue establishments and organ transplant 
centres. In addition, we are responsible for issuing 
export certificates.
The IMB also provides a service to stakeholders 
to assist in clarifying which products should be 
categorised as human medicines, veterinary 
medicines and medical devices. Such products 
fall under the remit of the IMB from a regulatory 
perspective and are distinct from other products 
which are outside the IMB’s remit.
HUMAN MEDICINES
BoRdeRlIne PRoduCT ClASSIFICATIon
Queries are routinely received in regard to the 
correct classification of human medicines, veterinary 
medicines and medical devices.
For products for human use, a classification service 
is operated for products which are on the borderline 
between human medicines and other products 
such as food supplements, cosmetics and medical 
devices. Requests for classification, whether 
external or internal, are presented to an internal, 
multi-disciplinary, human medicines Classification 
Committee.
The Committee, which met 11 times in 2013, consists 
of appropriately experienced IMB staff from across 
the organisation and is chaired by the Director of 
Scientific Affairs. During the past 12 months, a total of 
168 new products were considered consisting of 161 
internal applications and seven external applications. 
In addition, there were 33 products revisited from 
pre-2013.
The Committee has a close working relationship 
with the Food Safety Authority of Ireland (FSAI) 
and there were a number of referrals between both 
organisations during the course of 2013. The FSAI 
notified the IMB of 62 products that it considered 
to fall more appropriately under the IMB’s remit and 
these were reviewed and followed up as appropriate. 
The committee also engaged in regular dialogue with 
the Department of Health and with other European 
regulatory authorities.
The accompanying table outlines the numbers 
of classification queries for 2013 compared with 
previous years. Queries are generally evaluated 
within the normal 28 day timeframe and written 
explanations of the outcome are provided.
number of Applications Received 2009 2010 2011 2012 2013
Source Internal 114 72 132 127 161
 External 17 33 21 17 7
Classification Outcome Medicinal Product 88 63 88 91 108
 Medical Device 4 4 9 6 7
 Food Product 13 24 36 26 28
 Cosmetic Product 3 6 4 10 19
 Biocide    2 1 1
 Pending 21 7 12 6 1
 Other 2 1 2 4 4
 Total 131 105 153 144 168
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ClInICAl TRIAlS
The role of the IMB is to assess applications from 
sponsors to conduct clinical trials in Ireland. Sponsors 
include pharmaceutical companies and / or research 
institutions. The IMB approves the clinical trial 
protocols which describe in detail how each trial is 
to be conducted and outlines the steps that will be 
taken to protect the health of volunteers or patients.
In 2013, 102 clinical trials were approved to 
commence in Ireland. This represents an increase of 
over 30% in clinical trial applications compared to 
2012, which positively reflects increasing research 
and innovation conducted in Ireland. The key 
areas of interest continue to include oncology and 
haematology.  
voluntary Harmonisation Procedures
The IMB participated in 16 voluntary harmonisation 
procedures (VHP) during 2013 compared with five the 
previous year.  A VHP is a co-ordinated work sharing 
assessment procedure for multinational clinical 
trials. This procedure was established by the national 
competent authorities for clinical trials from across 
the EU. In four of these VHPs, the IMB acted as lead 
Member State for the assessment. In addition, the IMB 
led in 17 VHP amendments during the year.
new MARkeTIng AuTHoRISATIon 
APPlICATIonS 
Before a new medicine can be placed on the Irish 
market, it must be firstly assessed and authorised 
(licensed) by the IMB or the EMA. The assessment 
involves establishing that a medicine’s public health 
benefits outweigh its known risks. Where this is the 
case, it may be granted a marketing authorisation.
There are a number of routes through which a 
product can be authorised by the IMB. These include 
the national procedure, the mutual recognition 
procedure (MRP) and the decentralised procedure 
(DCP).  Both MRP and DCP involve the simultaneous 
submission of applications in a number of EU 
Member States.  The assessment involves the input 
from all of the relevant competent authorities in 
evaluating the benefit / risk of the product(s). The 
DCP route differs from MRP in that the product has 
not previously been authorised within the EU. 
During 2013, the following applications were 
assessed by IMB: 
•	 198	new	national	applications	(including	parallel	
product authorisations); 
•	 45	applications	made	under	the	MRP;	
•	 274	applications	made	under	DCP.
The IMB acted as reference (lead) Member State for 
the assessment of 12 of the MRP and DCP procedures. 
The centralised route is another mechanism whereby 
products can be authorised in Ireland. In this 
procedure, the assessment is carried out by the EMA 
while the authorisation is granted by the European 
Commission. The centralised route involves the 
submission of a single application to the EMA and 
the authorisation once granted is valid in all Member 
States.  The IMB was allocated as lead assessor 
(rapporteur) or joint lead assessor (co-rapporteur) 
for 15 new marketing authorisation applications by 
the Committee for Medicinal Products for Human 
use (CHMP) at the EMA in 2013. These included the 
following application types and treatment areas: 
•	 Respiratory;	
•	 Radiocontrast	agent	(ECHO);	
•	 Treatment	of	bile	acid	metabolism	disorders;	
•	 Alcohol	dependence;	
•	 IVF	media;
•	 Lysosomal	storage	disease.			
Based on 2013 allocations, the IMB was ranked fifth 
in the EU for rapporteurships for centrally authorised 
human products.
The total number of new products authorised in 
2013 was 752. This figure also includes 208 products 
authorised through the centralised route where IMB 
was not rapporteur or co-rapporteur. In overall terms, 
the number of products authorised has decreased 
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relative to previous years and this is reflective of a 
trend observed throughout the EU during 2013 which 
has been attributed to product patent lifecycles. 
new Applications
 
 
TRAdITIonAl HeRBAl And HoMeoPATHIC 
MedICInAl PRoduCTS
During 2013, seven traditional herbal medicinal 
products (THMPs) were authorised by the IMB. 
This is a simplified registration scheme which takes 
into account the tradition of use of these products. 
Legislation requiring registration for THMPs came 
into effect in full in 2011. The number of applications 
received by the IMB since that time has remained low 
with a total of 19 THMPs authorised by the end of 
2013.
There were seven homeopathic medicinal products 
registered during 2013 under the simplified rules 
scheme.
TRAnSFeR APPlICATIonS 
The IMB processed a total 144 transfer applications 
in 2013. Of these, 103 related to the transfer of an 
existing marketing authorisation to a new marketing 
authorisation holder while the balance related to a 
transfer of a marketing authorisation holder prior to 
authorisation.
 
vARIATIonS 
After a medicine has been authorised, the terms 
of the marketing authorisation may need to be 
changed and the process whereby these changes are 
implemented is known as a “variation”. Examples of 
variations include the addition of a new indication, 
a new potential side effect, or updates to the 
company’s manufacturing or contact details. In 
the past year, the IMB issued 17,749 variations to 
marketing authorisations for products authorised 
through the national or MR procedures. 
 
Articles 45 and 46 - Variations to  
Update Product Information
The IMB acted as rapporteur for two paediatric 
Article 45 procedures, one paediatric Article 46 
procedure and 13 procedures relating to Paediatric 
Investigational Plans (PIPs) during the past 12 
months. These are important procedures from 
a public health viewpoint as they increase the 
availability of medicinal products specifically 
indicated for use in children.
RenewAlS 
In 2013, 590 renewals to marketing authorisations 
for products authorised through the national or MR 
procedures were processed. The reduction of 10% on 
the previous year reflects the lifecycle of the products 
in question.
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SCIenTIFIC AdvICe 
Companies may also seek scientific advice from the 
CHMP. Scientific advice is a pre-authorisation activity 
which assists product and technology innovation 
and development.  During 2013, the IMB acted as 
lead in 38 scientific advice procedures for medicines 
proposed for the treatment of a broad range of 
conditions. Areas of focus included respiratory 
medicine, diabetes mellitus and musculo-skeletal 
conditions.
ConTRolled dRugS lICenSIng 
Import, export and holding of controlled drugs (for 
legitimate purposes) are subject to licensing. The 
Department of Health is the licensing authority while 
the IMB handles the administrative aspects of the 
application and licensing process.
Controlled drugs licensing Activity 2009-2013
 
Licensing activity, which consists primarily of export 
and import licences and letters of no objection, has 
increased marginally during recent years. 
VETERINARY MEDICINES
In the conduct of its veterinary medicines licensing 
activities, the IMB is committed to protecting the 
welfare of treated animals, including fish, poultry, 
bees and domestic animals, as well as ensuring the 
safety of foodstuffs obtained from animals treated 
with veterinary medicines. The assessment of 
veterinary products also includes an evaluation of  
any possible risks to the user as well as the 
elaboration of risk-management measures to control 
any risks. Finally, we also evaluate the potential 
impact of new veterinary medicines on  
the environment.
PRoduCT ClASSIFICATIon RequeSTS 
The IMB provides a service to stakeholders to assist 
in clarifying which products should be categorised 
as veterinary medicines. Such products fall under the 
remit of the IMB from a regulatory perspective and 
are distinct from other products which are outside 
the IMB’s remit such as biocides and feeding stuffs. 
During 2013, 33 product classification queries were 
received in respect of veterinary medicines. This 
represents a drop of more than 50% in the level of 
enquires compared to 2012.
new APPlICATIonS
Before a new veterinary medicine can be placed 
on the Irish market, it must be firstly assessed and 
authorised by the IMB or the European Medicines 
Agency. The decision on whether a medicine is 
authorised centrally in Europe or at a national level 
is generally dependent on the type of product in 
question and/or the preference of the marketing 
authorisation holder. When a company seeks an 
authorisation from the IMB for a new medicine, an 
assessment team of veterinary surgeons, pharmacists 
and other scientists will review the application to 
establish if the medicine’s animal and public health 
benefits outweigh its known risks.
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During 2013, the number of new product applications 
received by the IMB was 158 of which 16 were purely 
national applications. We assessed and approved 188 
applications, which is an increase of 24% on last year. 
The IMB continued to actively contribute to the 
European veterinary licensing system and issued 
50 new marketing authorisations as the reference 
Member State. In total, including also those 
applications where the IMB was a concerned Member 
State, the number of MRP and DCP licenses issued 
was 139 while 124 such applications were received. 
In the ‘centralised’ procedure, the EMA is responsible 
for conducting the initial assessment of veterinary 
medicines for which an EU-wide marketing 
authorisation is sought. Under this procedure, the 
Committee for Medicinal Products for Veterinary 
Use (CVMP) appoints members from two different 
EU countries to evaluate the application and these 
are known as the rapporteur and co-rapporteur. 
During 2013, the IMB acted as the rapporteur or 
co-rapporteur for seven centralised procedures 
(including extension applications to new target 
species). 
vARIATIonS
After a medicine has been authorised, the terms of 
the marketing authorisation may subsequently be 
varied. Examples of variations include the addition of 
a new indication or potential side effect, or updates 
to the company’s manufacturing or contact details. 
During 2013, the IMB approved 1,364 variations to 
authorisations granted through the national, MR 
or centralised procedures while 1,416 variations 
applications were received, an increase of 15%  
on 2012.
RenewAlS
New marketing authorisations are valid for five years 
from the date of first issue, after which time they are 
usually renewed for an indefinite period.
In 2013, 95 renewals to marketing authorisations for 
veterinary medicines authorised through the national 
or MR procedures were received while 67 were issued. 
The number of renewals issued was in line with 2012 
figures.
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woRk-In-PRogReSS APPlICATIonS
During 2013, the IMB reduced the overall work-in-
progress at the end of the year relevant to veterinary 
medicines to 656 units (comprised of various 
application types). This represented a notable annual 
decline of 21%. The overall work-in-progress overdue 
figure was also reduced by over 70% during 2013.
SCIENTIFIC ANIMAL PROTECTION
The IMB became the national competent authority 
responsible for the implementation of Directive 
2010/63/EU on the protection of animals used 
for scientific purposes on 1 January 2013. The 
accompanying national Regulations are set out in S.I. 
No. 543 of 2012. This authority was transferred from 
the Department of Health which regulated this area 
until 31 December 2012.
During its first year as the competent authority, the 
IMB issued a total of 81 project authorisations, 507 
individual authorisations and one establishment 
authorisation. There were also 22 preliminary 
inspections and seven compliance inspections 
undertaken in 2013. 
MEDICAL DEVICES
ClASSIFICATIon RequeSTS
The IMB received 45 applications for classification 
of medical devices or products queried as medical 
devices. Of these enquiries:
•	 48%	were	received	from	other	medical	device	
competent authorities in Europe or from the 
European Commission and related to complex 
classification questions;
•	 34%	of	applications	were	received	from	
external stakeholders such as medical device 
manufacturers or distributors; 
•	 16%	were	internal	queries	from	within	IMB;	
•	 2%	were	received	from	notified	bodies.
The IMB circulated six enquiries on medical device 
classification issues to other European medical device 
competent authorities with a view to seeking a 
consensus opinion in Europe on the classification or 
qualification of a specific product. 
In addition, four appeals to classification decisions 
taken by the IMB were received during 2013. 
ClInICAl InveSTIgATIon APPlICATIonS
The IMB received 10 applications for clinical 
investigations of a medical device to be conducted 
in Ireland comprising of nine new applications and 
one re-submission application. Five amendments to 
ongoing clinical investigations were received in 2013.
While there was an increase in the number of 
applications received in 2013 (compared with one in 
2012), the number of clinical investigations of medical 
devices ongoing in Ireland remains lower than 
expected. The last revision of the European medical 
devices legislation (Directive 2007/47/EC) put greater 
emphasis on the conduct of clinical investigations. 
However, an increase in clinical investigation activity 
in line with this has not been seen in Ireland. It is 
worth noting that the medical device legislation in 
Europe only requires application / notification to 
the IMB of pre-market clinical investigations from 
medical device manufacturers. This is a specific type 
of medical device research. Other types of clinical 
research such as research involving CE marked 
devices are generally not required to be notified 
under national or European legislation. Therefore, the 
number of research applications received by IMB may 
not necessarily be indicative of the clinical research of 
medical devices in Ireland.
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deSIgnATIon And MonIToRIng oF IRISH 
noTIFIed BodIeS 
During 2013, the IMB conducted two surveillance 
assessments of the National Standards Authority of 
Ireland (NSAI). One of these surveillance assessments 
was carried out in its US-based office while the 
other was carried out in its Dublin headquarters. 
In addition, two observed audits were conducted 
by IMB of NSAI staff auditing medical device 
manufacturing sites.
The IMB received 183 certification notifications, 
including certificate issuance, modification and 
withdrawal, which were then uploaded as required to 
the European EUDAMED database.
TeCHnICAl FIle RevIewS
In 2013, the IMB increased its focus on review of 
technical documentation both in the context of 
market surveillance activities and notified body 
oversight. A total of 17 technical file reviews were 
opened in 2013. It is intended to further expand this 
activity during 2014.
PRoduCT RegISTRATIonS
The IMB received 334 notifications of medical devices 
to the medical device register. These relate to class I, 
in-vitro diagnostic and custom made medical devices 
as well as system and procedure packs. Registration 
of these devices in the Member State in which the 
manufacturer or their authorised representative is 
based is required by legislation as there is a self-
declaration of conformity made by the manufacturer. 
During 2013, 26 organisations registered with the 
IMB as Irish based manufacturers or authorised 
representatives of class I, custom-made, in-vitro 
diagnostic medical devices, as manufacturers of 
system or procedure packs or as sterilisers of  
medical devices. 
queRIeS
During 2013, the medical devices team received 
355 pre-market queries relating to medical devices, 
in addition to those received by the IMB’s customer 
service team.
COSMETIC PRODUCTS
PRoduCT noTIFICATIonS
Manufacturers, importers and persons acting on 
their behalf who have responsibility for placing 
cosmetic products onto the EU market, are required 
to notify such placement. For the first half of the 
year, this could be done nationally (to the IMB 
and counterparts in other Member States) or via 
the European Commission’s Cosmetic Product 
Notification Portal (CPNP). Notification via this 
centralised portal became mandatory on 11 July 
2013.
The IMB received 819 cosmetic product notifications 
in the first six months of the year. The three most 
common categories of product notifications 
remained the same as in 2012 and were:
1. Lip products (20%)
2. Make-up products and make-up (20%)
3. Creams, emulsions, lotions, gels and oils (18%)
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AUTHORISATION/LICENSING OF SITES 
AND FACILITIES
The IMB is responsible for the regulation of 
manufacturers of human and veterinary medicines, 
and wholesalers of human medicines as well as blood 
and tissue establishments and organ transplant 
centres. We are also responsible for the approval of 
contract laboratories.   
Such sites and facilities are required to be authorised 
/ licensed by the IMB for the activities which they 
carry out that fall within the remit of the relevant 
legislation. The IMB will grant an authorisation or 
licence subject to compliance with relevant European 
/ National (as appropriate) legislation and guidelines. 
Compliance with these requirements is based on 
satisfactory outcomes of IMB inspections (see also 
the Safety and Compliance Monitoring section of this 
report – page 45).
The total number of licences / authorisations in place 
at year end for the past five years is presented by 
category in the accompanying table. 
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Total number of licences/Authorisations (Sites) 2009 2010 2011 2012 2013
Manufacturers of Medicines for Human Use 85 86 88 87 89
Manufacturers of Veterinary Medicines 25 27 24 23 24
Investigational Medicinal Products for Human Use 50 51 50 47 49
Wholesalers of Medicines for Human use 209 220 243 258 269
Blood Establishments 5 4 4 3 4
Tissue Establishments 13 16 22 21 23
Laboratory Approvals 13 16 16 17 16
Total 400 420 447 456 474
REGISTRATIONS FOR ACTIVE 
PHARMACEUTICALS INGREDIENTS AND 
BROKERS OF MEDICINAL PRODUCTS 
Under amendments (via the so-called ‘Falsified 
Medicines Directive’) to the Medicines Directive, 
2001/83/EC, that came into force at the beginning 
of 2013, manufacturers, importers and distributors 
of active substances were required to register with 
the IMB. Brokers of medicines were also required to 
register. 
During 2013, the IMB accepted 95 registrations 
relating to active substances consisting of 22 
manufacturer registrations, 35 importer registrations 
and 38 distributor registrations. There was also one 
registration accepted for a broker of medicines.
EXPORT CERTIFICATES 
Export certificates are required by health authorities 
in many third country markets as an indication that a 
product registered, authorised and / or manufactured 
in the country of origin is of appropriate quality. As 
Ireland is a large exporter of medicines and medical 
devices, companies exporting from here request a 
large number of certificates. Export certificates are 
also required in many third countries to facilitate the 
registration of cosmetic products. The inspection and 
authorisation / registration programmes operated 
by the IMB form the basis on which certificates 
are issued. Where possible, certificate formats as 
published by the World Health Organization are used.
There was an output of 4,264 export certificates in 
2012 as set out in the accompanying table:
Product Certification Activity  2009 2010 2011 2012 2013
Certification of Documents 235 234 239 272 223
Certificates of Good Manufacturing  269 255 272 276 252 
Practice for Active Substance and   
Finished Product Manufacturers 
Certificates for Medicines  964 1200 1416 1350 1510
Medical Device Free Sale Certificates 977 2142 1780 1522 1987
Cosmetic Free Sale Certificates n/a 174* 388 210 242
Other 56 28 51 16 50
Total 2501 4033 4146 3646 4264
*2011 was the first full year that the IMB was responsible for issuing certificates for cosmetics. 
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SAFETY AND COMPLIANCE  
MONITORING 
Post-market surveillance is a primary function of the IMB. 
This includes the ongoing monitoring of the safety of 
medicines, medical devices and other health products 
that have been authorised, licensed or registered for use in 
Ireland. 
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There are a range of tools employed to monitor 
the safety of health products including the 
assessment of reports of suspected adverse events / 
incidents and reactions (also known as side effects), 
conducting scheduled safety reviews, monitoring 
field safety corrective actions to medical devices and 
evaluating new and emerging data from trials and 
studies. Quality issues concerning how a product is 
manufactured, packaged, labelled or distributed and 
stored may also arise at the post-market stage.
In certain cases, where it is established that the 
risks of a particular product outweigh the benefits 
for those using it, the manufacturer and/or the IMB 
may decide that it is necessary to remove or recall 
that product from the market. We work with all 
stakeholders impacted to ensure that such recalls are 
managed in a timely and effective manner.
HUMAN MEDICINES
PHARMACovIgIlAnCe 
Pharmacovigilance is defined as the science and 
activities relating to the detection, assessment, 
understanding and prevention of adverse reactions, 
or side effects, associated with the use of medicines. 
The IMB monitors adverse reaction reports to look for 
new types, or changing trends in adverse reactions. 
In co-operation with pharmacovigilance professionals 
in Europe and further afield, we focus especially on 
serious and potentially life-threatening risks. If there 
appears to be a new and serious risk, the issue must 
be assessed to determine the impact on the overall 
benefit / risk profile of the medicine concerned and 
consideration is given as to how any new risks should 
best be managed and communicated to healthcare 
professionals and patients.
During 2013, the IMB received a total of 2,835 valid 
new adverse reaction reports associated with the use 
of human medicines in Ireland, consistent with the 
reporting rates seen in 2011 and 2012. In addition, 
3,304 follow-up reports were also received.
The majority of adverse reaction reports are 
notified to the IMB by pharmaceutical companies 
marketing the medicines, also known as marketing 
authorisation holders. Most of these reports will have 
been initially reported to the companies concerned 
by doctors, pharmacists and other healthcare 
professionals who may also report directly to the IMB. 
We also receive reports of adverse reactions directly 
from patients and members of the public.
Source of Suspected Adverse   
Reaction Reports %
Pharmaceutical company 64
Community Care doctor 9
General Practitioner 5
Hospital Doctor 4
Hospital Pharmacist 4
Community Pharmacist 4
Nurse 5
Patient/Consumer 1
Other 4
 
In keeping with experience elsewhere, reporting 
rates were highest for newly authorised medicines. 
Reporting rates are also influenced by their ease 
of recognition and may be stimulated by publicity 
about a particular medicine or reaction. In addition, 
reporting rates are also influenced by proactive 
and repeated requests to healthcare professionals 
to submit reports on certain medicines as part of 
ongoing post marketing surveillance, as well as other 
promotional and data collection activities. All reports 
received are carefully evaluated and monitored, with 
reports of experience with use regularly highlighted 
and reinforced by IMB communications.
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Reports submitted to the IMB in many instances 
arise from suspicions occurring during observation 
of an unexpected and/or unwanted event, in the 
context of use of a medicine. They also include 
adverse reactions known to occur in association with 
medicines, such as those described in the product 
information (summary of product characteristics and 
package leaflet) for a particular product.
The accompanying table indicates the medicines 
most frequently included in reports to the IMB. These 
account for almost 50% of the adverse reaction 
reports received during 2013. It is important to note 
that the inclusion of a medicine on this list cannot 
be taken as an indicator of safety or risk. The number 
of reports received cannot be used as a basis for 
determining the incidence of a reaction as neither 
the total number of reactions occurring, nor the 
number of patients using a medicine, is known.  
Reporting rates may also be stimulated by publicity 
about a medicine.
Of the reports received by the IMB during 2013, 
143 patients were reported to have died while on 
treatment. In many of these cases, the patients 
concerned had significant underlying illness and 
were treated with multiple medicines and /or surgery, 
which may also have contributed to the outcome. 
In addition, many of these cases were influenced by 
disease progression or other complications unrelated 
to the medicine. The majority were associated with 
medicines used in the context of products subject 
to close monitoring, those used in the management 
of severe underlying medical conditions, in  patient 
support programmes and special patient monitoring 
programmes such as those in place for clozapine. The 
following table outlines those medicines associated 
with the highest number of fatal outcomes.
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Class of Medicines/Substance                               number of Reports in 2013
Monoclonal Antibodies   503
Vaccines used in the primary immunisation programme 234
Clozapine 214
Novel Anticoagulants (NOACs)  136
Human Papilloma Virus (HPV) Vaccine   131
Tyrosine Kinase Inhibitors    94
Fingolimod            74
Interferon Beta     55
Bortezomib 41
Selective Serotonin Re-uptake Inhibitor (SSRI) Antidepressants 40
 
Product(s) Reports with a  
 fatal outcome
Clozapine 14
Denosumab 9
Rivaroxaban 8
Dabigatran 5
Darbepoetin alfa 4
Mefloquine 4
Escitalopram 4
Pregabalin 4
Sorafenib 4
Palivizumab 4
 
Online Reporting 
The online reporting system, available to healthcare 
professionals and patients / consumers, continued 
to be used during 2013 with some 459 reports 
submitted via our website by year end.
During 2013, the IMB continued to report all 
suspected serious adverse reactions occurring in 
Ireland electronically via EudraVigilance to the EMA.
Monitoring Compliance with  
Pharmacovigilance Obligations
Company / sponsor compliance with 
pharmacovigilance obligations is continuously 
monitored and the associated inspection programme 
continued in 2013. Inspections are jointly carried 
out by IMB pharmacovigilance and compliance 
colleagues with the pharmacovigilance team 
participating in four inspections during the year  
(see also Inspections and Audits on page 45).
 
VIGILANCE ASSESSMENT  
AND RISK MANAGEMENT
Vigilance assessment activities encompass particular 
aspects of benefit-risk management of medicines 
throughout the product lifecycle and include the 
evaluation of periodic safety update reports, risk 
management plans, and protocols and reports related 
to post-authorisation safety studies. These activities 
also include signal management, the approval of 
direct healthcare professional communications 
and educational materials for use by healthcare 
professionals and patients. In respect of a number 
of these activities, the IMB acted as rapporteur or 
co-rapporteur via the EMA’s Pharmacovigilance Risk 
Assessment Committee (PRAC).
Signal Management Activities
The IMB continued to contribute to work-sharing 
for signal detection within the EU during 2013 and 
acted as the lead in the detection and management 
of signals for 58  active substances. The IMB retained 
the responsibility for assessing any signals arising as a 
result of signal detection  for 21 centrally authorised 
active substances (or combination of active 
substances) incorporating 34 authorised products 
for which IMB is rapporteur. The PRAC, which was 
established in July 2012, played a critical role in 
the prioritisation of potentially new or changing 
signals and in making recommendations for further 
investigation or for labelling changes. During its 
first 12 months of operation, the PRAC evaluated 92 
signals and more than half of these led to labelling 
changes. The IMB was additionally responsible for the 
national implementation of these labelling changes 
for nationally authorised products following the PRAC 
recommendations.  
The IMB also participated in the Signal Management 
Review Team at the EMA on a regular basis which 
focuses on tools, methods and processes for signal 
detection as well as methodological guidance.
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Periodic Safety Update Reports
Periodic safety update reports (PSURs) are vigilance 
documents intended to provide an evaluation of 
the risk-benefit balance of a medicine. They are 
submitted by marketing authorisation holders at 
defined time points during the post-authorisation 
phase. 
During 2013, a new format and content for PSURs was 
required under law and new assessment processes 
have been implemented nationally. The PSUR is 
now a cumulative benefit-risk report rather than 
an interval safety report, thus allowing continuing 
analysis of benefit-risk. 
In addition, the European Union Reference Date 
(EURD) list became binding and further harmonised 
the frequency and dates of submission for PSURs. 
The phased approach for implementation of the EU 
single-assessment procedure commenced in 2013 
and now includes single assessments for products 
authorised centrally and where the active substance 
is authorised both centrally and nationally. The 
outcome of these procedures may lead to automatic 
regulatory action such as variation, suspension or 
revocation. The IMB also actively participated in 
the HMA PSUR work-sharing project, retaining our 
position in the top eight of national competent 
authorities in Europe in terms of lead Member State 
assessment responsibilities. 
During 2013, the IMB evaluated PSURs relating 
to 2,500 medicinal products. This includes PSURs 
submitted as national, mutual recognition, 
centralised, EU single-assessment and PSUR work-
sharing procedures.
Safety Referrals
2013 was a very active year in terms of EU safety-
related referrals with IMB acting as concerned 
Member State in 15 of these procedures. The IMB 
provided the lead on the assessment (as PRAC (co-)
rapporteur) for two of the major safety referral 
procedures. Experience to date has shown that the 
time taken to complete the assessment of referrals 
has fallen with the establishment of the PRAC. For 
example, for one type of EU referral the assessments 
have concluded in less than eight months compared 
to 15 months before July 2012. These prompter, high 
quality assessments allow faster optimisation of safe 
and effective use though drug labelling changes and 
restrictions when necessary.
Risk Management Plans and Risk 
Communications 
Since July 2012, all applications for drug marketing 
authorisations have, by law, had to include a risk 
management plan (RMP) documenting the proposed 
risk management system to be implemented if a 
marketing authorisation is granted. This facilitates 
the balancing of access and evidence with proactive 
planning both of post authorisation studies and risk 
minimisation measures. EU guidance on the format of 
RMPs was revised during 2013 and new assessment 
processes were implemented nationally. In addition, 
applications for new or initial RMPs submitted outside 
another regulatory procedure to national competent 
authorities has changed in line with revised EU 
variations guidelines. 
During 2013, the IMB evaluated 507 RMPs submitted 
as national, mutual recognition, decentralised and 
centralised procedures. The IMB demonstrated 
its continuing commitment to the new European 
pharmacovigilance processes by acting as PRAC 
rapporteur for five new marketing authorisation 
applications during the year.
As part of its role to promote and support the safe 
and effective use of medicines, the IMB reviewed 
and approved 53 Direct Healthcare Professional 
Communications (DHPCs) which provided new safety 
information or risk minimisation advice to prescribers. 
These communications were also published on 
the IMB website. The IMB also approved 71 sets of 
educational materials for distribution to healthcare 
professionals and/or patients.
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Post Authorisation Safety Studies (PASS)
During 2013, the IMB provided assessment input into 
120 post authorisation safety studies (PASS) protocols 
and reports. PASS are non-interventional studies 
carried out in order to obtain further information on 
the safety of medicinal products which are already 
authorised, or to measure the effectiveness of risk 
minimisation activities that have been introduced. 
The results of a PASS help to further evaluate the 
safety and benefit-risk profile of a medicine already 
in use and may have an impact on the marketing 
authorisation of the product.
BLOOD, TISSUES AND CELLS, ORGANS
HAeMovIgIlAnCe
The IMB is the competent authority for legislation 
concerning blood and blood components.
Haemovigilance refers to a set of organised 
surveillance procedures relating to serious adverse 
or unexpected events or reactions in donors or 
recipients and the epidemiological follow-up of 
donors.
The IMB continued its interaction with the National 
Haemovigilance Office (NHO) during 2013, including 
discussion of issues of mutual interest and concern at 
bilateral quarterly meetings. 
Following collaboration with the NHO, the IMB 
submitted an annual report on serious adverse 
reactions and events to the EU Commission during 
2013. The report reflected information received 
during 2012 and included information on 129 serious 
adverse reactions and 117 serious adverse events 
which met the mandatory legislative reporting 
requirements. While these figures reflect a decrease 
of approximately 25% for serious adverse event 
reports compared with the previous year, the overall 
reporting rates remain largely consistent. These 
figures also reflect the impact of changes to agreed 
EU reporting criteria. 
The EU Commission continued to progress 
harmonisation initiatives to develop a common 
approach to the provision of data by Member States 
through a Working Group on Haemovigilance 
first convened during 2007. During 2013, the IMB, 
in collaboration with colleagues from the NHO, 
actively contributed to the development of updated 
guidance.
TISSue And Cell vIgIlAnCe
The IMB is the competent authority in Ireland for the 
purposes of the EU tissues and cells legislation. The 
legislation focuses on standards of quality and safety 
for donations, procurement, testing, processing, 
preservation, storage and distribution of human 
tissues and cells.
There were a number of tissue and cell vigilance 
activities progressed during 2013. 
The three-year project co-funded by the EU Public 
Health group on Substances of Human Origin 
Vigilance and Surveillance (SOHOV&S) was brought to 
a conclusion. The IMB participated as a partner in this 
project which had a primary aim of supporting the 
establishment of effective vigilance and surveillance 
systems for tissues and cells used in transplantation 
and in assisted reproduction. 
The IMB submitted an annual report on serious 
adverse reactions and events, associated with tissues 
and cells to the EU Commission during 2013. The 
report reflected information received in 2012 and 
consisted of some 42 reports associated with use 
of tissues and cells, 38 of which met the legislative 
reporting requirements, including two serious 
adverse reactions and 36 serious adverse events. Both 
these figures represented a very slight decrease in 
reporting rates compared to the previous year. The 
remaining four donor reaction reports, while not 
fulfilling the mandatory reporting requirements, were 
included on a voluntary basis as requested by the 
Commission.   
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The EU Commission continued to progress 
harmonisation initiatives to develop a common 
approach to the provision of data by Member 
States through a Working Group on Tissues and 
Cells Vigilance. During 2013, the IMB continued 
to participate in the development of guidance for 
reporting which was updated during the year.
HuMAn oRgAnS FoR TRAnSPlAnTATIon
The IMB and the Health Service Executive (HSE) were 
appointed as the responsible national competent 
authorities for the legislation on standards of 
quality and safety of human organs intended for 
transplantation in 2012. During 2013, the IMB liaised 
with the HSE lead and colleagues responsible for this 
area in relation to the development of report forms 
and guidance to facilitate serious adverse reaction 
and event reporting. The IMB also shared information 
with the HSE in respect of reports received to date 
and supported appropriate follow up of relevant 
cases.
VETERINARY MEDICINES
PHARMACovIgIlAnCe
Pharmacovigilance is a post-authorisation activity 
designed to ensure the ongoing production and use 
of high-quality veterinary medicines that are effective 
and as safe as possible. The primary inputs into the 
national pharmacovigilance system are reports of 
suspected adverse events received by the IMB from 
marketing authorisation holders, veterinarians and 
the general public.
During the 12 months under review, the IMB received 
272 national reports of suspected adverse events to 
veterinary medicines. Reports received related to the 
following species:  
•	 Bovine	(116)
•	 Canine	(81)	
•	 Ovine	(40)
•	 Feline	(10)
•	 Equine	(5)
•	 Poultry	(5)
•	 Fish	(2)	
•	 Porcine	(2)	
•	 Caprine	(1)		
 
In addition, there were 10 reports of adverse effects in 
humans exposed to veterinary medicines. 
Of the 272 reports of suspected adverse events 
received, a total of 135 involved pharmaceutical 
products and 137 involved immunological products. 
The majority of reports related to the use of a single 
medicine. However, two or more products were 
implicated in 71 reports of which 13 related to the use 
of both pharmaceutical and immunological products 
concurrently. 
Overall, 144 reports involved suspected lack of 
expected efficacy with 114 involving suspected 
adverse reactions in the treated animals. Four reports 
related to violations of approved residue limits.  
As a result of suspected adverse event information 
received during 2013, the IMB requested an 
amendment to information included in the summary 
product characteristics of one product.
Periodic Safety Update Reports
The IMB received 909 applications for periodic safety 
update reports (PSURs) for veterinary medicines in 
2013. This represents a slight reduction of approx 5% 
compared to the 2012 data. 
The IMB completed the evaluation of 1,072 PSURs 
in 2013. This represents year-on-year increase of 
approximately 25%.
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Total PSURs Output 2009-2013 uSe oF veTeRInARy AnTIMICRoBIAlS  
In IRelAnd
Under a European programme known as the 
European Surveillance of Veterinary Antimicrobial 
Consumption (ESVAC), the IMB collects annual 
information on the consumption of antibiotics from 
each marketing authorisation holder. The data  for  
2012  show  that  there was an apparent  increase  in  
the  overall  usage  of  veterinary  antibiotics  of  14%  
(although  the  2011  baseline  might  be  seen  as  low 
by  historical  standards).  Medicated  premixes  and  
other  oral  formulations  that  are  used  primarily  
for  the  medication  of  pigs  and  poultry  account  
for  about  two  thirds  of  total  consumption. This  
consumption  pattern  is  relatively  consistent  with  
that  of  previous  years.  
The IMB continues to work with other EU veterinary 
medicines agencies and the EU Commission to 
help ensure that veterinary antibiotics are used 
responsibly in accordance with their approved 
conditions of use.
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MARKET COMPLIANCE – HUMAN AND 
VETERINARY MEDICINES
The IMB is responsible for a number of risk-based 
market surveillance programmes. These include 
proactive activities such as the sampling and 
analysis programme and the advertising compliance 
programme, and reactive activities such as the quality 
defect and recall programme. 
The IMB also operates an exempt medicinal products 
notification scheme designed to monitor the 
importation and supply of unauthorised medicinal 
products. In addition, we carry out a programme of 
regulatory compliance inspections at the premises 
of marketing authorisation holders. The latter is 
designed to assess the level of compliance against 
national legislation relating to the placing on the 
market and advertising of medicines.
SAMPlIng And AnAlySIS PRogRAMMe
The IMB’s risk based sampling and analysis 
programme is part of our monitoring of the quality 
and safety of medicines and our identification of 
borderline medicinal / non-medicinal products that 
may be on the Irish market. This is achieved through 
analytical testing and / or examination of packaging 
and labelling of medicines, active substances, 
borderline medicinal / non-medicinal products and 
enforcement-related samples. 
A total of 437 product samples were sent for 
analytical testing / examination work during 2013. 
Details are provided in the accompanying tables.
Examination of Packaging and Labelling 
The packaging and labelling of 246 medicinal and 
other products were examined. Of these, 68% 
were subjected to general packaging and labelling 
examinations, with a particular emphasis on the 
adequacy of the required safety and warning 
information on package leaflets. A further 27% 
of products were subjected to Braille compliance 
checks.    
The packaging and labelling of 162 medicines and 
other products available on the Irish market were 
examined. In total, 402 individual checks were carried 
out on the samples including a number relating to 
the safety information on package leaflets.   
36 IMB ANNUAL REPORT 2013
description of products examined                               number of samples examined
Medicines subject to risk-based compliance monitoring  
for packaging and labelling attributes 65
Parallel imported medicines subject to risk-based compliance  
monitoring for packaging and labelling attributes 61
Borderline medicinal/non-medicinal products  
(associated with IMB Classification Committee work) 20
Samples obtained for other IMB work 10
Products subjected to usability checks 6
Total 162
Product categories selected for analytical testing in 2013                           number of samples analysed
                                  Physico-chemical Analysis / Biological Analysis 
Enforcement-related products for human use 70
Nationally authorised medicines for human use 62
Biological active / intermediate pharmaceutical ingredients 35
Centrally authorised medicines for human use 33
Borderline medicinal / non-medicinal products for human use 18
Authorised veterinary medicines 14
Other product categories 20
                                                           Microbiological Analysis 
Nationally authorised medicines for human use 14
Nationally authorised medicines for veterinary use 5
Medicines for human use manufactured for export 4
Total 275
Of the products examined, 86% were authorised 
medicines. All of these products were examined for 
signs of counterfeiting and tampering and no issues 
were identified. The remaining 14% concerned work 
on mainly borderline products. Braille compliance 
checks were carried out on 26% of products while 4% 
were subjected to usability checks. 
Analytical Testing 
There were 275 medicinal and other product 
samples sent for analytical testing. These included 
156 samples sent to governmental laboratories in 
Ireland and 104 sent to Official Medicines Control 
Laboratories (OMCL) in other countries and to the 
European Directorate for the Quality of Medicines 
(EDQM) as part of European working-sharing 
programmes and other collaborations.  
Approximately 49% were authorised medicines, while 
35% related to enforcement and borderline medicinal 
/ non-medicinal products. There were 17 products 
manufactured in Ireland for export tested while 29 
samples were collected by our inspectors during 
inspections abroad.  A small number of exempt 
medicines were tested.  
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Participation in eu Co-ordinated Market 
Surveillance Activities
The IMB is an active participant in EU surveillance 
programmes that involve the sampling and analysis 
of medicines. This is achieved by participation in 
the OMCL network co-ordinated by the EDQM in 
Strasbourg. 
The 2013 programme included: 
•	 Centrally	authorised	medicines:	 
- 29 sampled in Ireland for testing at OMCLs  
 in other Member States and 5 tested at the  
 IMB’s OMCL (Public Analyst’s Laboratory,  
 Galway).  
- 21 of the 34 products were sampled as part of  
 an anti-counterfeiting collaboration.  
•	 MRP/DCP:	 
- 8 MRP / DCP medicines sampled in Ireland  
 and analysed at other Member State OMCLs.  
- 5 MRP/DCP products analysed at the IMB’s  
 OMCL.
•	 Other	products:	 
- A number were analysed at the IMB’s  
 request at OMCLs in other Member   
 States. For example, 23 products underwent  
 microbiological analysis at the Finnish and  
 Czech OMCLs.   
•	 As	part	of	a	European-wide	project,	the	IMB	
organised the analysis of 29 biological samples 
that were obtained during an inspection in China. 
The analysis work was done in collaboration with 
OMCLs in Germany, Sweden, the UK, Denmark 
and Italy.  
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Principal Findings
Findings
While the majority of samples tested were compliant with their specifications,  
29 of out-of-specification results were also obtained.  These included, for example, 
eight products that did not comply with the Ph. Eur. subdivision of tablets test and 
eleven products that did not comply with their assay specification. There were 21 
deficiencies identified in the analytical methods and specification documents used 
by manufacturers of medicines. Appropriate follow-up actions were taken in each 
case.
19 non-compliances were identified across 17 authorised medicinal products and in 
2 borderline medicinal / non-medicinal products. Of these, 13 related to Braille non 
compliances while three related to incorrect information in package leaflets or in 
other product information, including the safety warning information. The final three 
related to unauthorised products that included medicinal claims on the packaging.  
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quAlITy deFeCTS And ReCAllS
The IMB’s quality defects and recalls programme 
investigates, on the basis of risk to public and animal 
health, reports of suspected quality defects in both 
human and veterinary medicines and in their related 
active substances. The IMB also co-ordinates any 
subsequent recall actions on the Irish market. Reports 
are received both nationally and through a global 
network of regulators via a rapid alert system.
number and Types of quality defects 
A total of 774 quality defects were reported to, or 
identified by, the IMB during the past 12 months. 
Medicines for human use accounted for 743 quality 
defect reports with 31 reports concerning veterinary 
medicines. 
The most common categories of defect were:
•	 Stability	issues	(14%);
•	 Non-compliance	with	marketing	 
authorisation (11%);
•	 Contamination	issues	(11%);
•	 Reports	of	undeclared	active	 
ingredients in products (7%);
•	 Lack	of	sterility	assurance	(5%).
These categories are generally consistent with those 
reported in 2012.
The accompanying table illustrates how the various 
quality defect issues were classified in 2013. For 
comparison, the corresponding figures for the 
previous four years are also presented.
Of the total number of defects, 533 were determined 
to affect Ireland. In these cases, the defective batch or 
batches were either on the Irish market and / or were 
manufactured in Ireland. 
Critical quality defects, which are those defects 
defined as potentially life-threatening or a serious 
risk to health, accounted for 235 of the total reports 
received. Of these, 56 were deemed to affect 
Ireland. These included 19 product contamination 
issues, 18 lack of sterility issues and five falsified 
medicine issues. However, in none of the cases was 
a falsified product identified on the Irish market. 
Of the remaining 15 critical cases affecting Ireland, 
one concerned a veterinary medicine, while the 
remainder related to human medicines.  
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year  2009 2010 2011 2012 2013
Minor Quality Defects 147 241 314 236 230
Major Quality Defects 345 332 364 303 300
Critical Quality Defects 105 173 231 189 235
Number of Quality Defect Reports Not Justified 17 5 8 13 9
Total Number Quality Defects 614 751 917 741 774
Sources of quality defects 
As in previous years, pharmaceutical companies  
and other competent authorities accounted for 
the majority of reports of human medicine quality 
defects received.
Recalls of Human and veterinary Medicinal 
Products 
In order to protect the health and safety of patients, it 
is deemed necessary in certain cases to withdraw, or 
recall, products from the Irish market. During the year 
in review, 109 medicine recalls occurred. Of these, 107 
related to human medicines and two to veterinary 
medicines. 
As regards the level of recall, 16% were to patient/
user level, 48% to pharmacy/retail level and 37% to 
wholesale level. 
Exempt medicines accounted for 21% of recalls of 
human medicines while compounded products for 
human use accounted for 11%. Of the total number of 
recalls from the Irish market, 26% related to products 
manufactured at an Irish facility.
The most common causes of a human medicine 
recalls were:
•	 Lack	of	sterility	assurance	(16)
•	 Non-compliance	with	GMP	(15)
•	 Stability	issues	(14)
•	 Non-compliance	with	marketing	authorisation	(11)
•	 Printed	packaging	component	(9)
•	 Non-printed	packaging	component	(8)
•	 Contamination	issues	(7)
In respect of veterinary medicines, one recall related 
to a product mix-up issue and one to a non-printed 
packaging component issue.
ReTAIl SAleS MonIToRIng 
exempt Medicinal Products Programme
Medicines placed on the Irish market must be 
authorised by the IMB or, in the case of centrally 
authorised products, by the European Commission. 
However, European regulations do provide for an 
exemption to this rule. In this case, registered doctors 
and dentists are permitted to prescribe unauthorised 
medicines for individual patients under their direct 
responsibility in order to fulfil the special needs of 
those patients. Such products are defined as ‘exempt 
medicinal products’.
Under the medicinal products Regulations, 
wholesalers and manufacturers of medicines are 
obliged to notify certain information to the IMB in 
relation to any exempt products that they source. 
This is done by submitting electronic notification to 
an IMB database. This information facilitates, when 
required, the effective recall of any defective exempt 
medicine from the Irish market.
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Source of Reports Human Medicines veterinary Medicines
Companies (Manufacturers, distributors and/ 
or marketing authorisation holders) 372 17
Other Competent Authorities (Regulators) 280 13
IMB Staff Members 49 1
Hospital Pharmacists 21 
Community Pharmacists 13 
Patients and/or Members of the Public 6 
Physicians and Nurses 2 
During 2013, 1,290,347 packs of exempt medicines 
were notified. We continue to work with stakeholders 
in several areas to identify and develop solutions 
aimed at limiting the use of exempt medicines in 
Ireland.
general Retail Sale Investigations
The IMB monitors the sale of consumer healthcare 
products by retail outlets such as grocery shops, 
health food shops and, in some instances, 
pharmacies, using a proactive and reactive risk 
based programme. Of the 98 products investigated 
in the past year, 19 were removed from sale as they 
breached medicines legislation in various ways. For 
example, some were unauthorised products while 
others included medicinal claims. 
Regulatory Compliance Inspections 
These risk-based inspections are carried out at the 
premises of marketing authorisation holders. The 
inspection seeks to determine the level of compliance 
with the legal requirements for the marketing and 
advertising of medicines. Three inspections were 
carried out in 2013 and a number of non-compliances 
were identified.  These were followed up and the 
IMB monitored the implementation of corrective 
actions at companies concerned. This inspection 
activity is linked to the IMB’s advertising compliance 
programme.
Human Medicines Advertising Compliance 
Programme
It is important that in the interests of public health, 
the benefits, uses and effects of medicines are 
promoted responsibly. It is the role of the IMB to 
monitor and review advertising and promotion 
activities by the industry for compliance with the 
requirements of the Medicinal Products (Control of 
Advertising) Regulations, 2007.
Just under 400 advertisements were reviewed 
for compliance in 2013. While the majority were 
found to be compliant, a number of non-compliant 
advertisements were also identified. One was 
required to be withdrawn.
The five elements of the programme are shown in the 
table below:
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 Total Advertisements non-Compliances    
  Reviewed Identified
Proactive Monitoring: Pre-planned Projects 12 271* 17 individual advertisements were   
   non-compliant
Proactive Monitoring: Randomly 25 88* 16 individual advertisements were   
Selected Projects    non-compliant
MAH Inspections Performed 3 Multiple Nine major deficiencies identified  
   across a number of areas. Two related  
   directly to advertising activities.
Complaints Received 16 49* Five advertisements were found to   
   be non-compliant
Queries Received 60 45* 12 advertisements were found to   
   be non-compliant
*Note: Some of these figures are approximate. They may include website advertisements, and each page of a website  
 is counted as one advertisement, because multiple pages can have multiple advertisements.  
In all cases of non-compliance identified via the 
different elements of the programme, the IMB 
supervised the adoption of the necessary corrective 
and/or preventative actions by the marketing 
authorisation holder.   
MEDICAL DEVICES
vIgIlAnCe 
The IMB’s reporting system for incidents and Field 
Safety Corrective Actions (FSCA) associated with 
medical devices is intended to protect the health 
and safety of patients, users and others by reducing 
the likelihood of the same type of incident or 
FSCA occurring elsewhere and to correct product 
problems.
 
2013 Reports in Summary 
A total of 2,268 medical device vigilance reports were 
received and assessed representing a slight increase 
on 2012. This continues the upward trend in the 
number of vigilance cases received annually. 
Of the vigilance reports received in 2013, 58% were 
from manufacturers while 37% were received from 
competent authorities. In total, 38% of the reports 
received were as a result of an incident on the Irish 
market.
European regulatory action followed in respect 
of 58% of the reports received. In Ireland, the IMB 
published 543 manufacturer’s field safety notices 
online which directly affected the local market 
representing a 23% increase compared with 2012. 
These notices are intended to inform users of safety 
issues relating to medical devices.  A total of 182 
product removals were conducted in Ireland in 2013. 
Safety information was also highlighted to the public 
through IMB safety notices. There were 16 such 
notices sent to relevant interest groups and published 
on the IMB website. During the year in review, the 
IMB issued 112 national competent authority reports 
which represents a 38% increase on 2012. 
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2013 Reports by Product Type
Orthopaedic implants, due to the continued 
reporting of revision procedures associated with 
the ASR Articular Surface Replacement and ASR XL 
Acetabular system manufactured by DePuy, and 
infusion and transfusion devices accounted for a large 
proportion of vigilance reports received. In addition, 
there were also a number of reported revision 
surgeries in relation to implanted defibrillation leads. 
The accompanying chart outlines the types of general 
medical devices associated with the highest number 
of reports received. 
In the area of in-vitro diagnostic medical (IVD) 
devices, the largest number of vigilance reports 
received related to clinical biochemistry. Field safety 
corrective actions relating to clinical biochemistry 
reagents and analysers continued to have a high 
impact on the number of IVD vigilance cases.
43IMB ANNUAL REPORT 2013
500
450
400
350
300
250
200
150
100
50
0
Orthopaedic 
implants
463
Respiratory
75
Surgical 
equipment
140
Catheter
68
Infusion / 
transfusion / 
249
Diagnostic imaging
71
Active and 
non-active
106
vigilance Reports Received - general Medical devices
180
160
140
120
100
80
60
40
20
0
162
14
32
51
12
Clinical
biochemistry
CoagulationHaematologyMicrobiology Blood transfusion /
transplantation
Immunology
21
vigilance Reports Received - Ivd Medical devices
CoMPlIAnCe
Medical device compliance activities are focused 
on protecting the health and safety of those who 
use medical devices by ensuring that all devices on 
the Irish market comply with the relevant European 
directives. 
In 2013, a total of 665 compliance cases were 
reviewed and managed. Similar to previous 
years, issues identified in the past 12 months and 
investigated as part of compliance cases included 
labelling problems, missing or incorrectly attached CE 
marking and classification issues. Of the total cases 
notified to the IMB, 87% were from other competent 
authorities and mainly related to notified body 
certificate withdrawals.
The IMB finalised a retailer guide in late 2013 on key 
elements of legislation relating to the sale of medical 
devices in Ireland.
MARKET COMPLIANCE OF COSMETICS
PRoACTIve MARkeT SuRveIllAnCe
Post market surveillance of cosmetic products 
includes a national sampling programme and 
involves close co-operation between the IMB and the 
HSE. In this context, the HSE Environmental Health 
Service and the three Public Analysts’ Laboratories 
based in Cork, Dublin and Galway were involved in 
the preparation of the market surveillance schedule 
and the subsequent proactive sampling and analysis 
of cosmetic products on the Irish market. 
The new Cosmetic Products Regulation, EU 
Regulation 1223/2009, came into effect in July 2013 
and introduced good manufacturing practice (GMP) 
requirements for cosmetic product manufacture 
in line with ISO 22716:2007. The IMB undertook 
a pilot GMP inspection programme where three 
manufacturers were inspected to this standard. 
Opportunities for improvement were highlighted as 
an output from these inspections. 
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There is no pre-market approval of cosmetic products 
on the European market and, therefore, the safety 
of cosmetic products is monitored through post 
market surveillance. This includes a review of product 
labelling and of the product information file (PIF). 
The requirement to have a product information file 
in place prior to placing a cosmetic product on the 
market is mandatory and is given legal status by 
Article 11 of the Cosmetic Products Regulation. A 
number of product information files were proactively 
requested by the IMB for technical review.  Labelling 
reviews were also carried out as part of the proactive 
surveillance campaign.
ReACTIve MARkeT SuRveIllAnCe
Reactive surveillance includes investigation of quality 
related complaints (compliance cases) and reports of 
undesirable effects relating to the use of cosmetics 
(vigilance cases). During the year in review, 153 
compliance cases were initiated and these accounted 
for the vast majority of investigations. There were 17 
vigilance cases investigated, while seven products 
were recalled / withdrawn from the Irish market.
Reactive surveillance of cosmetic products also 
includes investigation of incoming RAPEX Alerts 
(EU safety alerts for cosmetic and other consumer 
products). The National Consumer Agency (NCA) is 
the national contact point for Rapex Alerts in Ireland. 
In conjunction with the HSE, the IMB investigated 
111 alerts on the basis of risk and, where appropriate, 
market action was taken. In all, three of the products 
were found on the Irish market. In respect of each 
of these, a reaction report was submitted to the 
European Commission outlining the market actions 
taken.
INSPECTIONS AND AUDITS 
As part of our regulatory role, the IMB is focused on 
ensuring industry compliance with relevant standards 
and legislation. Our inspections and audits work 
programme includes:
•	 Regular	inspections	of	manufacturers	and	
wholesalers of medicines to check for compliance 
to EU guidelines on Good Manufacturing Practice 
(GMP) and Good Distribution Practice (GDP), 
respectively. 
•	 Inspection	of	clinical	trial	sites	for	compliance	
with EU and International Conference on 
Harmonisation (ICH) guidelines on Good Clinical 
Practice (GCP). The GCP inspection programme 
includes inspection of sponsor companies, 
investigators, contract research organisations and 
laboratories and applies to clinical trials approved 
in Ireland and those performed in support of 
national and EU marketing authorisations.
•	 Inspection	for	compliance	with	Good	
Pharmacovigilance Practice of the systems put 
in place by marketing authorisation holders 
for dealing with reports of adverse reactions to 
medicines.
•	 Regular	audit	of	the	NSAI,	the	notified	body	for	
medical devices that is designated by the IMB. 
•	 Proactive	audit	of	manufacturers	of	Class	I	
medical devices and ‘for cause’ audits as required, 
for example, as part of the follow-up to a defect.
•	 Inspection	of	blood,	tissue	and	cells,	and	organ	
establishments for compliance with applicable 
EU guidelines on the quality and safety of blood, 
blood products, tissues and cells, and human 
organs intended for transplantation. 
•	 Inspection,	often	in	conjunction	with	the	Garda	
National Drugs Unit, of manufacturers and 
wholesalers of medicines containing controlled 
drugs (CD) and of precursors (chemicals that 
can be used in the preparation of illicit drugs) to 
check for compliance with security and record-
keeping requirements for these controlled 
substances. 
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oveRvIew oF THe 2013  
InSPeCTIon PRogRAMMe
During the 12 months under review, 313 inspections 
and audits were performed compared to 315 in 
2012 and 300 in 2011. The average number of 
days required to close-out inspections and audits 
conducted was 103.
In the past year, there were:
•	 115	GMP	inspections	carried	out	at	
manufacturing sites. These included 24 
inspections in non-EEA countries, 16 of which 
were carried out at the request of the EMA 
for centrally authorised products. Of the GMP 
inspections carried out, 16% were of active 
substance manufacturers.
•	 126	inspections	performed	to	assess	
compliance with GDP and controlled drugs 
(CD) requirements. Of these, 123 related to the 
distribution of medicines, including controlled 
drugs, and three related to the distribution of 
active substances.
•	 17	GCP	inspections	completed,	of	which	12	
were carried out at investigator sites in Ireland. 
Five inspections related to centrally-authorised 
medicines and were conducted at the request of 
the EMA. One of these took place at a contract 
research organisation (CRO) in Ireland.  
•	 Four	pharmacovigilance	inspections	carried	
out at the facilities of Irish based marketing 
authorisation holders.
•	 19	medical	device	audits	performed.	
 - Two were surveillance audits of the NSAI,  
 the notified body for medical devices in  
 Ireland. One of these audits was carried  
 at the NSAI’s offices in Dublin and was  
 observed by the European Commission’s 
  Food and Veterinary Office (FVO) while the  
 other was performed in the NSAI’s offices 
 in New Hampshire, USA. 
 - Three observed audits of the NSAI   
 were performed at the premises of device  
 manufacturers.
 - Two joint assessment audits were carried  
 out by the IMB in conjunction with the FVO  
 for assessment of designating authorities for  
 medical devices outside of Ireland. 
 - Three audits were performed of  
 authorised representatives of medical  
 device manufacturers and three were  
 performed of manufacturers of custom  
 made medical devices. There were also three  
 audits of in-vitro diagnostic manufacturers  
 and the remaining three audits were of  
 general medical device manufacturers.
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Performance Results and Statistics   2009 2010 2011 2012 2013
No. of national inspections and audits performed 238 293 271 289 279
No. of foreign inspections and audits performed 28 30 29 26 34
% inspections and audits closed on time (≤ 90 days) 58 62 66 61 63
Average time for close-out (days) 112 194 79 76 103
•	 10	blood	establishment	inspections	completed.	
These included six inspections of facilities 
maintained by the Irish Blood Transfusion Service 
(IBTS) and an inspection undertaken at the 
request of the Medicines Authority of Malta of its 
National Blood Transfusion Service. 
•	 16	tissue	establishment	inspections	carried	out.
•	 Three	inspections	carried	out	to	assess	
applications for authorisation for establishments 
involved in organ transplantation.
•	 Three	GMP	inspections	conducted	at	cosmetics	
manufacturers in Ireland as part of a pilot 
inspection programme.
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ENFORCEMENT 
Illegal activity involving the manufacture, supply and 
sale of medicines or medical devices can potentially 
have consequences for public health. It is the role of 
the IMB to investigate potential breaches of human 
medicinal product, medical device and the majority 
of other legislation within its remit. Where necessary, 
we will take the appropriate corrective action 
including possible legal proceedings.
enFoRCeMenT CASeS And deTAIned 
MedICIneS
In 2013, a total of 3,932 enforcement cases were 
initiated by the IMB, compared to 3,911 for 2012. 
While this represents a stabilisation on the number 
of cases being initiated, the number of dosage units 
detained increased to 919,965. This represents a 20% 
increase in the numbers of units, such as tablets and 
capsules, when compared with 2012. The profile of 
the detentions changed in comparison to 2012 also 
with sedative products accounting for 51% (19% in 
2012) of detentions and weight loss products and 
erectile dysfunction products accounting for 19% 
(20% in 2012) and 11% (6% in 2012), respectively. 
This may be partly explained by detections of larger 
quantities of sedative products during inter-agency 
operations by the IMB, Revenue’s Customs Service 
and An Garda Síochána. The majority of these illegal 
supplies appeared to originate from China, USA, India 
and UK.  
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year 2009 2010 2011 2012 2013
Product detained 494,502  822,484 762,641  758,276  919,965   
 Dosage Units Dosage Units Dosage Units Dosage Units Dosage Units
Cases opened 3,729 3,936 4,549 3,911 3,932
Prosecutions 2 5 9 9 9
Product destroyed 2,601kg 1,400kg 4,519kg 1,065kg 4,194kg
Summary of IMB 2013 enforcement data
InTeR-AgenCy Co-oPeRATIon And 
PAngeA vI
The IMB continues to liaise with other enforcement 
agencies, both nationally and internationally, 
to prevent and detect the unauthorised flow of 
medicines and medical devices.  Co-operation 
with Revenue’s Customs Service and with An 
Garda Síochána continued as evidenced by the 
joint approach in advance of Operation Pangea VI 
and during its execution in September. This global 
initiative, co-ordinated by INTERPOL, to identify and 
act against illegal websites supplying falsified and 
illegal medicines, involved 200 national agencies 
worldwide from 99 countries. It led to the detention 
in Ireland of nearly 200,000 tablets and capsules with 
an estimated value in excess of over €600,000.
dISTRICT CouRT PRoSeCuTIonS
The IMB initiated nine prosecutions in the District 
Courts during the course of 2013. This is the same 
number of prosecutions as for 2011 and 2012.
The offences involved included the;
•	 Importation	of	medicines	without	manufacturing	
authorisations;
•	 Supply	of	prescription	only	medicines	without	
prescriptions;
•	 Procurement	and	supply	of	prescription	only	
medicines without marketing authorisations;
•	 Wholesale	of	medicines	without	a	wholesaler’s	
authorisation;
•	 Advertising	of	prescription	only	and	
unauthorised medicines.
Products containing active substances indicated 
for mood stabilisation, sports performance 
enhancement, erectile dysfunction and weight loss 
were included in these prosecutions.
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LEGISLATIVE AND REGULATORY 
DEVELOPMENTS
The remit and role of our organisation continues to change 
and expand in line with national and European legislative 
changes and in response to the addition of further 
competencies. 
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This section of the 2013 annual report outlines 
the most significant legislative and regulatory 
developments during the past year for each of the 
healthcare products we regulate, how these changes 
influenced the work of the IMB and, where relevant, 
the associated impact on stakeholders.
Details are also provided of the IMB’s significant 
programme of work carried out under the Irish 
Presidency of the Council of European Union, a six 
month period during which Ireland was at the centre 
of decision-making in Europe. 
IRISH PReSIdenCy oF THe CounCIl oF THe 
euRoPeAn unIon
The Irish Presidency was a considerable area of 
focus for the IMB from January to June 2013. In total, 
we hosted 22 meetings during this period with 
approximately 1000 delegates visiting Ireland for IMB 
organised events. 
Each meeting was focused on contributing to the 
overall Irish and European objective of ensuring 
public health through co-operation, consistency 
and development of standards throughout Europe. 
Overall, the IMB’s contribution to the Presidency 
was considered highly successful with very positive 
feedback received from participants and, critically, 
essential progress made in respect of a number of 
important regulatory issues.
The IMB’s Presidency programme included a number 
of joint meetings, which brought together key 
European committees and organisations to discuss 
a range of current regulatory issues. Of particular 
note, was the first joint meeting of CHMP, PRAC 
and CMDh which are the three key committees 
with responsibility for the authorisation and safety 
monitoring of human medicines. The Irish Presidency 
also included the first ever combined meeting of 
both the HMA and the Competent Authorities for 
Medical Devices (CAMD). During this meeting the 
IMB also facilitated medical devices and veterinary 
medicines stakeholder meetings. 
In addition, the IMB’s contribution to the Presidency 
included the provision of a high level of support 
to the Department of Health in its chairing 
of the European Council’s Working Party on 
Pharmaceuticals and Medical Devices. This working 
party had a substantial work programme during 
the Irish Presidency with two proposals for medical 
devices Regulations, the Regulation on clinical 
trials of medicinal products, and the transparency 
legislation before the Council. A total of seven days 
of meetings of the Council working party were 
specifically dedicated to discussions of the medical 
devices proposals. In addition, the Irish Presidency, at 
the request of the Council working party, convened 
an additional seven days of meetings of an ad hoc 
group of experts in medical devices to discuss the 
technical aspects of the relevant Annexes to the 
proposals.
In relation to the Clinical Trials proposals, the Irish 
Presidency held 10 meetings of the Council Working 
Party on Pharmaceuticals and Medical Devices 
dedicated to the Clinical Trials dossier.
The IMB provided expert support to the Department 
of Health for its period as chair of the Council working 
party meetings, and directly chaired the additional 
expert group meetings.
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HUMAN MEDICINES
HeAlTH (PRICIng And SuPPly oF MedICAl 
goodS) ACT 2013 
The Health (Pricing and Supply of Medical Goods) 
Act 2013 came into effect in June. This Act outlines 
the circumstances under which medicines are 
considered interchangeable (often referred to as 
generic substitution). The purpose of the legislation is 
to provide for generic substitution of medicines that 
are considered interchangeable so that a pharmacist 
can dispense a less expensive medicine than the 
one prescribed. During 2013, the IMB collaborated 
closely with the Department of Health and HSE in the 
implementation of this legislation. 
The IMB is responsible for the establishment, 
consultation, publication and maintenance of a list 
of interchangeable medicinal products which will 
be grouped together under their respective active 
substance, strength and pharmaceutical form(s). 
The process for publishing the list of interchangeable 
medicinal products was commenced in August 
2013 and work on extending the list will continue 
for the foreseeable future. In conjunction with the 
Department of Health and the HSE, 40 priority 
substances for inclusion on the list have been 
identified. The approach to the generation of the list 
has been determined on the basis of maximising cost 
benefit to the State and to patients.  
During 2013, the IMB published 11 active substances 
to the interchangeable list which is maintained on 
the IMB website. In each case, the IMB consulted with 
the relevant marketing authorisation holders prior to 
adding a medicine or a group of medicines to the list. 
The IMB also supported the various communications 
initiatives introduced to raise awareness and 
understanding of generic and interchangeable 
medicines.
The IMB continues to engage with the Department 
of Health and the HSE to ensure that the approach 
on interchanging medicines and generic substitution 
remains focused on the context of the wider national 
health system needs.
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ReSPondIng To MedICIneS SHoRTAgeS
During 2013, the IMB continued to collaborate 
closely with the Department of Health and the 
HSE in relation to the management of shortages 
of medicines within the Irish market place. One of 
the mechanisms used by IMB to aid continuity of 
supply to the market place in the event of a shortage 
includes the granting of a temporary authorisation 
for a batch (or batches) of a product known as a 
‘batch specific request’. During 2013, IMB issued 152 
such requests to prevent or alleviate shortages.
ongoIng IMPleMenTATIon oF eu 
PHARMACovIgIlAnCe legISlATIon
The IMB continued its work with stakeholders 
including the EMA, other national regulators and 
industry to support the phased implementation of 
the pharmacovigilance legislation. While still in the 
early stages of operation, the initial indicators from 
the introduction of this strengthened legislation 
and the establishment of the PRAC as a public 
health focused body are generally positive. The 
new legislation is resulting in more systematic risk 
management planning, greater coordination of real 
time signal management, and faster assessment and 
decision-making. As a result, there is a strengthening 
of the link between pharmacovigilance assessments 
and regulatory action such as labelling changes to 
optimise the safe and effective use of medicines. 
 
Medicines Subject to Additional Monitoring
During 2013, the EMA published the initial list of 
medicines that are subject to additional monitoring. 
The introduction of the symbol for these products (an 
inverted black triangle) is an important deliverable of 
the new pharmacovigilance legislation. There is also 
a requirement for the inclusion of explanatory text 
in the product information and materials distributed 
to healthcare professional and patients. This 
information outlines why the symbol is present and 
encourages reporting of adverse reactions. 
Specific information for healthcare professionals 
and patients was published on the IMB website and 
related articles were published in a number of health 
publications. A national guideline for marketing 
authorisation holders on the implementation of the 
additional monitoring scheme was finalised by the 
IMB and will be published in January of 2014. 
FAlSIFIed MedICIneS dIReCTIve
In July 2011, the EU adopted new legislation (Directive 
2011/62/EU, amending Directive 2001/83/EC) on 
falsified medicines for human use. The directive 
aims to strengthen the protection of patients and 
consumers by preventing falsified (counterfeit) 
medicines entering the legal supply chain. During 
2013, as part of the progressive implementation of 
the provisions of the Directive, the IMB established 
a registration scheme for manufacturers, importers 
and distributors of active substances and for brokers 
of medicines.   
guIdelIneS on good dISTRIBuTIon 
PRACTICe (gdP) oF MedICInAl PRoduCTS 
FoR HuMAn uSe
Revised EU GDP Guidelines were published by the 
EU Commission on the 7 March 2013 (2013/C 68/01) 
and replaced the GDP Guidelines published in 1994 
(94/C 63/03). These updated guidelines, effective 
from 8 September 2013, were subsequently revised 
again to address a number of typographical errors. 
The updated version (2013/C 343/01) became 
applicable as of 24 November 2013. The guidelines, 
which form the basis for IMB inspections, apply not 
only to wholesalers and manufacturers of medicinal 
products but also incorporate specific requirements 
for brokers involved in activities relating to the sale or 
purchase of medicinal products. 
ongoIng IMPleMenTATIon oF THe 2010 
vARIATIonS RegulATIon 
The provision of the variations regulations which 
relates to the application of European requirements, 
such as timelines and work-sharing, to medicines 
authorised through the national route, came into 
effect in August 2013. The IMB is now applying these 
requirements.  
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new ClInICAl TRIAlS legISlATIon
The European Commission is proposing new 
legislation in an effort to increase the number of 
clinical trials being carried out in Europe. The IMB 
continued to contribute to the consultation process 
surrounding these new proposals during 2013. The 
new regulation is anticipated to be introduced in 
early 2014.
ConTRIBuTIng To THe euRoPeAn And 
gloBAl RegulAToRy neTwoRk
europe
Throughout 2013, the IMB continued to actively 
participate in the European medicines regulatory 
systems. IMB scientific and technical staff contributed 
to a broad range of committees and working parties, 
preparing papers as appropriate, at the European 
Medicines Agency, the European Commission, the 
Heads of Medicines Agencies, and at other fora.
In addition to our regular participation at a European 
level, highlights from the past year included the 
following: 
•	 As	part	of	the	IMB’s	continued	active	contribution	
to the work of the PRAC, the Irish PRAC delegate 
continued to fulfil the role of Vice-Chair of the 
committee.
•	 The	IMB’s	Pharmacovigilance	and	Risk	
Management Lead acted as Regulatory Chair for 
the ICH Implementation Working Group on the 
new E2C R2 guideline on Periodic Benefit Risk 
Evaluation Reports.
•	 IMB	experts	were	significantly	involved	in	
initiatives to facilitate the transition from 
implementation to operation of the new 
EU pharmacovigilance legislation. This 
included participation in a three year EU-wide 
pharmacovigilance project entitled SCOPE 
(Strengthening Collaborations for Operating 
Pharmacovigilance in Europe). The project 
was launched in November 2013 with the aim 
of assisting Member States in operating the 
requirements of the legislation. The IMB will 
also lead the impact assessment topic in a work 
package on risk communications. In addition, the 
IMB is an active participant in a work package 
on lifecycle pharmacovigilance with a particular 
focus on risk management planning and benefit-
risk evaluation through the product lifecycle. 
•	 The	IMB	contributed	to	three	EMA/Member	
State project teams (PT) concerned with 
collection of key information on medicines 
(PT1), better analysis and understanding of data 
and information (PT2), and committees and 
communications with stakeholders (PT3).
•	 The	IMB	continued	its	contribution	to	the	
development of Good Vigilance Practice Modules 
as a member of the project coordination group 
of the HMA European Risk Management Strategy 
Facilitation Group.
world Health organization
The IMB Pharmacovigilance Manager continued to 
represent the World Health Organization (WHO) as 
a member of the Board of the Uppsala Monitoring 
Centre (UMC) and WHO Collaborating Centre for 
International Drug Monitoring during 2013. 
IMB staff also participated at the annual meeting 
of national centres participating in the WHO 
international drug monitoring programme in 
September 2013 and continued to provide details of 
reports received nationally to the WHO for inclusion 
on its international database. 
The volume of adverse reaction reports from Ireland 
continued to fall within the highest reporting rates 
among participating countries (116 full country 
members as of quarter four 2013). As can be seen 
from the accompanying graph, Ireland ranked as the 
twelfth highest reporter for the year during 2013. 
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AdveRTISIng CoMPlIAnCe PRogRAMMe
IMB staff attended and presented at the second 
annual meeting of the Forum on Advertising of 
Medicines (FOAM), which was hosted in London 
by the MHRA. This forum comprises advertising 
regulators from 30 countries including all EU Member 
States. It was set up under the auspices of the HMA.  
FOAM aims to provide a platform to exchange 
information about regulatory practice and about 
advertising cases with cross-border relevance, and to 
share information about how regulatory challenges 
are addressed in different countries.   
AdvISoRy CoMMITTee FoR HuMAn 
MedICIneS
The Advisory Committee for Human Medicines, 
which is appointed by the Minister for Health, 
assists and advises the IMB Board in relation to any 
matters pertaining to the safety, quality or efficacy of 
medicines for human use. The committee met four 
times during 2013 and in addition to considering 
matters referred to it by the Board, it also reviewed 
the licenses for human medicinal products as 
approved by the IMB’s Management Committee. 
There are also a number of sub-committees 
appointed by the Advisory Committee for Human 
Medicines. 
•	 The	Clinical	Trials	Sub-Committee	met	12	times	
during the year. The Committee considered the 
suitability of trials submitted for approval under 
the European Communities (Clinical Trials on 
Medicinal Products for Human Use) Regulations 
2004, (S.I. No. 190 of 2004).
•	 The	Herbal	Medicines	Sub-Committee	met	
twice in 2013. The Committee considered a 
number of matters including the Traditional 
Herbal Medicinal Products Registration Scheme 
and updates from the Committee on Herbal 
Medicinal Products of the EMA.
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VETERINARY MEDICINES
ConTRIBuTIng To THe euRoPeAn 
RegulAToRy neTwoRk
The primary focus of the IMB is on our contribution 
to the work of the Heads of Veterinary Medicines 
Agencies (HMA-V). In addition to quarterly meetings 
of the HMA, there are a number of working groups 
including the European Surveillance Strategy group 
and the Antimicrobial Resistance group to which 
the IMB also contributes. The former is tasked with 
improving the co-operation between Member States 
in respect to work-sharing on periodic safety update 
reports and other pharmacovigilance initiatives. The 
latter group is tasked with implementing the HMA 
Strategy and Action Plan on veterinary antibiotics 
and related areas. The IMB was active also in other 
HMA groups, including those relating to new 
legislation and one dealing with timetabling of new 
applications in the centrally authorised system. Many 
of the meetings took the form of teleconferencing 
rather than physical meetings. 
The European regulatory network continues to wait 
for new legislative proposal for veterinary medicines, 
which is being elaborated by the European 
Commission. In recognition that the new legislation 
might not be implemented before 2017, the HMA 
is continuing to examine ways to better cooperate 
under the existing legislative framework, including 
how to improve the efficiency of EU procedures as 
well as how best to control autogenous vaccines.
ConTRIBuTIng To nATIonAl HeAlTH 
InITIATIveS
The IMB met with the Environmental Protection 
Agency (EPA) to discuss the disposal of veterinary 
medicines and spent product in this country. The 
IMB provided the EPA with information on the use of 
sheep dips.  It is expected that the EPA will monitor 
the use of the products concerned over the coming 
years.
The IMB also participated in a working group of the 
Food Safety Authority of Ireland. The task of the 
group is to prepare a report on the risk of antibiotic 
resistance transfer posed by food.
AdvISoRy CoMMITTee FoR veTeRInARy 
MedICIneS 
The Advisory Committee for Veterinary Medicines is 
the IMB’s independent expert committee that advises 
on matters relating to the authorisation of veterinary 
medicines in Ireland. It met three times during the 
course of 2013 and considered such matters as:
•	 An	improvement	in	the	warnings	of	a	vaccine	for	
livestock;
•	 An	application	to	switch	a	method	of	supply	for	
an antiparasitic product for companion animals;
•	 The	IMB	policy	on	the	supply	of	veterinary	
vaccines for cattle;
•	 The	annual	report	of	suspected	adverse	reactions	
to veterinary medicines in Ireland for 2012;
•	 The	annual	report	on	the	consumption	of	
veterinary antibiotics in Ireland for 2012;
•	 The	peer	review	of	various	applications	that	had	
been considered previously by the IMB.
MEDICAL DEVICES
RevISIon oF euRoPeAn MedICAl devICeS 
dIReCTIveS
Negotiation on the two proposed regulations on 
medical devices and in-vitro diagnostics continued 
in 2013 during and after the Irish Presidency of the 
European Council. The aim of the two proposals is to 
provide a legislative framework for the manufacture 
and placing on the market of medical devices and 
in-vitro diagnostic devices to ensure a high level of 
protection for patients and healthcare professionals. 
Both proposals are large and complex but represent 
significant development and improvement in 
comparison to the existing legislation. 
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It is not yet certain when agreement on the 
legislative proposals will be reached. The proposals 
are subject to the ordinary legislative process so 
require examination both at the European Council 
and the European Parliament levels. 
The IMB has contributed extensively over the past 
number of years to working groups and subgroups 
focused on the development of the expected new 
regulatory system and we will continue to support 
the Department of Health in this regard as required.
euRoPeAn CoMMISSIon’S JoInT PlAn FoR 
IMMedIATe ACTIonS on MedICAl devICeS
In February 2012, the European Commissioner 
for Health and Consumers wrote to all European 
Ministers for Health outlining a ‘joint plan of 
immediate actions’ with the objective of reinforcing 
the existing regulatory system for medical devices 
in advance of the proposed revision to the medical 
devices legislation. The plan outlined actions for 
Member States and the Commission in the areas of 
functioning of notified bodies, market surveillance, 
coordination, communication and transparency. In 
advance of the legislative proposal being finalised, 
the IMB remains committed to contributing to the 
joint plan. 
oversight and Performance of notified Bodies for 
Medical devices
Under the joint plan, the performance of notified 
bodies for medical devices and their oversight was 
subject to significant attention and development at 
European level during 2013. 
In January, a joint assessment scheme for notified 
bodies for medical devices was implemented 
across Europe on a voluntary basis. The IMB helped 
establish a subgroup of the European Notified Body 
Operations Group (NBOG) to plan this scheme, 
develop common criteria, documents and guidance 
and coordinate the joint assessments. This scheme 
required the national authority in each Member 
State (that was responsible for the oversight of a 
notified body that certified the highest risk (class 
III) medical devices) to be accompanied during a 
notified body audit by a joint assessment team. The 
joint assessment team comprises of European expert 
assessors of notified bodies, experts from other 
Member State’s national authorities and from the 
European Commission’s health inspection division, 
the Food and Veterinary Office (FVO). 
During 2013, 21 of the 23 countries responsible 
for class III notified bodies were subject to joint 
assessment while the remaining two will be 
completed in 2014. The IMB directly participated 
as experts in five joint assessments of EU notified 
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bodies in 2013. Further contributions are planned 
for 2014. The IMB was also subject to a successful 
joint assessment in their surveillance audit of NSAI in 
December 2013. 
This joint assessment scheme will now continue on 
an ongoing mandatory basis in accordance with 
a new Regulation on notified bodies which was 
published and came into effect in the last quarter  
of 2013.
There has been extensive consultation with NSAI 
and with both the Department of Health and the 
Department of Enterprise, Jobs and Innovation, to 
discuss the implications for notified bodies of the 
near future and medium term legislative changes.
Market Surveillance
At EU level, the joint plan has also resulted in a 
review of activities conducted by Member States in 
the area of market surveillance. This has provided 
a platform from which a coordinated approach 
to surveillance can be developed and allows for 
enhanced co-operation and targeted proactive 
market surveillance, including joint activities. To 
ensure we fully contribute to these developments, 
the IMB has set out a re-development proposal for 
its market surveillance activities to include greater 
emphasis on proactive and reactive surveillance 
across the product life-cycle. This revised approach 
will be implemented in 2014. 
Another area of focus for the IMB includes building 
capability to meet future requirements of the joint 
plan and Implementing Regulation 920/2013 in the 
medium term and the new legislative requirements 
in the longer term.
ConTRIBuTIng To THe euRoPeAn And 
gloBAl RegulAToRy neTwoRk
Co-operation between the HMA and the 
Competent Authorities for Medical devices 
networks
The IMB continued to promote discussions during 
2013 on developing co-operation and partnership 
between the HMA and Competent Authorities 
for Medical Devices (CAMD) which are the inter-
authority networks for medicines and medical device 
competent authorities respectively. Although these 
networks represent distinct regulatory frameworks, 
there are many aspects and technologies that 
are of common interest. In addition, the systems 
and structures around these networks could be 
developed for mutual benefit.
enhancing and Resourcing the european Medical 
devices Regulatory network
The IMB is participating in the inter-authority 
taskforce which was established under the Irish 
presidency and has been mandated to review the 
structures and functioning of the existing European 
devices regulatory system with a view to bringing 
further enhancements.
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The IMB also continued to engage actively during 
2013 in discussions with other European competent 
authorities, the European Commission and relevant 
stakeholders on how to optimise resourcing of the 
network for medical device regulation in Europe. 
These discussions included significant dialogue 
with the medical device industry associations and 
involved examination of methods to change current 
funding models for medical device regulatory 
authorities to fee-based models. 
enhancing the International Medical device 
Regulatory network
During 2013, the IMB was invited to join the 
management committee of the International Medical 
Device Regulators Forum (IMDRF). This forum 
includes regulators from Australia, Brazil, Canada, 
China, the EU, Japan, the Russian Federation and 
the US. It seeks to promote the harmonisation of 
medical device regulation across the globe. This is 
an important development in terms of the IMB’s 
contribution to the international network. 
The IMB also continued to actively participate in 
IMDRF and associated working groups during the 
past year. These working groups are focussed on 
progressing specific initiatives which are aimed at 
harmonising the global regulation of areas such as 
product submission and UDI requirements.
AdvISoRy CoMMITTee 
FoR MedICAl devICeS 
The Advisory Committee for Medical Devices 
met three times in 2013. Regular updates were 
provided on key medical device issues, regulatory 
developments, the revision of the medical devices 
legislation and IMB activities in regulating medical 
devices. 
The Committee also invited a number of external 
stakeholders, such as academic researchers, to make 
presentations to the Committee in respect of their 
activities.
ADVANCED THERAPIES 
An advanced therapy medicinal product (ATMP) 
is a biological medicinal product which is a gene 
therapy medicinal product, a somatic cell therapy 
medicinal product or a tissue engineered product.  
This definition is set out in Directive 2001/83/EC, 
as amended to reflect new innovative therapeutic 
products. Given their innovative nature, applications 
for marketing authorisations for advanced therapy 
products proceed through the centralised procedure 
in accordance with Regulation 726/2004/EC.  
During 2013, the IMB continued to actively 
participate in the EMA’s Committee for Advanced 
Therapies (CAT). The IMB’s internal group on 
biological products and ATMPs also continued to 
meet regularly as a forum for information exchange 
and for discussion of topics relevant to the regulation 
of ATMPs, blood, tissue and biological products. 
The IMB’s guide to hospital based manufacturers of 
ATMPs was published in February 2013.
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PRECURSOR CHEMICALS
During 2013, amendments were made to the 
two main European Regulations on precursor 
chemicals (Regulations (EC) No. 273/2004 and 
No. 111/2005). The amending regulations are 
Regulation (EU) No. 1258/2013 and Regulation (EU) 
No. 1259/2013 respectively. The main objective of 
these amendments is to strengthen the rules for 
registration and licensing of operators and users, in 
order to prevent diversion of scheduled substances 
towards the production of illicit drugs. 
These amendments had an effective date of 30 
December 2013 with the exception of one of the 
requirements relating to category 2A scheduled 
substances which will only become obligatory as of 
30 June 2015.
COSMETICS
In November, the European Union (Cosmetic 
Products) Regulations 2013 (S.I. No. 440 of 2013) came 
into force. These gave full effect to Regulation (EC) 
No 1223/2009 on cosmetic products, which came 
into force in July 2013. These national regulations 
designated the IMB as competent authority for 
cosmetics, allocated powers to the IMB and the HSE 
and set out offences and penalties.
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SCIENTIFIC ANIMAL PROTECTION
The IMB became the competent authority 
responsible for the implementation of Directive 
2010/63/EU on the protection of animals used 
for scientific purposes on 1 January 2013. The 
accompanying national Regulations are set out in SI 
No. 543 of 2012. This authority was transferred from 
the Department of Health which regulated this area 
until 31 December 2012.
During 2013, the IMB further developed the 
operational processes, authorisation procedures, 
policies, application forms and accompanying 
guidelines necessary to implement the requirements 
of the legislation. There was a specific focus on the 
implementation of the 3R principles (reduction, 
refinement and replacement of animal testing). The 
IMB also completed the recruitment of the necessary 
expertise required to fulfil our role as national 
competent authority. 
The IMB continued to interact with the Department 
of Health in relation to the overall implementation 
of the legislation and its potential impact on animal 
research in this country. There was also significant 
engagement with stakeholders within the research 
sector in order to highlight and explain what is 
required of them under the legislation. Engagement 
also commenced in respect of the development of  
an associated fee model for the future. 
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STAKEHOLDER ENGAGEMENT 
AND COMMUNICATIONS 
The IMB is committed to expanding and improving our 
communications activities and to ensuring that all our 
stakeholders have timely access to relevant safety, licensing 
and regulatory information. This commitment is one of our 
core strategic goals and will continue to be an area of focus 
and development over the coming years.
A number of significant communications programmes and 
initiatives took place during 2013.
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STAkeHoldeR engAgeMenT 
Consultative Panel on the Legal Classification of 
Medicines
The Consultative Panel on the Legal Classification 
of Medicines was established in 2011 to consider 
policies relating to the legal classification of human 
medicines and to encourage consultation and debate 
in this area.  The Panel was independently chaired 
and consisted of external representatives drawn from 
a wide range of interested stakeholders including 
patients, healthcare professionals, the Department 
of Health and relevant government agencies. 
The panel concluded its work in 2013 and made 
recommendations to address current unmet needs 
in the availability of non-prescription medicines. The 
IMB is currently working to implement processes to 
address these issues and this is an area of priority 
focus for 2014.
Meetings with Stakeholders – Human Medicines
During 2013, there were a number of meetings held 
with industry representative groups including the 
Association of Pharmaceutical Manufacturers in 
Ireland (APMI), the Irish Pharmaceutical Healthcare 
Association (IPHA), the Irish Health Trade Association 
(IHTA) and Pharmachemical Ireland. These provide 
a forum for discussion of items of mutual interest. 
Among the main topics of discussion were timelines 
and deliverables, interchangeable medicines, 
increasing the submission of THMP applications, 
improving the quality of submissions, GMP and 
market compliance.
There was also one meeting of the Advertising 
Compliance Technical Group which includes 
representatives from the IMB and industry. Issues of 
mutual interest were discussed including clarification 
of the IMB’s interpretation of a number of aspects 
of the Medicinal Products (Control of Advertising) 
Regulations 2007 and anonymised feedback 
on findings from our advertising compliance 
programme.
Meetings with Stakeholders – veterinary 
Medicines
The IMB held several meetings with applicants 
in relation to ongoing or proposed applications 
where IMB is to be the reference member state in 
future European application procedures. We also 
held a number of meetings with the Department 
of Agriculture, Food and the Marine in relation to 
matters of mutual interest and met with a number 
stakeholders from the agricultural sector throughout 
the year.
Meetings with Stakeholders – Medical devices 
Regular meetings with key industry stakeholder 
groups continued during 2013. These included 
meetings with the Irish Medical Devices Association 
(IMDA) and the Irish Medical and Surgical Trade 
Association (IMSTA). These meetings provide the 
IMB with an opportunity to update stakeholders on 
regulatory developments at national and European 
level. They also allow the IMB to be kept up-to-date 
on issues affecting the medical devices industry. 
A key topic for discussion during 2013 was the 
European Commission’s joint plan for immediate 
actions and the ongoing revision of the medical 
devices legislation.
Presentations to Stakeholders
As in recent years, the IMB invested significant time 
in delivering a programme of presentations and 
talks at a range of external stakeholder events such 
as meetings, seminars, conferences and training 
courses. In addition, a programme of presentations 
was delivered to undergraduate and post graduate 
students studying courses related to the role of 
the IMB.
Such presentations contribute to the IMB goal 
of providing stakeholders such as healthcare 
professionals and regulatory professionals with 
access to relevant, up-to-date information. The 
presentations are delivered by IMB staff from across 
the organisation and cover all products and functions 
under our remit. While some are general in nature 
and primarily focused on explaining the role of 
the IMB, others were more specific and dealt with 
specialist areas and/or new regulatory developments. 
A full list of all presentations delivered during 2013 is 
provided in Appendix 2.
evenTS
Irish Presidency of the Council of the european 
union
As outlined earlier in this report, the Irish Presidency 
was a considerable area of focus for the IMB in the 
first half of 2013. We hosted a total of 22 meetings 
during this period with approximately 1000 delegates 
visiting Ireland for IMB organised events. Important 
progress was made across a range of key regulatory 
issues during the Irish Presidency which also included 
a number of joint meetings bringing together key 
European committees and organisations.
european Risk Summit
The IMB, in association with the Irish Presidency of 
the Council of the European Union and with the 
support of the King’s Centre for Risk Management 
and the Nickel Institute, hosted the European Risk 
Summit in Trinity College Dublin on 11 and 12 June 
2013.
This significant event was attended by approximately 
100 Irish and international experts comprising policy-
makers, regulators, governing bodies, industry and 
academia from the chemicals, food, environmental, 
healthcare and pharmaceuticals sectors.
The purpose of the Risk Summit was to discuss the 
advantages of evidence and risk-based rulemaking 
as well as the challenges of formulating European 
directives / regulations and, by extension, national 
legislation on hazard classifications.
The programme included a series of panel discussions 
that highlighted the challenges for risk-based policy 
making in a number of distinct regulatory areas/
issues including:
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•	 Promoting	science	based	regulation	in	Europe	–	
challenges & opportunities;
•	 The	role	of	smart	and	better	regulation:	Lessons	
from the Member States;
•	 Hazard	classifications	and	risk	assessments	–	
implications for regulation;
•	 Applying	the	substitution	principle	–	a	scientific	
analysis with regard to its use in European 
directives and regulations;
•	 Institutional	oversight	for	risk-based	policy	
making – The establishment of the European 
Parliamentary working group on risk.
The meeting also encouraged a fostering of dialogue 
and collaboration among the relevant stakeholder 
community to address the challenges in this area.
Information days and Seminars 
IMB information days and seminars provide 
regulatory guidance and updates to a range of 
stakeholders. As well as presentations from IMB staff 
and, where appropriate, external contributors, the 
events enable all attendees to submit questions, 
seek clarifications and network with colleagues. The 
following events were held during 2013:
•	 A	webinar	event	outlining	the	IMB’s	approach	
to the development of the interchangeable list 
of medicinal products was held in February. 
The topics covered included an overview of 
the approach to stakeholder consultation and 
publication of the lists. The event attracted a 
wide range of industry stakeholders with an 
interest in this area.  
•	 The	IMB	hosted	a	Topra	networking	event	in	
October 2013. This was an evening seminar 
focussed on a number of topics of regulatory 
interest including DCP submissions, the new 
clinical trial regulation and the IMB’s role in 
the development of a list of interchangeable 
medicines.  
•	 A	veterinary	information	day	was	held	on	24	
October 2013. The programme was focused on 
updating stakeholders on recent changes in the 
regulatory framework for veterinary medicines in 
advance of publication of the EU Commission’s 
proposed new legislation in this area. Attendees 
were encouraged to actively contribute to 
discussions and the event also provided an 
opportunity for networking.
•	 DIA	Europe	held	an	information	day	on	the	
new Common European Submission Platform 
(CESP) on 20 November 2013 in co-operation 
with the IMB. CESP provides a simple and secure 
mechanism for the exchange of information 
between applicants (companies) and regulatory 
agencies. This joint DIA/IMB event provided the 
latest information on the CESP system. It focused 
specifically on the practical use of this newly 
implemented solution designed to enable the 
simultaneous delivery of applications to the 
various EU regulatory agencies.
•	 A	PDA	Conference,	in	co-operation	with	the	
IMB, was held in Dublin on 9 and 10 July. The 
Conference was entitled ‘Current and Emerging 
EU Regulations and Inspection Trends’ and 
included a number of IMB presentations. 
BT young Scientist and Technology  
exhibition 2013
For the fourth year in succession, thousands of 
students as well as teachers, parents and members 
of the general public from all over Ireland visited the 
IMB’s exhibition stand at the BT Young Scientist and 
Technology Exhibition. The exhibition took place in 
mid-January in the RDS. 
Our stand focused on building awareness of the 
significant role the IMB plays in protecting public 
and animal health. In particular, the important 
issue of medicines and medical devices safety was 
highlighted. As in previous years, the stand also 
focused on the many interesting science related 
career opportunities that are available in the 
healthcare products industry.
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PuBlICATIonS
guidance documents
IMB guidance documents provide stakeholders, 
primarily from the industry sectors we regulate, 
with advice and direction in respect of legislation 
and regulatory requirements. New and updated IMB 
guidance documents are published regularly on our 
website with alerts issued to website subscribers. 
During 2013, ten new guidance documents 
were published while a large number of existing 
documents were updated. A full list of these 
documents is provided in Appendix 3. 
newsletters
Medicinal Products Newsletter
This newsletter provides regulatory updates for those 
working in the pharmaceutical and cosmetics sectors 
on Irish and European legislation, new/revised IMB 
regulatory publications and stakeholder events such 
as information days. 
Four Medicinal Product Newsletters were published 
during 2013. Topics covered included:
•	 List	of	Interchangeable	Medicinal	Products	
(Generic Substitution); 
•	 Clinical	Trials	–	Reference	Safety	Information	(RSI);
•	 Revisions	to	EU	GMP	Guidance;
•	 New	laws	regulating	the	retail	of	cosmetic	
products;
•	 Clarification	of	the	requirements	for	marketing	
authorisation holders regarding communications 
to healthcare professionals;
•	 Implementation	of	text	highlighting	additional	
monitoring requirements;
•	 Report	on	veterinary	antimicrobial	consumption	
in 2012;
•	 General	sale	wholesale	distributors	-	update	
to the annual compliance assessment report 
and changes to the inspection process and its 
frequency; 
•	 Update	on	the	Variations	Regulation;	
•	 Controlled	drugs	–	Licence	endorsement	
requirements;  
•	 New	EU	Regulation	for	cosmetic	products.	
The newsletter is published on the IMB website 
and issued to those who subscribe to the IMB alerts 
system via our website. 
Drug Safety Newsletter
Seven issues of the IMB’s Drug Safety Newsletter 
were distributed to doctors, dentists and pharmacists 
during 2013. The publication was disseminated via 
both post and electronically until the end of 2013, 
with arrangements made to facilitate electronic only 
distribution from the start of 2014. All issues of the 
Drug Safety Newsletter are also published on the 
IMB website. Topics covered in the past year included 
a wide range of safety issues a full list of which is 
provided in Appendix 3.  
Medical Devices Newsletter 
This newsletter provides regulatory and safety 
updates for those working in the medical devices 
sector and professionals working in the health area 
who regularly use or purchase medical devices. It 
provides updates on Irish and European legislation, 
on safety issues as well as details of IMB medical 
devices publications and stakeholder events. A list of 
the main topics covered during 2013 is included in 
Appendix 3.
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external Articles
Human Medicines
There were 17 articles published in MIMS Ireland 
by the IMB during 2013. One article was published 
each month with the remainder included in special 
supplements. A further two articles were published 
in the Irish Medicines Formulary. In addition, two 
articles on the topic of medicines under additional 
monitoring were published in the IPU Review and the 
Irish Medical Times respectively. 
The full list of topics covered in these articles 
in included in Appendix 3. All articles were also 
published on the IMB website.
Veterinary Medicines
Consistent with our objective to improve stakeholder 
knowledge on the use of veterinary medicines, we 
contributed several articles to the veterinary/trade 
publications - It’s Your Field.
The topics covered in these articles are listed in 
Appendix 3.
Safety warning and notices 
Throughout 2013, the IMB published various warning 
statements and notices on safety issues or benefit/
risk evaluations of human medicines. There were 
53 Direct Healthcare Professional Communications 
concerning human medicines published on the 
IMB website and issued to subscribers. Separately, 
16 medical devices safety notices were sent to the 
relevant stakeholder groups and published online. 
In excess of 500 manufacturers field safety notices 
concerning medical devices on the Irish market were 
also published on the IMB website.  
The PRAC published agendas, minutes, meeting 
highlights, notifications of safety reviews and 
signals throughout 2013 and these were all made 
available via the IMB website. Such transparency in 
medicines regulation is essential in building trust 
among stakeholders, promoting engagement in the 
processes, and aiding understanding of the rationale 
and evidence supporting recommendations and 
actions impacting drugs and care.
Selling Cosmetic Products in Ireland:  
A guide for Retailers
In October, the IMB published a guide for retailers 
informing them of their responsibilities under 
recently introduced European legislation governing 
the sale of cosmetics. The leaflet includes guidance 
on understanding label information, the storage 
and transportation of cosmetics, and the checks 
to perform when buying from suppliers. Advice on 
product recalls and actions to take if a consumer 
experiences a side effect after using a cosmetic 
product is also included.  
All retailers who sell cosmetic products should be 
aware of these new laws. The purpose of the leaflet is 
to bring the changes to their attention and, in doing 
so, assist retailers to meet their legal obligations.
Retailers can download copies of the leaflet from 
www.imb.ie while printed versions can be ordered 
from brochures@imb.ie
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MedIA CoMMunICATIonS
Throughout 2013, we continued our media 
communications programme to proactively 
communicate important safety messages and to build 
awareness of the role of the IMB. We prepared 32 
press releases and statements concerning safety and 
regulatory issues to ensure consumers, healthcare 
professionals and other stakeholders received timely 
and accurate information and advice. In a number 
of instances, these communications resulted in 
national and regional media interviews with an IMB 
spokesperson. 
Among the issues highlighted by IMB press releases 
during the past year were:
•	 Irish	consumers	have	increased	awareness	of	
generic medicines
•	 3	out	of	5	people	read	product	information	for	
prescription medicines
•	 Publication	of	initial	list	of	interchangeable	
medicines containing groups of atorvastatin 
products 
•	 Operation	Pangea	VI	targeting	the	online	sale	of	
falsified and illegal medicines
•	 Advice	on	seasonal	maintenance	of	automated	
external defibrillators (AED)  
The IMB also published a number of press releases to 
highlight successful prosecutions related to the illegal 
supply of unauthorised medicines.
In addition, we responded to a total of 449 queries 
from national, local and specialist media during the 
year. Drafting responses to such queries involves 
subject matter experts from across the organisation. 
BRAnd IdenTITy
The role and functions of the IMB have increased 
significantly over the 17 years since it was established 
in 1996. Consequently, our current name and brand 
identity does not accurately reflect the nature and 
character of our organisation and our identity has 
not evolved in step with our size and expanding 
new areas of responsibility. The current name of our 
organisation also contributes little to supporting 
our strategic objectives which now extend beyond 
medicines alone. 
As a result, it has been decided by the Board of 
the IMB to change the name of the organisation to 
better reflect the range of products and processes 
we now regulate. The new name to the replace the 
Irish Medicines Board is the Healthcare Products 
Regulatory Authority (HPRA). The introduction of 
the new name is provided for in the Health (Pricing 
and Supply of Medical Goods) Act 2013 and it is 
anticipated it will become operational in mid 2014. 
We will also be launching a new corporate website at 
that time.
In preparation for the adoption of the new name, 
the IMB initiated a project to develop a new brand 
identity incorporating a logo and a style guide. The 
latter document provides clear direction on the 
application of the new brand across all platforms and 
publications. This project was completed during 2013.
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PuBlIC ConSulTATIonS
Public consultations enable the IMB to identify the 
needs and expectations of stakeholders so that we 
may incorporate their views into the way our services 
are planned and delivered.
During 2013, the IMB completed public consultations 
on:
•	 Fees	proposed	for	2014
•	 Draft	Guide	to	Cosmetics	for	Responsible	Persons
•	 Draft	Guide	to	Distribution	of	Cosmetic	Products
The IMB also makes submissions to third party 
consultations where the topic is related to or impacts 
our regulatory functions and the broader public 
health agenda. In 2013, we provided comments 
in respect of 8 public consultations from the 
Department of Health, HIQA, the Pharmaceutical 
Society of Ireland, and other bodies. 
weBSITe
The website www.imb.ie is a key component of 
our communications programme. The site includes 
information about the primary functions and 
activities of the IMB while it also facilitates the 
dissemination of information to a wide variety 
of audiences including patients and consumers, 
healthcare professionals and industry personnel. 
We are committed to the continued development 
and enhancement of the website to ensure it is 
easy to navigate and allows users to quickly find 
the content they require. For the second successive 
year, we completed a user feedback survey to 
identify areas for improvement. The results of this 
research are also being utilised in the development 
of our new website – www.hpra.ie – which will be 
a key element of the project to change the name 
of the Irish Medicines Board to the Health Products 
Regulatory Authority. Development of the new site 
began in 2013 with the appointment of a project 
team involving representatives from across the 
organisation. This project will be completed during 
the first six months of 2014.   
2013 Statistics
•	 Almost	225,000	unique	visitors	accessed	
the website during the past twelve months 
representing an annual increase of 32%. There 
was in excess of half a million visits in total.
•	 Of	those	who	accessed	the	site,	39%	were	new	or	
first time users of the site. 
•	 Among	the	most	popular	sections	of	the	website	
were the human and veterinary medicines 
listings, and the new interchangeable medicines 
listing.
Interchangeable and generic Medicines
The Health (Pricing and Supply of Medical Goods) 
Act 2013 provides for the introduction of a system 
of generic substitution and reference pricing 
for authorised medicines. This legislation was 
commenced on 24 June 2013.
The role of the IMB under this legislation is 
to establish, publish and maintain a ‘List of 
Interchangeable Medicines’ on our website. Following 
completion of a consultation process, the initial list 
including interchangeable atorvastatin medicines 
was published on www.imb.ie on 7 August 2013. For 
the remainder of the year, the IMB added a number 
of other active substances to the list and this will 
continue during 2014. Active substances are being 
added incrementally following the appropriate 
consultation process. 
Products are grouped together according to their 
active substance, strength, pharmaceutical form and 
the route of administration. Users of the list can also 
download pdf documents listing the interchangeable 
products for each active substance. The publication 
of this list on our website coincided with the 
development of an easier to use search function.
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FReedoM oF InFoRMATIon
The IMB is subject to the Freedom of Information Acts 
1997 and 2003. The Acts assert the right of members 
of the public to obtain access to official information 
to the greatest extent possible consistent with public 
interest and the right to privacy of individuals. During 
2013, the IMB received 12 Freedom of Information 
requests all of which were non personal.
PARlIAMenTARy AFFAIRS 
oireachtas Joint Committee on Health and 
Children
During 2013, the IMB was invited to attend the 
Oireachtas Joint Committee on Health and Children 
on three occasions. Discussion areas included 
medical devices and the IMB’s role in respect of 
interchangeable medicines. 
Parliamentary questions 
In 2013, the IMB received and responded to 46 
parliamentary questions, half the number received 
in 2012. There were also 76 other requests from 
the Department of Health, other government 
departments or members of the Oireachtas during 
the year. Of the total number of queries (122), the 
three largest categories related to human medicines 
(52), staff and payroll (26) and cosmetics (10). Many of 
the queries relating to human medicines concerned 
the availability or supply of product, market 
shortages, or personal importation.
CuSToMeR SeRvICeS
Approximately 3,000 queries were received and dealt 
with by the customer services team during 2013. 
These included queries from industry representatives, 
healthcare professionals and members of the public. 
Queries were received primarily via email and by 
phone. 
In addition to the queries managed by customer 
services staff, a range of stakeholder queries are 
addressed by specialist staff across the organisation. 
Many of these queries come from healthcare 
professionals requesting information about specific 
medicines. A large number of pre-market queries 
relating to medical devices are also received each 
year. In total, 355 queries were received that related 
specifically to medical devices during 2013.
ReSeARCH
How Consumers Source Medicines Information 
and Related use of the Internet
This Behaviour & Attitudes commissioned research 
involved face to face interviews with 1,000 adults and 
focused primarily on consumers’ views and behaviour 
in respect of:
•	 Sources	of	information	and	advice	on	medicines.
•	 The	use	of	the	internet	as	a	source	of	medicines	
information and possibly supply.
Among the key findings were: 
•	 Two	thirds	of	people	(63%)	state	that	they	always	
read the product information when taking a 
prescription medicine.
•	 One	in	two	people	always	seek	advice	from	a	
healthcare professional before taking a new over 
the counter medicine.
•	 GPs	and	consultants	are	the	most	trusted	sources	
of information on medicines for some six out 
of 10 people (64%) with three out of 10 people 
(31%) citing pharmacists.
•	 Nine	out	of	10	people	(87%)	confirm	they	
understand the product information (leaflets and 
packs) accompanying their medicines.
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In relation to the internet, the results showed that: 
•	 One	in	three	adults	(36%)	with	internet	access	
uses the internet as an information source on 
medicines.
•	 Over	half	(59%)	use	it	to	research	a	particular	
health problem.
•	 Almost	4	out	of	10	people	(37%)	using	online	
channels for information are attempting to 
diagnose health symptoms (self-diagnosis).
•	 Actual	purchase	of	medicines	online	is	low	with	
2% of all adults claiming to have done so which 
equates to approximately 60,000 people. 
Consumer Awareness of and Attitudes Towards 
generic Medicines
Also part of the Behaviour & Attitudes commissioned 
research, the results of this survey showed that there 
is a high level of consumer awareness and acceptance 
of generic medicines. Overall:
•	 Eight	out	of	ten	respondents	(82%)	would	accept	
a generic medicine if offered it by their doctor or 
pharmacist.
•	 Nine	out	of	ten	consumers	(92%)	who	had	
personally used generic medicines said that they 
had a positive experience overall. 
•	 Three	quarters	(72%)	of	consumers	said	they	
were familiar with the term ‘Generic Medicine’.
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ORGANISATIONAL MANAGEMENT 
AND DEVELOPMENT
The IMB is committed to having the requisite corporate functions, 
systems and supports in place to deliver on our public health 
mission. We must be flexible and proactive as an organisation to 
respond to regulatory and other external developments, and to 
adopt necessary changes in how we deliver our services. We must 
also ensure that the highest levels of corporate governance are 
developed and maintained. 
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HuMAn ReSouRCeS 
The IMB’s people management practices and policies 
continue to be central to the achievement of our 
strategic goals and are designed to attract and 
retain the skills necessary to maintain organisation 
capability. The impact of the Haddington Road 
Agreement in 2013 required that we adapt our 
work practices to enable us to manage our human 
resources with the flexibility necessary to respond 
to changing national circumstances. Amongst the 
primary projects and statistics from 2013 were the 
following:
•	 A	significant	focus	of	human	resources	activity	
during 2013 was completion of a business 
requirements phase for the replacement of the 
human resources IT system.  Following selection 
of a suitable vendor via a public procurement 
process, dedicated resources were assigned to 
undertake preparatory work on data extraction 
and cleansing in Q3 2013 in advance of the data 
migration deadline of January 2014. Training 
on the replacement system was scheduled to 
commence in January 2014 with the expectation 
that the system replacement would ‘go live’ by 
June 2014.
•	 The	organisation’s	first	leadership	development	
programme concluded in 2013.  The objectives of 
the programme were:
 - To support the development of managers  
 within IMB, to evaluate the skills they have  
 and  how they are applying them in order  
 to become more effective managers and   
 leaders, currently and in the future to further  
 IMB’s mission;
 - To develop skills and behaviours in line with  
 the IMB’s Leadership Capability Framework; 
 - To foster collaboration across different  
 functions and promote an understanding of  
 cross functional roles and projects.
 As this first programme was conducted on a 
pilot basis, a full review was completed following 
its conclusion. This review recommended the 
commencement of a second programme. The 
subsequent application and selection process 
was concluded in November 2013 and the 
second programme is to commence in January 
2014 with 10 participants. 
•	 The	Human	Resources	department	undertook	
a review of the operation of the performance 
management programme (PDP) process in the 
second half of 2013 which included feedback via 
an all staff survey. An action plan was prepared 
to progress the implementation of outcomes and 
recommendations and this will commence in 
January 2014.
•	 Recruitment	of	staff	in	specialist	areas	related	
to new competencies undertaken in 2012 was 
completed in 2013 in line with Department of 
Health approvals.
•	 Members	of	the	Human	Resources	team	were	
heavily engaged in the management of the 
impact on staff of the introduction of changed 
working hours mandated by the terms of the 
Haddington Road agreement which applied 
to public sector bodies.   These changes also 
included the reduction of salaries for staff with 
effect from July 2013 as well as ongoing deferral 
of incremental payments during the course 
of the agreement. Explanatory workshops 
and individual face-to-face meetings gave 
rise to increased workload between June and 
September 2013. In addition, preparatory work 
was completed in advance of the introduction 
of the Public Service Sick Leave Scheme which 
introduced changes to sick leave arrangements 
for public sector employees scheduled to apply 
with effect from 2014.
•	 The	IMB	for	the	first	time	introduced	an	employee	
assistance programme in September 2013 to 
provide confidential employee support through 
telephone support, face to face counselling and 
the provision of specialist information across a 
broad range of issues.  
•	 The	IMB	continued	to	be	in	compliance	with	the	
3% target set by the Disability Act 2005.
•	 Absence	management	practices	are	in	place	and	
attendance statistics are monitored routinely 
and recorded in both management and Board 
reports. The overall absence rate for 2013 was 
2.07%.
InFoRMATIon TeCHnology And CHAnge 
MAnAgeMenT 
The Information Technology and Change 
Management department is responsible for all 
aspects of organisational technology, data and 
telecommunications. The department also manages 
the IMB Project Management Office and delivers 
specialist business services, including business 
analysis and project management support, both 
within, and external to the organisation.   
The organisational Project Management Office (PMO) 
came into full operation in 2013. The PMO formally 
manages projects and provides IMB management 
with the necessary information to support the 
planning process while ensuring that organisational 
initiatives are fully aligned with corporate strategy.
Technology is recognised as a key component in 
supporting regulatory activities at both national 
and international levels. Over recent years, the IMB 
has played a leading role in developing standards 
and technologies through its engagement with 
programmes at the EMA, the European Commission 
and the HMA forum. The IMB is represented on the 
EU Telematics Management Board and also leads 
a number of key initiatives relating to electronic 
submissions and data standards. The IMB is also 
actively engaged at national level through its 
involvement with the National Health Data Standards 
Committee and in liaison with other relevant 
agencies, such as the HSE, NSAI and HIQA.  During 
2013, the IMB also contributed to the development of 
the eHealth Strategy for Ireland and was recognised 
for its role in developing the national medicines 
catalogue. The IMB also committed to engagement 
with the European Commission’s Horizon 2020 
research programme and will actively seek 
opportunities to contribute over the lifetime of the 
programme.
IMB technologies are strategically positioned to 
support the effective and efficient operation of the 
organisation. Many of the key systems are designed 
to interface with both national and EU systems. 
An example of this is the European EudraVigilance 
system designed to collate adverse reactions to 
medicinal products. In addition, the IMB provides 
data to the HSE to support its pricing and medicines 
substitution processes. In keeping with the 
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government strategy for shared service provision, 
the IMB also provides hosting services to a number of 
organisations, and works closely with organisations 
such as the Office of the Revenue Commissioners. 
European legislation is increasingly focussed 
on the technology elements required to satisfy 
legal requirements. In this context, the IMB must 
continuously review its capability to develop 
appropriate solutions. 
During 2013, there was a strong focus on developing 
the key requirements for the IMB’s new workflow 
technology solutions. This work was completed by 
the end of 2013, with a tender process for the new 
technology due for publication in early 2014. This 
technology is designed to consolidate and replace a 
number of legacy solutions. Work also commenced 
on the selection and implementation of a new HR 
solution and the development of a new website 
which is due for launch in mid-2014. The IT and 
change management team was also very active in the 
development of processes and technology interfaces 
to support the introduction of the interchangeable 
medicines and generic substitution programme by 
Government.
In 2013, work was undertaken on developing IMBs 
stakeholder engagement mechanisms together with 
potential process improvement initiatives relating to 
medical devices, veterinary science and compliance 
areas.   
Common electronic Submission Portal
A key activity for the IMB is the development and 
management of the Common Electronic Submission 
Portal (CESP) on behalf of the wider EU regulatory 
community. We provide technical support through 
the operation of a helpdesk facility and we work 
with all relevant stakeholders throughout the year to 
deliver an optimum solution. 
In 2013, the CESP portal activity levels grew 
substantially, handling over 100,000 submissions on 
behalf of 20 European regulatory organisations and 
many hundreds of pharmaceutical companies.
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CHIeF eXeCuTIve’S oFFICe
The Chief Executive’s Office is responsible for 
communication, strategy and planning, quality 
management and a number of information functions 
for external stakeholders. It also provides the 
secretariat for the benchmarking programme across 
EU medicines agencies.
BeMA
The Benchmarking of European Medicines Agencies 
(BEMA) programme provides assurance to the 
heads of the EU medicines agency network with 
respect to the quality of the systems and practices in 
place in agencies for regulating medicines and is a 
resource for sharing of best practices. The IMB’s chief 
executive is co-chair of the BEMA steering group with 
the head of the Paul Ehrlich Institute in Germany. 
The IMB provides the secretariat for the group and 
is responsible for visit logistics. During 2013, we 
continued to lead the steering group as assessment 
visits were undertaken in this benchmarking cycle. 
The IMB’s own benchmarking assessment visit 
took place in October 2013. It was preceded by a 
self-assessment using the BEMA questionnaire, the 
results of which were sent to the assessors in August. 
The completed self-assessment report formed the 
basis for the assessor’s focus during the visit, during 
which the three assessors from Austrian, Greek 
and UK agencies interviewed senior staff, reviewed 
evidence and rated the ‘maturity’ of the IMB’s 
management and scientific quality systems according 
to a predefined capability maturity model. Several 
proposed ‘best practices’ for our project management 
office, leadership development programme, and 
contribution to the European network were accepted 
by the assessors, who also nominated a further best 
practice in the close link between our strategic and 
business planning objectives and the objectives 
in staff’s individual performance development 
plan. Some ‘opportunities for improvement’ were 
highlighted as actions to enhance the quality of our 
services. 
The IMB is pleased with the outcome of the visit 
which reflected well on the achievements of recent 
years, and with the assessors’ overall compliment to 
the IMB’s strong dedication to quality in general and 
to the BEMA programme in particular.
 
quality Management
During 2013, the IMB’s quality management system 
continued to be extended with respect to a number 
of new functions and legislative requirements. 
These included new and amended processes under 
the falsified medicines Directive, 2011/62/EU, our 
functions for scientific animal protection according 
to the European Union (Protection of Animals Used 
for Scientific Purposes) Regulations 2012, and the 
new competence given to the IMB during 2013 
for the establishment and maintenance of lists of 
interchangeable medicines under the Health (Pricing 
and Supply of Medical Goods) Act 2013.
CoRPoRATe AFFAIRS
2013 was another busy and productive year for 
Corporate Affairs which is responsible for the delivery 
of a number of key service areas to the organisation. 
These include building and accommodation 
management as well as the provision of reception, 
canteen, travel, library and event management 
services. The department also manages legal 
matters, international co-operation and Freedom 
of Information requests. In addition, it provides 
secretarial support to the Board and Committees 
ensuring adherence to best practice in the area of 
corporate governance.
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extension to the IMB offices
The IMB building, Kevin O’Malley House, was 
extended upward by two floors during the course 
of 2012 and 2013 with the certificate of practical 
completion being granted on 12 July 2013. The 
extension of two new floors has ensured that all IMB 
staff can be housed in one building. The project was 
completed to satisfaction on time and under budget 
with four of the existing floors remaining fully in use 
throughout the duration of the build.
event Management
As outlined earlier in this report, the IMB hosted 22 
meetings involving approximately 1000 delegates 
during the Irish Presidency of the Council of the 
European Union. The number of delegates attending 
each meeting varied with the largest events 
taking place in Dublin Castle and the Convention 
Centre Dublin. The logistics for all these meetings 
were organised and managed in-house by an IMB 
team. This included online registrations, venue 
management, onsite support and social events. 
This approach ensured cost effective delivery of all 
these meetings while also allowing IMB staff to deal 
directly with delegates which resulted in very positive 
feedback from attendees.  
In addition, the IMB held three events in 2013 which 
were not related to the European Presidency. These 
were also organised and managed in-house. 
Freedom of Information
During 2013, the IMB received 12 Freedom of 
Information requests (as outlined on page 70). 
Board and Committees
The Corporate Services section provides secretarial 
support to the Board and Committees of the IMB 
and ensures adherence to best practice in the area of 
corporate governance.
•	 The	Board	of	the	IMB	met	seven	times	in	2013	
and considered a number of strategic matters 
including corporate policy, planning and 
finance matters. The latter included monthly 
management accounts, annual budgets and the 
financial statements for 2012. The Board also 
reviewed update reports from the Statutory 
Advisory Committees and the Audit Committee. 
In addition, it noted the licences for all medicinal 
products as approved by the Management 
Committee.
 The number of meetings attended by each Board 
member during 2013 is as follows:
•	 The	Audit	Committee,	a	subcommittee	to	the	
Board, met four times in 2013. Further details are 
provided in the IMB’s Financial Statements for 
2013. 
•	 Also	during	the	year	in	review,	the	Advisory	
Committee for Human Medicines met three 
times, the Advisory Committee for Veterinary 
Medicines met three times and the Advisory 
Committee for Medical Devices met three times.
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Board Member number  number 
 of meetings of meetings 
 held during  attended during 
 the period  the period  
 the member the member 
 was on was on
 the Board the Board 
Mr. Michael D. Hayes 7 7  
(Chair)
Mr. Pat Brangan  7 7
Mr. Wilfred J. Higgins   7 6
Ms. Ann Horan  7 6
Prof. Mary Horgan 7 4
Dr. Elizabeth Keane 7 5
Mr. Brendan McLaughlin 7 7
Mr. Noel O’Donoghue 7 3
Prof. Caitriona O’Driscoll 7 4
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•	 The	Herbal	Medicines	Sub-Committee,	a	sub-
committee to the Advisory Committee for 
Human Medicines, met once in 2013. The Clinical 
Trials Sub-Committee is also a sub-committee to 
the Advisory Committee for Human Medicines 
and it met twelve times in the past year.
•	 The	Legal	Supply	Classification	Committee,	
which is a specially constituted temporary 
subcommittee to the Board, met twice in 2013.
FInAnCe
It is the role of the finance section to manage and 
safeguard the finances of the IMB. It must ensure that 
the IMB fulfils its legislative requirements and applies 
best practice to the governance of its affairs. All 
procedures are carried out using standard operating 
procedures under the quality management system. 
The 2013 financial statements presented in 
conjunction with this report were prepared by 
the finance team and submitted for audit to the 
Comptroller and Auditor General. All financial 
transactions during the period under review are 
reflected and reported upon in these statements 
as is our commitment to the highest standards of 
corporate governance.
oveRvIew oF eneRgy uSAge In 2013
Since 1 January 2011, the IMB, as a public sector body, 
has been required to report annually on its energy 
usage and actions taken to reduce consumption in 
accordance with S.I. 542 of 2009. These regulations 
transpose the Energy End Use Efficiency and Energy 
Services Directive (Directive 2006/32/EC) into Irish 
law.
The IMB uses electricity for lighting, air conditioning 
or heating as required and the provision of hot water. 
Natural gas is used for central heating.
In 2013, the IMB consumed  887 MWh of energy, 
consisting of:
•	 605	MWh	of	electricity;	
•	 0	MWh	of	fossil	fuels;
•	 282	MWh		of	renewable	fuels.
Actions undertaken in 2013
In the past year, the IMB continued to focus on energy 
performance by maintaining framework agreements 
for the supply of both electricity and natural gas. Both 
of these framework agreements were established 
by the Office of Government Procurement (formerly 
the National Procurement Service) for the supply 
of electricity and natural gas to the Irish public 
sector. The agreements are intended to maximise 
volume discounts and provide for reductions in 
administrative and transaction costs for suppliers and 
public sector purchasers. 
IMB cost savings were in the region of 5.3% for 
electricity and 5% for gas (compared to the cost 
of going directly to the market). The organisation 
consumed 27% more energy in 2013 than 2012 as a 
result of extending a live building upwards by two 
floors, populating the floors and some IMB electricity 
being consumed in the building process. 
In 2013, the IMB replaced its single glazed windows 
on the upper floors to more energy efficient double 
glazed windows. On the two new floors, PIR lighting 
and photo sensitive lighting have been installed in 
all areas. In addition, the ventilation system is a heat 
recovery system and the air conditioning is an energy 
efficient three pipe simultaneous heating and cooling 
system incorporating inverter motor control. Dyson 
hand dryers have been installed in seven bathroom 
areas. All of the above will result in greater energy 
savings.
Total energy Savings
In total, initiatives undertaken prior to 2010 and the 
measures outlined above have saved the IMB 117 
MWh on average annually up to and including 2012. 
2013 was an unusual year for the organisation with 
regard to expansion of the building and the energy 
used in the construction phase.  It is anticipated 
that the energy savings from the building work 
undertaken will become visible in 2014.
Actions Planned for 2014
In 2014, the IMB intends to maintain energy 
performance by continuing its participation in newly 
contracted framework agreements for the supply of 
both electricity and natural gas to the public sector. It 
is anticipated that both these framework agreements, 
which will again be accessed via the Office of 
Government Procurement, will deliver savings when 
compared to the costs of going directly to the market. 
It is important to note that the Office of Government 
Procurement contract rates are fixed until the end of 
2014 for electricity and January 31 2015 for gas. 
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BoARd MeMBeRS And oTHeR InFoRMATIon
Board Members: Mr. Michael Hayes (Chairman) 
 Mr. Pat Brangan 
 term expired 31/12/2013; re-appointed 22/05/2014
 Mr. Wilfrid Higgins 
 term expired 31/12/2013; re-appointed 22/05/2014
 Ms. Ann Horan
 Prof. Mary Horgan   *
 Dr. Elizabeth Keane **
 term expired 31/12/2013; re-appointed 22/05/2014
 Mr. Brendan McLaughlin 
 term expired 31/12/2013
 Mr. Noel O’Donoghue
 Prof. Caitriona O’Driscoll
 Dr. Diarmuid Quinlan ***
 
 The Board was appointed by the Minister for Health on 18/01/2011.
 *     Prof. Mary Horgan was appointed on 08/11/2011.
 **   Dr. Elizabeth Keane was appointed on 24/10/2012.
 *** Dr. Diarmuid Quinlan was appointed on 22/05/2014.
 
Bankers: Allied Irish Bank
 1-3 Lower Baggot Street
 Dublin 2
 Bank of Ireland Corporate 
 2 Burlington Plaza
 Burlington Road
 Dublin 2
Solicitors: Eugene F. Collins
 Temple Chambers
 3 Burlington Road
 Dublin 4
Head Office: Kevin O’Malley House
 Earlsfort Centre
 Earlsfort Terrace
 Dublin 2
Auditors: Comptroller and Auditor General
 Dublin Castle
 Dublin 2 
CORPORATE GOVERNANCE
The Irish Medicines Board (the IMB) was established under the terms of the Irish Medicines Board 
Act, 1995 (as amended), and is governed by a Board which was appointed by the Minister for Health. 
The Board of the IMB (the Board) consists of a chairman and eight unremunerated non executive 
members.
The IMB is committed to the highest standards of Corporate Governance and has implemented the 
Department of Finance “Code of Practice for the Governance of State Bodies”. This Code of Practice, 
which was issued to the IMB in January 2002, incorporates many of the principles under which the 
IMB operates, taking account of the size and legal nature of the organisation. 
An updated Code of Practice was published by the Minister for Finance in June 2009, to take account 
of administrative and legislative developments in the corporate governance framework since 2001. 
The IMB has carried out a detailed review of this updated Code, to ensure that its provisions are still 
reflected in the principles under which the IMB operates.
The IMB has in place an extensive Code of Conduct and conflicts of interest policy for all staff, 
committees and Board members. The IMB applies the highest standards of disclosure and 
transparency in respect of interests held by staff, committees and Board members.
AudIT CoMMITTee
The IMB has an audit committee comprising three Board members, which met on 4 occasions during 
2013. This committee is responsible for reviewing internal control matters, together with any other 
issues raised by the external auditors, the Board or management. The external auditor is invited 
annually to meet with the audit committee to brief them on the outcome of the external audit and 
the audit committee meets annually with the internal auditor. In 2013 the internal auditor reported 
to the audit committee on the areas of procurement and payments, banking and finance, and 
financial and asset management.
In 2010 the IMB re-appointed Crowleys DFK as internal auditor to the Board under a three-year 
contract. This contract expired during 2013 and following a competitive tendering process, BDO 
were appointed as internal auditor in January 2014 under a three year contract. The audit committee 
has also been involved with the review of the quality systems as described below.
quAlITy SySTeMS
During 2013, the finance section of the IMB continued the process of implementing and reviewing 
standard operating procedures (SOPs) under the quality management system. This process 
involved a critical review and analysis of internal controls and processes throughout the section 
with particular emphasis on risk management. This system now underpins the internal control 
environment and feeds into the internal audit process and ultimately into the audit committee.
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ReMuneRATIon PolICy - BoARd MeMBeRS And eXeCuTIve dIReCToRS
Remuneration and travel expenses paid to Board members are disclosed in note 17 to the 
financial statements. The Chairman receives remuneration as directed by the Minister for Health in 
accordance with the Irish Medicines Board Act, 1995. Other Board members receive travel expenses 
in accordance with circulars issued by the Department of Health. The Chief Executive is remunerated 
in accordance with guidelines issued from Government and other Executive Directors are paid in 
accordance with Department of Health pay scales. 
ReMuneRATIon CoMMITTee
The IMB has established a remuneration committee as a sub-committee of the Board to review the 
remuneration of the Chief Executive, in accordance with guidelines issued by the Department of 
Finance and the Department of Health. The Chief Executive’s remuneration is disclosed in note 18 to 
the Financial Statements.
InTeRnAl ConTRol
The Board is responsible for the IMB’s systems of internal control. Such systems can only provide 
reasonable and not absolute assurance against material misstatement or loss. The systems of 
internal controls in use in the IMB are described more fully in the Chairman’s report on page 4.
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STATeMenT on InTeRnAl FInAnCIAl ConTRolS
1. I, as Chairman, acknowledge that the Board is responsible for the body’s system of internal 
financial control.
2. The IMB system of internal financial control can provide only reasonable and not absolute 
assurance against material error, misstatement or loss.
3. The Board confirms that there is an ongoing process for identifying, evaluating and managing 
the significant risks faced by the IMB. The IMB maintains a risk register which is reviewed and 
updated by management, considered by the audit committee and presented to the Board.
 Management are responsible for the identification and evaluation of significant risks applicable 
to their areas of business together with the design and operation of suitable internal controls. 
These risks are assessed on a continuing basis and may be associated with a variety of internal 
or external sources including control breakdowns, disruption in information systems, natural 
catastrophe and regulatory requirements. These risks are recorded in the risk register.
 Management reports fortnightly on operational issues and risks and how they are managed 
to the Management Committee. The Management Committee’s role in this regard is to review 
on behalf of the Board the key risks inherent in the affairs of the IMB and the system of actions 
necessary to manage such risks and to present their findings on significant matters via the Chief 
Executive to the Board.
 The Chief Executive reports to the Board on behalf of the executive management on significant 
changes in the work of the IMB and on the external environment, which affects significant 
risks. The Director of Finance and Corporate Affairs provides the Board with monthly financial 
information, which includes key performance indicators. Where areas for improvement in the 
system are identified, the Board considers the recommendations made by the Management 
Committee.
 An appropriate control framework is in place with clearly defined matters which are reserved 
for Board approval only or, as delegated by the Board, for appropriate Management Committee 
approval. The Board has delegated the day-to-day management of the IMB and established 
appropriate limits for expenditure authorisation to the Management Committee. The Chief 
Executive is responsible for implementation of internal controls, including internal financial 
control.
 The system of internal financial control is monitored in general by the processes outlined above. 
In addition, the Audit Committee of the Board reviews specific areas of internal control as part of 
their terms of reference.
4. The Board have carried out a review of the effectiveness of internal financial control, in order to 
demonstrate compliance with the Code of Practice. This review was carried out at its meeting on 
5 June 2014.
Mr. Michael Hayes 
Chairman to the Board
Date: 30 June 2014
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STATEMENT OF BOARD MEMBERS’ RESPONSIBILITIES
The Board is required by the Irish Medicines Board Act, 1995 to prepare financial statements for each 
financial year which give a true and fair view of the state of affairs of the IMB and of its surplus or 
deficit for that period.
In preparing those statements the Board is required to:
•	 select	suitable	accounting	policies	and	apply	them	consistently
•	 make	judgements	and	estimates	that	are	reasonable	and	prudent
•	 disclose	and	explain	any	material	departures	from	applicable	accounting	standards,	and
•	 prepare	the	financial	statements	on	a	going	concern	basis	unless	it	is	inappropriate	to	presume	
that the IMB will continue in existence.
The Board is responsible for keeping proper accounting records which disclose with reasonable 
accuracy at any time the financial position of the IMB and which enable it to ensure that the financial 
statements comply with the IMB Act and with accounting standards generally accepted in Ireland.  It 
is also responsible for safeguarding the assets of the IMB and hence for taking reasonable steps for 
the prevention and detection of fraud and other irregularities.
 
  
On behalf of the Board
Chairman Board Member
Mr. Michael Hayes Mr. Wilf Higgins
Date: 30 June 2014
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COMPTROLLER AND AUDITOR GENERAL 
REPORT FOR PRESENTATION TO THE HOUSES OF THE OIREACHTAS
I have audited the financial statements of the Irish Medicines Board for the year ended 31 December 
2013 under the Irish Medicines Board Act, 1995. The financial statements, which have been prepared 
under the accounting policies set out therein, comprise the accounting policies, the statement of 
income and expenditure, the balance sheet, the cash flow statement and the related notes. The 
financial statements have been prepared in the form prescribed under Section 18 of the Act, and in 
accordance with generally accepted accounting practice in Ireland as modified by the directions of 
the Minister for Health in relation to accounting for superannuation costs.
ReSPonSIBIlITIeS oF THe BoARd
The Board is responsible for the preparation of the financial statements, for ensuring that they give 
a true and fair view of the state of the Board’s affairs and of its income and expenditure, and for 
ensuring the regularity of transactions.
ReSPonSIBIlITIeS oF THe CoMPTRolleR And AudIToR geneRAl 
My responsibility is to audit the financial statements and report on them in accordance with 
applicable law.
My audit is conducted by reference to the special considerations which attach to State bodies in 
relation to their management and operation.
My audit is carried out in accordance with the International Standards on Auditing (UK and Ireland) 
and in compliance with the Auditing Practices Board’s Ethical Standards for Auditors.
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SCoPe oF AudIT oF THe FInAnCIAl STATeMenTS
An audit involves obtaining evidence about the amounts and disclosures in the financial statements, 
sufficient to give reasonable assurance that the financial statements are free from material 
misstatement, whether caused by fraud or error. This includes an assessment of
•	 whether	the	accounting	policies	are	appropriate	to	the	Irish	Medicines	Board’s	circumstances,	
and have been consistently applied and adequately disclosed.
•	 the	reasonableness	of	significant	accounting	estimates	made	in	the	preparation	of	the	financial	
statements, and
•	 the	overall	presentation	of	the	financial	statements.
I also seek to obtain evidence about the regularity of financial transactions in the course of audit.
In addition, I read the Board’s annual report to identify material inconsistencies with the audited 
financial statements. If I become aware of any apparent material misstatements or inconsistencies, I 
consider the implications for my report.
oPInIon on THe FInAnCIAl STATeMenTS
In compliance with the directions of the Minister for Health, the Board accounts for the costs of 
superannuation entitlements only as they become payable. This basis of accounting does not 
comply with Financial Reporting Standard 17 which requires such costs to be recognised in the year 
the entitlements are earned. 
In my opinion, except for the accounting treatment of the Board’s superannuation costs and 
liabilities, the financial statements have been properly prepared in accordance with generally 
accepted accounting practice in Ireland and give a true and fair view of the state of the Board’s affairs 
at 31 December 2013 and of its income and expenditure for 2013.
In my opinion, proper books of account have been kept by the Board. The financial statements are in 
agreement with the books of account.
MATTeRS on wHICH I RePoRT By eXCePTIon
I report by exception if
•	 I	have	not	received	all	the	information	and	explanations	I	required	for	my	audit,	or
•	 my	audit	noted	any	material	instance	where	money	has	not	been	applied	for	the	purposes	
intended or where the transactions did not conform to the authorities governing them, or
•	 the	information	given	in	the	Board’s	annual	report	is	not	consistent	with	the	related	financial	
statements, or
•	 the	statement	on	internal	financial	control	does	not	reflect	the	Board’s	compliance	with	the	
Code of Practice for the Governance of State Bodies, or
•	 I	find	there	are	other	material	matters	relating	to	the	manner	in	which	public	business	has	been	
conducted.
I have nothing to report in regard to those matters upon which reporting is by exception.
Patricia Sheehan 
For and on behalf of the
Comptroller and Auditor General 
10 July 2014
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ACCOUNTING POLICIES
 
HISToRICAl CoST ConvenTIon
The Financial Statements are prepared in accordance with generally accepted accounting principles 
under the historical cost convention and comply with the financial reporting standards of the 
Accounting Standards Board, with the exception of superannuation - see note below.
InCoMe ReCognITIon
Income is recognised in the financial statements on the following basis:
•	 In	the	case	of	applications	for	marketing	authorisations	(new	applications,	variations	to	existing	
authorisations, or transfers) and clinical trial applications, income is recognised in the financial 
statements when a valid application form is received.  
•	 In	the	case	of	wholesale	and	manufacturing	licences	and	maintenance	of	marketing	
authorisations, fees are payable annually and a full year’s income is accrued in each  
financial year.
eXPendITuRe ReCognITIon
Expenditure is recognised in the financial statements on an accruals basis as it is incurred.
RePoRTIng CuRRenCy And CuRRenCy TRAnSlATIon
The financial statements are prepared in euros.
Transactions in currencies other than euro are recorded at the rates ruling at the date of the 
transactions or at a contracted date.  Monetary assets and liabilities are translated into euro at the 
balance sheet date or at a contracted date.  Exchange differences are dealt with in the income and 
expenditure account.  
TAngIBle ASSeTS
Tangible Assets excluding Premises
Tangible assets excluding premises are stated at cost less accumulated depreciation.  Depreciation is 
calculated in order to write off the cost of tangible assets to their estimated residual values over their 
estimated useful lives by equal annual instalments.
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The estimated useful lives of tangible assets by reference to which depreciation has been calculated 
are as follows:
Fixtures and Fittings :  5 years
Computer Equipment :  3 years
Improvements to Premises : 10 years
Premises
The IMB purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2 
on 22 December 2004. The value capitalised was equal to the purchase price plus those costs directly 
attributable to bringing the asset into use.
No depreciation has been calculated on the value of premises, as the remaining useful economic life 
is estimated to be greater than 50 years.
TAXATIon
The IMB is exempt from liability to Corporation Tax under Section 227 of the Taxes Consolidation Act, 
1997.
deBToRS
Known bad debts are written off and specific provision is made for any amount the collection of 
which is considered doubtful. 
SuPeRAnnuATIon
The superannuation scheme operated by the IMB is in accordance with the Local Government 
(Superannuation Revision) (Consolidation) Scheme, 1986. It is an unfunded statutory scheme and 
benefits are met from current income as they arise.
The charge to salaries and wages is stated gross of superannuation deductions of € 749,418 (2012 -       
€ 687,798). The surplus for the year on page 92 is then shown both before and after superannuation 
transactions for the year. The income and expenditure reserve on the balance sheet is split between 
retained reserves and superannuation reserves in note 11. The balance on the superannuation 
reserve represents the cumulative superannuation deductions made since 1996.
By direction of the Minister for Health, the provisions of FRS 17 are not being complied with.  
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PRovISIonS
A provision is recognised when the IMB has a present obligation as a result of a past event, it is 
probable that this will be settled at a cost to the IMB and a reliable estimate can be made of the 
amount of the obligation.
lIBRARy
No value has been placed on the books, audio-visual resources and electronic databases in the 
library.  Expenditure on these items is written off in the year in which it is incurred.
leASeS
All leases are treated as operating leases and the rentals thereunder are charged to the Income and 
Expenditure account on a straight line basis over the lease period. 
 
91IMB ANNUAL REPORT 2013
  2013 2012
 Notes € €
Fee Income 2  20,225,400 20,065,633 
Other Income 3  4,430,585 3,927,031 
   
   24,655,985  23,992,664 
    
 
     
Salaries and Wages 4  17,765,250  17,215,472   
Other Operating Costs 5 4,823,934 5,190,035 
Depreciation 1  1,150,820 1,027,957 
     
   23,740,004  23,433,464 
    
Surplus for the year before write     
back of Superannuation contributions  915,981 559,200 
    
Staff Superannuation Contributions   749,418 687,798 
    
 
Surplus for the year   1,665,399  1,246,998
    
 
Balance brought forward   22,873,899 21,626,901  
    
Balance carried forward    24,539,298  22,873,899 
    
 
All income and the surplus for the year arises from continuing activities. 
Chairman Board Member
Mr. Michael Hayes Mr. Wilf Higgins
30 June 2014
The accounting policies on pages 89 to 91 and the notes on pages 95 to 101 form part of the financial 
statements.
 
STATeMenT oF InCoMe And eXPendITuRe
for the year ended 31 December 2013
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  2013 2012
 Notes € €
Tangible Assets 1 25,890,663  23,162,452 
     
Current Assets     
Debtors and Prepayments 6 644,387  948,557 
Stock of Stationery  2,407  2,703 
Cash at Bank and in Hand 12  160,832 187,175 
Short Term Deposits   12,940,623  15,500,825
      
  13,748,249 16,639,260
    
 
Creditors - Amounts falling     
due within one year    
 
Creditors and Accruals 7  6,372,942 7,407,809
Mortgage 13 793,332  793,332 
     
  7,166,274  8,201,141
    
Net Current Assets   6,581,975  8,438,119 
    
Long Term Liabilities     
Mortgage 13  7,933,340 8,726,672
    
 
TOTAL NET ASSETS   24,539,298  22,873,899 
    
 
Financed by     
Income and Expenditure Reserve 11  24,539,298  22,873,899 
     
  24,539,298  22,873,899
     
 
Chairman Board Member
Mr. Michael Hayes Mr. Wilf Higgins
30 June 2014
The accounting policies on pages 89 to 91 and the notes on pages 95 to 101 form part of the financial 
statements.
 
BAlAnCe SHeeT
as at 31 December 2013
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  2013 2012
 Notes € €
Reconciliation of surplus to net cash     
inflow from operating activities     
 
Surplus for Year  1,665,399 1,246,998 
Depreciation Charge  1,150,820 1,027,957 
(Increase)/Decrease in Debtors  228,197 487,014
(Increase)/Decrease in Stocks  296 (234) 
Increase/(Decrease) in Creditors - amounts    
falling due within one year  (1,035,225) 203,671
Deposit Interest   (183,195) (272,921) 
Bank Interest and Charges  393,502 422,839 
Loss/(Gain) on Disposal of Fixed Assets  (1,290) (460) 
    
Net Cash Inflow      
from Operating Activities  2,218,504 3,114,864 
     
Cash Flow Statement     
 
Net Cash Inflow from Operating Activities  2,218,504 3,114,864 
     
Return on Investments and Servicing of Finance 8 (133,976) (169,293)
Capital Expenditure 8 (3,877,741) (1,170,446) 
Management of Liquid Resources 8 2,560,202 (831,508) 
Financing 8 (793,332) (793,332)
 
Increase/(Decrease) in Cash   (26,343) 150,285
    
Reconciliation of net cash flow to movement in net debt     
    
Increase/(Decrease) In Cash  (26,343) 150,285
Increase/(Decrease) In Short Term Deposits  (2,560,202) 831,508
(Increase)/Decrease In Long Term Finance  793,332 793,332
    
Change In Net Funds/(Debt)  (1,793,213) 1,775,125
Net Debt at start of year  6,167,996 4,392,871
    
Net Funds/(Debt) at end of year 9 4,374,783 6,167,996
 
The accounting policies on pages 89 to 91 and the notes on pages 95 to 101 form part of the financial 
statements.
Cash Flow Statement
for the year ended 31 December 2013
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1. Tangible Assets Fixtures and Computer  Leasehold Improvements Premises Total  
 Fittings Equipment Improvements Premises    
 € € € € € €
 Cost       
Balance as at        
1 January 2013  988,481 9,004,202 502,445 3,574,558 21,097,235 35,166,921
         
Additions for the year  163,538  916,361  - 740,330 2,058,802 3,879,031
 Disposals for the year (17,136) (71,487)  -  -  - (88,623)
    
 As at        
31 December 2013 1,134,883 9,849,076 502,445  4,314,888 23,156,037 38,957,329
    
 Depreciation       
Balance as at        
1 January 2013 923,872 8,562,116   400,703 2,117,778 -  12,004,469
         
Charge for the year 62,277 606,809 50,245 431,489  - 1,150,820
 Disposals for the year  (17,136)  (71,487)  -     -     -  (88,623)
        
 As at        
31 December 2013 969,013 9,097,438 450,948 2,549,267  - 13,066,666
         
   
 Net Book value at        
31 December 2013 165,870 751,638 51,497 1,765,621 23,156,037 25,890,663
        
 Net Book value at        
1 January 2013  64,609 442,086 101,742 1,456,780 21,097,235 23,162,452
2. Income
      2013     2012
      €     €
 Fee Income  
 Clinical Trials 152,714  148,326 
 Human Medicine - National Fees 6,597,201  6,875,259
 Human Medicine - European Fees 5,809,092  5,943,402 
 Veterinary Medicine - National Fees 1,226,329  1,163,520
 Veterinary Medicine - European Fees 1,682,126 1,564,656 
 Compliance Department 4,406,871  4,123,445
 Medical Devices 351,067  247,025 
   20,225,400  20,065,633 
 Other Income ( Note 3 ) 4,430,585 3,927,031 
 Total Income 24,655,985 23,992,664
    
 Certain fees, totalling €16,623,534 are required by law to be disposed of in accordance  
with the directions of the Minister for Finance.    
    
 
notes to the Financial Statements
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3. Other Income 2013     2012
      €     €
 Dept of Health Funding 3,937,000  3,545,000
 Conference Fee Income 6,100  108,650 
 Deposit Interest 183,195  272,921 
 (Loss)/Gain on Disposal of Fixed Assets 1,290 460
 IT Income 303,000 -
     
  4,430,585 3,927,031
4. Salaries and Wages 2013     2012
      €     €
 Salaries and Wages  15,948,022  15,448,788 
 Pensions 359,984  373,692 
 Social Welfare Costs 1,457,244  1,392,992
 
  17,765,250 17,215,472
    
 The average number of staff employed during the year was 317 (2012 - 297).   
Staff employed at 31 December 2013 can be analysed across the following departments : -   
 
  2013 2012 
 
 Chief Executive 10  12 
 Compliance 62  60 
 Finance & Corporate Affairs 19  18 
 Human Products Authorisation & Registration 103  105 
 Human Products Monitoring  46  42 
 Human Resources  9  8 
 IT & Change Management 14  14 
 Scientific Affairs 2  2 
 Veterinary Sciences  25  23 
 Pensioners  25  24 
 
   315  308
 Pension related deductions for Public Servants of €1,011,911 were deducted from staff   
during the year and paid over to the Department of Health.   
  
notes to the Financial Statements
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5. Operating Costs 2013     2012
      €     €
 
 Accommodation Costs 1,281,687  1,464,548
 Travel, Representation and Training  920,613  734,240 
 Bank Charges and Interest 398,152  428,324 
 Legal & Professional Fees  124,286  151,892 
 Stationery, Publications and Postage 409,221  419,163 
 Other Operating Costs 1,689,975  1,991,868
    
  4,823,934 5,190,035
 Operating costs of €4,823,934 includes an amount of €5,665 related to staff hospitality.
6. Debtors (all due within one year) 2013     2012
      €     €
 
 Trade Debtors 336,335 431,040 
 Prepayments 186,716 324,609 
 Other Debtors  121,336  192,908
    
  644,387  948,557
 
7. Creditors (amounts falling due within one year) 2013     2012
      €     €
 
 Trade Creditors  268,817 379,248 
 Accruals 5,563,837 6,519,183 
 Revenue Commissioners 540,288 509,378 
    
   6,372,942  7,407,809 
notes to the Financial Statements
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notes to the Financial Statements
for the year ended 31 December 2013
8. Gross Cash Flows 2013     2012
      €     €
 Returns on Investment and Servicing of Finance:  
 Deposit Interest 259,169  257,645
 Bank Interest and Charges (393,145) (426,938)
     
 (133,976) (169,293) 
 
 Capital Expenditure  
 Payments to acquire Tangible Fixed Assets (3,879,031) (1,170,906) 
 Receipts from sales of Tangible Fixed Assets 1,290 460  
     
 (3,877,741) (1,170,446) 
 Management of Liquid Resources  
 (Increase)/Decrease in Short Term Deposits 2,560,202 (831,508) 
     
 2,560,202 (831,508) 
 Financing  
 Increase/(Decrease) in Long Term Finance (793,332) (793,332) 
     
 (793,332) (793,332) 
    
9. Analysis of Changes in Net Funds/(Debt) As At  As At
  01/01/2013 Cashflow 31/12/2013
 Cash at Bank and in Hand  187,175 (26,343) 160,832 
 Short Term Deposits 15,500,825  (2,560,202) 12,940,623 
 Debt Due Within One Year (793,332) 0 (793,332)
 Debt Due After One Year (8,726,672) 793,332  (7,933,340)
  6,167,996 (1,793,213) 4,374,783
10. Administration Expenses 2013 2012
 Surplus for the year was calculated having charged :     
 Auditor’s Remuneration 17,390  17,390 
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11. Movement on Income and Expenditure Reserves As At  As At
  01/01/2013 Movement 31/12/2013
 
 Retained Reserves 16,399,855  915,981  17,315,836
 Staff Superannuation Contributions  6,474,044  749,418  7,223,462 
      
  22,873,899  1,665,399 24,539,298
12. Cash and Bank Balances 2013     2012
      €     €
 Current Account Balances 160,302 186,798
 Cash on Hand 530  377
    
  160,832 187,175
13. Long Term Liabilities 
  Mortgage  
 On 22 December 2004 the Board purchased its premises at Kevin O’Malley House, Earlsfort Centre,   
Earlsfort Terrace, Dublin 2. The purchase was financed by way of a mortgage, secured on the premises,  
of  €20,400,000 over 20 years from Bank of Ireland Corporate Lending.   
 
  The Irish Medicines Board is committed to making the following capital repayments on its mortgage :
  2013     2012
      €     €
 - within one year 793,332  793,332 
 - between one and five years 3,173,328  3,173,328 
 - after five years 4,760,012  5,553,344
    
   8,726,672  9,520,004 
14. Interest Rate Exposure 
 The IMB have taken all necessary steps to minimise its interest rate exposure by fixing 2/3s of the 
borrowings for the mortgage duration. The balance of the borrowings are fully offset by cash reserves. For 
2014 it is estimated that the net borrowings for which an interest rate exposure may arise is €0.   
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15.  Financial Commitments  2013     2012
      €     €
 Operating Leases
 Amounts payable during the next twelve   
months in respect of leases which expire
 - within one year (in respect of Ormonde House) -  54,530   
 - within one year (in respect of Longphort House) - 70,369
 - after five years (in respect of Alexandra House) 285,984  285,984 
    
   285,984  410,883 
    
 Included in Accommodation Costs (Note 5) is expenditure of €410,883 under operating leases.
 On 28 January 2005 the IMB signed a leasehold interest in respect of the 5th floor, Alexandra House, 
Earlsfort Centre, Dublin 2. At 31 December 2013 this lease had 8 years and four months remaining.  
On 1 June 2010 the IMB signed a leasehold interest in respect of the 3rd floor, Longphort House, 
Earlsfort Centre, Dublin 2. This lease terminated on 31 May 2013. 
On 1 September 2012 the IMB signed a leasehold interest in respect of the ground floor, Ormonde House, 
Earlsfort Centre, Dublin 2. This lease terminated on 31 August 2013.
16.  Capital Commitments  2013     2012
      €     €
 Contracted For (Contract Signed)  440,000 2,657,000 
 Not Contracted For 2,600,000  890,000 
    
   3,040,000  3,547,000
17.  Board Remuneration  2013     2012
      €     €
 Chairman’s Salary  20,520 20,520 
 Board Members’ Travel Expenses 6,710 8,554 
    
   27,230 29,074 
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18.  Staff Remuneration  2013     2012
      €     €
 Chief Executive’s Total Remuneration    
Basic Salary 151,186 156,386
 
   151,186 156,386 
 The Chief Executive’s pension entitlements do not extend beyond the standard entitlements in the model 
public sector defined benefit superannuation scheme.
19. Related Party Transactions    
There have been no transactions with related parties which require disclosure under Financial Reporting 
Standard 8.    
 
      
20. Prompt Payment Of Accounts    
The Irish Medicines Board ( IMB ) confirms that it is complying with EU law in relation to prompt payments 
of account.    
 
      
21. Exchange Rates     
The exchange rates used in preparing these financial statements were as follows :     
 
 2013      €1 = STG £0.8348     
 2012      €1 = STG £0.8174     
      
22. Provisions    
The Board has been notified of a number of legal proceedings or potential proceedings. The information 
usually required by FRS 12 Provisions, contingent liabilities and contingent assets is not disclosed as the 
Board believes that to do so would be prejudicial to the outcome.
      
23. Going Concern    
The Board has a reasonable expectation, at the time of appoving the financial statements, that the IMB 
has adequate resources to continue its operations. For this reason, the Board continues to adopt the 
going concern basis in preparing the financial statements.    
 
      
24. Approval of Financial Statements    
The financial statements were approved by the Board on 5 June 2014.
notes to the Financial Statements
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APPENDIX 1
COMMITTEE MEMBERS
MAnAgeMenT CoMMITTee
Mr. Pat O’Mahony  
Chief Executive
Dr. Gabriel Beechinor  
Director of Veterinary Sciences
Dr. Joan Gilvarry 
Director of Human Products Monitoring
Ms. Frances Lynch 
Director of Human Resources
Mr. John Lynch 
Director of Compliance
Ms. Suzanne McDonald  
Director of Information Technology and  
Change Management
Dr. Mike Morris 
Director of Scientific Affairs
Dr. Lorraine Nolan 
Director of Human Products  
Authorisation and Registration
Ms. Rita Purcell 
Director of Finance and Corporate Affairs
BoARd
Mr. Michael D. Hayes – Chairman
Mr. Pat Brangan*
Mr. Wilfrid J. Higgins*
Ms. Ann Horan
Prof. Mary Horgan
Dr. Elizabeth Keane*
Mr. Brendan McLaughlin*
Mr. Noel O’Donoghue
Prof. Caitriona O’Driscoll 
 
* Term ended 31 December 2013
AudIT CoMMITTee
Mr. Pat Brangan
Ms. Ann Horan
Mr. Brendan McLaughlin
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AdvISoRy CoMMITTee FoR HuMAn 
MedICIneS
Prof. Mary Horgan – Chairman
Dr. Paul Browne
Dr. Kevin Connolly
Dr. Desmond Corrigan
Prof. Tom Fahey
Prof. David Kerins
Ms. Marita Kinsella
Prof. Patrick Murray
Dr. Brian O’Connell
Mr. Ronan Quirke
Dr. Patrick A. Sullivan
Prof. Peter Weedle
AdvISoRy CoMMITTee FoR veTeRInARy 
MedICIneS
Mr. Pat Brangan – Chairman
Dr. Ruaidhri Breathnach
Ms. Eugenie Canavan
Mr. Michael F. Clancy
Dr. Martin Danaher
Dr. Rodhri Evans
Dr. Helena Kelly
Mr. Des Leadon
Dr. Nola Leonard
Mr. Ciaran Mellet
Mr. John Moriarty
Mr. John Underhill
AdvISoRy CoMMITTee FoR MedICAl 
devICeS
Mr. Wilfrid J. Higgins – Chairman
Dr. Gillian Carlos McDowell
Dr. Geoffrey Chadwick
Mr. Darragh Hynes
Dr. Jonathan Lyne
Prof. Fergal O’Brien
Prof. Richard Reilly
Ms. Mary Sharp
Ms. Maebh Smith
Mr. Sean Paul Teeling
Prof. Wil van der Putten
Dr. Vivion Crowley
ClInICAl TRIAl SuB-CoMMITTee oF 
AdvISoRy CoMMITTee FoR HuMAn 
MedICIneS
Dr. Patrick A. Sullivan – Chairman
Dr. Liam Bannan
Prof. David Bouchier-Hayes
Dr. Geraldine Boylan
Dr. Paul Browne
Dr. Peter Daly
Prof. Timothy Dinan
Dr. Catherine Kelly 
Dr. Thomas Peirce
Dr. John Taaffe
Dr. Bryan Whelan
Dr. Lee Helman (CT Expert)
Dr. Filip Janku (CT Expert)
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AdvISoRy SuB-CoMMITTee  
FoR HeRBAl MedICIneS
Dr. Des Corrigan – Chairman
Dr. James Barlow
Dr. Kevin Connolly
Mrs. Ingrid Hook
Ms. Claudine Hughes
Ms. Anna-Maria Keaveney
Dr. Celine Leonard
Dr. Donal O’Mathuna
Dr. Camillus Power
Dr. Helen Sheridan
Ms. Anne Varley
Dr. Emma Wallace
eXPeRTS SuB-CoMMITTee oF THe 
AdvISoRy CoMMITTee FoR HuMAn 
MedICIneS
Prof. Mary Horgan – Chairman
Dr. Colin Buckley
Dr. Owen Carey
Dr. Linda Coate
Dr. Kevin Connolly
Dr. James Colville
Dr. Noreen Dowd
Dr. Stephen Eustace
Dr. Stephen Flint
Dr. Tim Fulcher
Dr. Joseph Galvin
Dr. Patrick Gavin
Dr. Paul Gallagher
Dr. Kevin Kelleher
Dr. Catherine Kelly
Dr. Mary Keogan
Prof. David Kerins
Dr. Lorraine Kyne
Dr. Mark Ledwidge
Prof. Aiden McCormick
Dr. Frank Murray
Dr. Yvonne O’Meara
Mr. Ashley Poynton
Dr. Brion Sweeney
Dr. Jogin Thakore 
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APPENDIX 2      
PRESENTATIONS 2013
THIRd level / eduCATIonAl PReSenTATIonS
Institution Course Presentation Title
Athlone IT Veterinary Nursing Regulation of Veterinary Medicines 
DIT Biomedical Science European Blood Directive – The IMB Perspective
HSE Medicines Management  The role of the IMB / Quality and Safety Reporting 
 Seminar for Nurse Educators 
HSE Medicines Management  IMB Role in Interchangeable / Generic Medicines 
 Seminar for Nurse Educators 
RCSI Nurse Midwife Prescribing Role of the IMB (2 presentations)
RCSI Nurse Midwife Prescribing Pharmacovigilance (2 presentations)
RCSI Pharmacy Regulation of New and Generic Medicines
RCSI Pharmacy Regulatory Affairs and Regulatory Authorities
RCSI Pharmacy The Regulation of Biotechnology
RCSI Pharmacy Advanced Therapy Medicinal Products
Sligo IT Medical Biotechnology and   IMB Inspections / Pharmacovigilance 
 Pharmaceutical Science  
St. Johns,  Veterinary Nursing Regulation of Veterinary Medicines  
Cork
TCD Pharmacy Authorisation of Medicines
TCD Pharmacy Reporting Quality Defects
TCD Pharmaceutical Medicine The Role of the Pharmacopoeia in the  
  Regulation of Medicines
TCD Pharmaceutical Medicine Non Clinical Drug Development 
TCD Pharmaceutical Medicine Quality Defects and Recalls
TCD Pharmaceutical Medicine Overview of Pharmacovigilance in the EU
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THIRd level / eduCATIonAl PReSenTATIonS (ConTInued)
Institution Course Presentation Title
TCD Pharmaceutical Medicine New EU Pharmacovigilance Legislation
TCD Pharmaceutical Medicine Pharmacovigilance Communications
TCD Pharmaceutical Medicine Traditional Herbal Medicinal Products
TCD Hospital Pharmacy  Pharmacovigilance and Risk Management
TCD Biomedical Sciences  Biopharmaceuticals - Introduction to EU Regulation
TCD Last-Ireland  Implementation of Directive 2010-63-EU (2 presentations)
UCC Pharmacy and Medicine Adverse Reactions
UCC Pharmacy and Medicine Notification of Adverse Events
UCD Nursing - Prescription of Medications Role of the IMB (2 presentations)
UCD Nursing - Prescription of Medications Pharmacovigilance (2 presentations)
UCD Veterinary Medicine Regulation of Veterinary Medicines 
UCD Veterinary Nursing Regulation of Veterinary Medicines 
UCD Biotechnology  Biopharmaceuticals – Introduction to EU Regulation  
  (2 presentations)
UCD Biopharmaceutical Engineering Biopharmaceuticals – Introduction to EU Regulation 
UCD / SVUH Nurse Education Centre Medical Device Incident User Reporting
RegulAToRy PReSenTATIonS
event/organiser Presentation Title
British Herbal Medicine Association (BHMA) The Borderline Interface – An Irish Perspective
Biomedical / Clinical Engineering  Medical Devices Vigilance System and User Reporting 
Association of Ireland
DIA Impact of Revised Pharmacovigilance Legislation on   
 Regulatory Communications
DIA  Quality Update – Current Developments – Process Validation
DIA The Risk Management Plan as a Post-Authorisation Dossier
EPA / GMO Technology Conference The Regulation of Clinical Trials 
European Forum for Qualified Person  PRAC: The Experience to Date 
for Pharmacovigilance 
HSE Vaccine Preventable  Vaccine Licensing and Safety 
Diseases Conference 
IPHA Communication with Stakeholders - The Regulators   
 Perspective
International Pharmaceutical Federation (FIP) Draft EMA Guideline on Process  Validation
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RegulAToRy PReSenTATIonS (ConTInued)
event/organiser Presentation Title 
International Society of Pharmacovigilance The Pharmacovigilance Risk Assessment Committee
International Symposium on Medicinal  Medical Devices Vigilance 
Products and Medical Devices  
Irish Clinical Research Infrastructure Network (ICRIN) EU Regulation of Clinical Trials
Irish Clinical Research Infrastructure Network (ICRIN) National Impact of Proposed Regulation and Experience to  
 Date with VHP
Irish Fertility Society Eurocet Coding / Regulatory Updates
National Haemovigilance Office Conference Blood Legislation and Haemovigilance
National Haemovigilance Office Conference Medical Devices Regulation, Vigilance and User Reporting
National Haemovigilance Office Conference Blood Legislation and the Role of the IMB
NSAI Medical Devices Vigilance
National Symposium on Biologic Medicines (NIBRT) The Regulatory Process for Biosimilars
Parenteral Drug Association Role of the IMB / Future Challenges
Parenteral Drug Association EU Draft CHMP Guideline and Expected changes to GMP  
 Annex 15 on Process Validation
Parenteral Drug Association Presentations relating to ‘Current and Emerging EU   
 Regulations and Inspection Trends’
PharmaChemical Ireland Innovation and Excellence – The Contribution of the Regulator
Royal Victoria Eye and Ear Hospital  Regulation of Advanced Therapies 
– Corneal Stem Cell and Tissue  
Engineering Symposium 
SOHOV&S (Vigilance and Surveillance  Communication Issues in Tissues and Cells 
of Substances of Human Origin) Project  
SOHOV&S (Vigilance and Surveillance of  European Training of Vigilance Officers 
Substances of Human Origin) Project  
TOPRA Module 3 – An Agency Perspective
Voluntary Hospitals Risk Management Forum Medical Devices Legislation and the Role of the IMB
APPENDIX 3
PUBLICATIONS AND ARTICLES 2013
ReTAIleR InFoRMATIon leAFleTS 
Topic Published
Selling Cosmetic Products in Ireland – A  Guide for Retailers  October 
 
 
dRug SAFeTy newSleTTeRS 
edition Articles
February  - Tredaptive (Nicotinic Acid/Laropiprant) – Suspension of Marketing Authorisation 
52nd  Edition - Restriction of indications for trimetazidine (Vastarel) 
 - Use of the IMB online ADR report forms and Drug Safety Newsletter (DSN) for CPD  
  purposes 
 - INSERT: New guidance on treatment of paracetamol overdose with intravenous   
  acetylcysteine
May  - Changes to arrangements for Drug Safety Newsletter distribution 
53rd Edition - The Pharmacovigilance Risk Assessment Committee (PRAC) 
 - Medicines Subject to Additional Monitoring Requirements: Update 
 - Metoject solution for injection, pre-filled syringes: Caution in use 
May - Strontium ranelate (Protelos): Restricted indications, new contraindications, and   
54th Edition  warnings due to risk of serious cardiac disorders 
 - Lenalidomide (Revlimid): Risk of serious hepatic adverse reactions-routine monitoring  
  of liver function now recommended 
 - Methylphenidate-containing medicines: Availability of web-based educational tools 
 - Cinacalcet (Mimpara): Risk of QT prolongation/ventricular arrhythmias
July  - Diclofenac: The same cardiovascular precautions now apply for diclofenac as for   
55th Edition  selective COX-2 inhibitors 
 - Codeine: Restricted use as an analgesic in children and adolescents 
 - Dianette (Cyproterone acetate 2mg/ethinylestradiol 35mcg): New risk minimisation  
  measures to further mitigate the known risk of thromboembolism 
 - Lariam: Updated product information and availability of guidelines for healthcare  
  professionals/alert cards for patients 
 - Hydroxyethylstarch (HES) infusion solutions: PRAC recommends suspension of licenses 
 - PRAC recommendations
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dRug SAFeTy newSleTTeRS (ConTInued) 
edition Articles
October - Novel Oral Anticoagulants (NOACs) and risk of bleeding: Reinforcement of risk   
56th Edition  minimization advice for dabagatrin (Pradaxa), rivaroxaban (Xarelto) and  
  apixabab (Eliquis) 
 - Metoclopramide-containing medicines: Update on outcome of review and revised  
  recommendations for use
December - Ondansetron for intravenous use - updated information on posology to mitigate  
57th Edition  dose-dependent risk of QT interval prolongation 
 - Agomelatine (Valdoxan): New contraindication and a reminder of the importance of  
  liver function monitoring 
 - Restrictions to the use of Short Acting Beta Agonists (SABAs) in obstetric indications 
 - Trazodone: Reminder of the risk of postural hypotension and somnolence in the elderly  
  particularly in the context of polypharmacy
December - Intravenous iron-containing medicines: New recommendations to manage and   
58th Edition  minimise risk of allergic reactions 
 - Cabazitaxel (Jevtana): Potential for medication error due to incorrect reconstitution 
 - Medicines subject to additional monitoring requirements-update 
 - Use of the IMB online adverse reaction reporting system for the DSN for CPD purposes 
 - INSERT: Quick guide to medical device incident user reporting
IMB HuMAn MedICIneS ARTICleS – eXTeRnAl PuBlICATIonS 
Topic Publication Month
Diclofenac: Further evidence that the cardiovascular risk with   MIMS January 
diclofenac is higher than other non-selective NSAIDs and  
similar to COX-2 inhibitors 
Acetylcysteine: New guidance on treatment of paracetamol overdose MIMS February
Updated Pharmacovigilance Legislation IMF February
Tredaptive: Suspension of MA MIMS March
Restriction of indications for trimetazidine-containing products (CV supplement) MIMS March
iaCME: Use of the IMB online ADR report forms and DSN for CPD purposes. MIMS April
Methylphenidate: Availability of web-based educational tools MIMS May
Revlimid (lenalidomide): Risk of serious hepatic adverse reactions  MIMS May 
(oncology supplement) 
Strontium ranelate (Protelos and Osseor): Updates to product information  MIMS June 
on risks of venous thromboembolism and severe allergic skin reactions
109IMB ANNUAL REPORT 2013
110 IMB ANNUAL REPORT 2013
IMB HuMAn MedICIneS ARTICleS – eXTeRnAl PuBlICATIonS (ConTInued)
Topic Publication Month
Dianette (cyproterone acetate 2mg /ethinylestradiol 35 micrograms) –  MIMS July 
New risk minimisation measures to further mitigate the known risk  
of thromboembolism   
Diclofenac: The same cardiovascular precautions now apply  MIMS August 
for diclofenac as for selective COX-2 inhibitors 
Changes to arrangements for DSN distribution IMF August
Codeine: Restricted use as an analgesic in children and adolescents MIMS September
Medicines subject to additional monitoring Irish Medical Times September
Medicines subject to additional monitoring IPU Review October
Lariam (Mefloquine): Updated product information and availability  MIMS October 
of guidelines for healthcare professionals/alert cards for patients
Medicines subject to additional monitoring MIMS November
Medicines subject to additional monitoring (Diabetes Supplement) MIMS November
Restrictions to the use of Short Acting Beta Agonists MIMS December 
(SABAs) in obstetric indications
Medicines subject to additional monitoring December 2013 (Compendium) MIMS December
Diclofenac: The same cardiovascular precautions now apply for diclofenac  MIMS December 
as for selective COX-2 inhibitors (Supplement-Rheumatology)
IMB veTeRInARy MedICIneS ARTICleS – eXTeRnAl PuBlICATIonS 
Topic Publication Month
Flukicides update It’s Your Field Spring
Classification of the method of supply of veterinary medicines in Ireland. It’s Your Field Summer
Functions of the IMB in relation to animal remedies It’s Your Field Autumn
Applying for a marketing authorisation – the process It’s Your Field Winter
 
InduSTRy guIdAnCe doCuMenTS 
document title new/Revision date
Guide to Good Distribution Practice of medicinal products for human use New December
Guide to wholesaling and brokering of medicinal products for human use in Ireland Revision December
Guide to the completion of the Hospital Blood Bank Annual Report Revision December
Guide to labels and leaflets for human medicines Revision December
Guide to transfers of product authorisations and parallel product authorisations Revision December 
for human medicines 
Guide to the attainment of Qualified Person status in Ireland Revision November
Guide to applications for establishments regulated by Directive 2010/63/EU New November
Guide to preparation of a site master file for establishments regulated  Revision November 
by Directive 2010/63/EU and S.I. No. 543 of 2012 
Guide to applications for individuals regulated by Directive 2010/63/EU  Revision November 
and S.I. No. 543 of 2012
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IMB MedICAl devICeS newSleTTeR 
edition Main Topics
April  −   Irish Presidency of the Council of the European Union and  
       the impact on medical devices regulation
 −   The Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR)
 −   Harmonised standards
 −   The medical device vigilance system and revision of Vigilance Guidelines MEDDEV Rev. 8
September  −   Introduction to volumetric arc therapy in Ireland
 −   Safe use of automated external defibrillators 
 −   New EU Commission Implementing Regulation on the designation and  
      supervision of notified bodies 
 −   European Commission recommendation on unique device Identification of medical devices 
IMB MedICAl devICeS ARTICle – eXTeRnAl PuBlICATIon
Topic Publication Month
Focus on role of in-vitro diagnostic scientific officer in IMB  AMLS Converse  December 
 magazine: Partners 
 in Pathology
 
InduSTRy guIdAnCe doCuMenTS (ConTInued)
document title new/Revision date
Guide for custom-made dental device manufacturers on compliance with European  New November 
Communities (Medical Devices) Regulations 1994 
Guide to the Definition of a Human Medicine Revision November
Guide to the quality system for general sale wholesale distributors Revision November
Guide to ethics committee assessment of project applications under  Revision October 
Directive 2010/63/EU and S.I. No. 543 of 2012 
Guide to Renewal of Marketing Authorisations - Human Medicines Revision September
Guide to cosmetic products for Responsible Persons Revision September
Guide to interchangeable medicines Revision September
Guide to Cosmetics Revision September
Guide to the decentralised and mutual recognition procedures for veterinary  Revision August 
medicinal products using Ireland as RMS 
Guide to registration requirements for active substance manufacturers,  Revision June 
importers and distributors in Ireland  
Guide to distribution of cosmetic products in Ireland Revision June
Guide to completing a non-technical project summary for a project under  Revision May 
Directive 2010/63/EU and S.I. No. 543 of 2012 
Guide to practices exempt from the scope of Directive 2010/63/EU Revision May 
and S.I. No. 543 of 2012 
Guide to completion of tissue establishment annual report  Revision May
Guide to completion of the tissue establishment annual report Revision May 
 for reproductive tissues and cells
Guide to electronic submissions - human medicines Revision May
Guide to interchangeable medicines New May
Guide to applying for a variation to a blood establishment authorisation New April
Guide to applying for a variation to a tissue establishment authorisation New April
Guide to display of chemical group symbols on product literature of sheep anthelmintics New April
Guide to electronic transmission of ICSRs and SUSARs associated  Revision March 
with the use of human medicines 
Guide to refusals and appeals Revision March
Guide to parallel imports - human medicines Revision March
Guide to hospital-based advanced therapy medicinal products New February
Guide to invented names of veterinary medicines New February
Guide to electronic submissions - veterinary medicines Revision January
Guide to parallel imports for veterinary medicines New January
Guide to the regulatory requirements for the procurement of human tissues  Revision January 
and cells intended for human application 
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APPENDIX 4      
GLOSSARY
euRoPeAn And nATIonAl CoMMITTee/woRkIng gRouP PARTICIPATIon
Committee/working group organisation Meetings Per  
  Annum
Competent Authority for Medical Devices (CAMD) CAMD 2
Notified Body Operations Group (NBOG) CAMD 3
Compliance and Enforcement Working Party (COEN) CAMD 3
Committee Of Experts on Minimizing Public Health Threats  Council of Europe 2 
Posed by Counterfeiting of Medical Products and Similar Crimes 
European Pharmacopoeia Commission  Council of Europe 3
Pompidou Group – Drug Precursors Council of Europe 1
P-SC-COS (Committee of Experts on Cosmetics) Council of Europe 1
Implementation Group on Generic Substitution and Reference  Pricing   Department of Health 6
Medication Safety Forum Department of Health 4
Market Surveillance Forum Department of Jobs  4 
 Enterprise & Innovation 
Market Surveillance Regulation & Consumer Product  Department of Jobs 1 
Safety Regulation for Cosmetic Products DJEI Enterprise & Innovation  
Official Medicines Control Laboratories Network –  EDQM 8 
European Directorate for Quality of Medicines (EDQM) 
Committee for Advanced Therapies EMA 11
Committee for Medicinal Products for Human Use (CHMP) EMA 11
Committee for Medicinal Products for Veterinary Use (CVMP) EMA 11
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EUROPEAN AND NATIONAL  
COMMITTEE / WORKING GROUP   
PARTICIPATION
Committee/working group organisation Meetings Per  
  Annum
ECommittee for Orphan Medicinal Products (COMP) EMA 11
Committee on Herbal Medicinal Products (HMPC) EMA 6
GMDP Inspectors Working Group EMA 4
Pharmacovigilance Inspectors Working Group (Human) EMA 2
Pharmacovigilance Inspectors Working Group (Veterinary) EMA 2
GCP Inspectors Working Group EMA 4
Paediatric Committee (PDCO) EMA 12
Pharmacovigilance Risk Assessment Committee (PRAC) EMA  13 (includes 
  informal meetings)
Scientific Advice Working Party EMA 11
Biologics Working Party EMA 11
Telematics Committee - Management Board EMA 4
New and Emerging Technologies Working Group EU Commission 2
In-Vitro Diagnostic Technical Working Group EU Commission 1
Borderline and Classification Medical Device Expert Group (MDEG) EU Commission 2
Clinical Investigation and Evaluation Working Group EU Commission 3
Competent Authorities for (1) Blood, (2) Tissues and Cells  EU Commission 6 
and (3) Organs for Transplantation 
Haemovigilance – Common Approach EU Commission 1
Cosmetic Borderline Working Group EU Commission 2
Cosmetic Standing Committee and Working Group EU Commission 2
Drug Precursors Working Group EU Commission 2
MDEG Working Group on Vigilance EU Commission 2
Medical Device Expert Group EU Commission 3
Unique Device Identifier Group EU Commission 2
Vigilance and Surveillance of Substances of Human Origin (SoHO V & S) EU Commission /  1 
 SoHO V & S 
European Commission Sub-working Group on Cosmetovigilance European Commission 2
PEMSAC (Platform of European Market Surveillance Authorities  European Commission 2 
for Cosmetics) Market Surveillance 
PEMSAC (Platform of European Market Surveillance Authorities European Commission 2 
for Cosmetics) Analytical Methods 
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Committee/working group organisation Meetings Per  
  Annum
Competent Authority for Medical Devices European Commission 1
HTA Advisory Committee  HIQA 2
Medicines Reconciliation Advisory Group HIQA 3
Clinical Trial Facilitation Group (CTFG) HMA 6
Co-ordination Group for Mutual-recognition and Decentralised HMA 11 
 Procedures (Human) CMD(h) 
Co-ordination Group for Mutual-recognition and Decentralised  HMA 11 
Procedures (Veterinary) CMD(v) 
Working Group of Enforcement Officers HMA 2
Working Group of Quality Managers HMA 2
Working Group of Communications Professionals HMA 2
HMA ICT Working Groups HMA 
Homeopathic Medicinal Products Working Group (HMPWG) HMA 2
PSUR Work-Sharing Working Party HMA 11
Steering Group on Medicines for Older People HSE 3
IMB – UK Department for Business Innovation & Skills Ireland/UK Working Group 5
Anti-doping Committee Irish Sports Council 4
Healthcare Standards Consultative Committee National Committee 4
IMB – HSE – National Organ Donation and Transplant Office (NODTO) National Working Group 2
Cosmetics Standards Advisory Group NSAI 2
EPA Health Advisory Committee EPA 3
Permanent Forum on International Pharmaceutical Crime PFIPC 1
Committee of Officials PIC/S 2
GDP Working Group PIC/S 2
Heads of Medicines Agencies meetings – Human Presidency 4
Heads of Medicines Agencies meetings – Veterinary Presidency 4
National Immunisation Advisory Committee RCPI 6
Board of the UMC/WHO Collaborating Centre WHO 3
WHO National Pharmacovigilance Centres Meeting WHO 1
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AED Automated External Defibrillator 
APHA Animal and Plant Health Association
APMI Association of Pharmaceutical Manufacturers in Ireland 
ASR Annual Safety Report 
ATMP Advanced Therapy Medicinal Product
BEMA Benchmarking of European Medicines Agencies
CAMD Competent Authority for Medical Devices 
CAT Committee for Advanced Therapies 
CD Controlled Drugs 
CESP Common European Submission Portal
CHMP Committee for Medicinal Products for Human Use 
CMC Central Management Committee 
CMD(h) Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human
CMD(v) Co-ordination Group for Mutual Recognition and Decentralised Procedures - Veterinary 
CMS Concerned Member State
COMP  Committee for Orphan Medicinal Products 
CTFG  Clinical Trials Facilitation Group 
CVMP  Committee for Medicinal Products for Veterinary Use 
DCP  Decentralised Procedure 
EDQM European Directorate for Quality of Medicines 
EEA European Economic Area 
EMA European Medicines Agency 
EUDAMED European Database on Medical Devices
FSCA Field Safety Corrective Action
GCP Good Clinical Practice 
GDP Good Distribution Practice 
GHTF  Global Harmonisation Task Force
GMP Good Manufacturing Practice
GVP Good Vigilance Practice 
APPENDIX 5       
GLOSSARY
H1N1 Abbreviation for the influenza virus associated with the 2009 Flu Pandemic 
HIQA Health Information and Quality Authority 
HMA Heads of Medicines Agencies
HMPC Committee on Herbal Medicinal Products 
HPSC Health Protection Surveillance Centre 
HPV Human Papillomavirus 
HSE Health Service Executive
HTA Health Technology Assessment
IAHS Irish Association of Health Stores 
IBTS Irish Blood Transfusion Service 
ICH International Conference of Harmonisation 
IHTA Irish Health Trade Association 
IMDA Irish Medical Devices Association 
IMDRF International Medical Device Regulators Forum
IMF Irish Medicines Formulary
IMSTA  Irish Medical and Surgical Trade Association
IPHA Irish Pharmaceutical Healthcare Association
IVD In-Vitro Diagnostics 
JIDA Journal of the Irish Dental Association 
MAH Marketing Authorisation Holder 
MEDDEV Medical Devices Guidance Document from the European Commission
MIMS Monthly Index of Medical Specialities 
MRA Mutual Recognition Agreement
MRLs Maximum Residue Limits 
MRP Mutual Recognition Procedure 
NBOG  Notified Body Operations Group 
NCA National Consumer Agency 
NHO National Haemovigilance Office
NODTO National Organ Donation and Transplantation Office 
NSAI National Standards Authority of Ireland 
OMCL Official Medicines Control Laboratories 
OTC  Over-the-Counter 
PCI Pharmachemical Ireland 
PDCO  Paediatric Committee 
PDP Performance Development Programme
PFIPC Permanent Forum on International Pharmaceutical Crime
PIC/S Pharmaceutical Inspection Co-operation Scheme 
PRAC Pharmacovigilance Risk Assessment Committee
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PSUR Periodic Safety Update Report
QWP Quality Working Party 
RMP Risk Management Plan 
RMS  Reference Member State 
SoHOV&S Substances of Human Origin Vigilance and Surveillance 
THMP Traditional Herbal Medicinal Product
UMC Uppsala Monitoring Centre 
VMD Veterinary Medicines Directorate 
WHO World Health Organization 
Our Mission
To protect and enhance public and animal health 
through the regulation of medicines, medical devices 
and healthcare products.
Our strategIc gOaLs and BaLanced scOrecard
STAKEHOLDERS 
Enhance healthcare product safety and patient outcomes by effective risk management 
and market surveillance.
Deliver clear, relevant and timely communications to patients, consumers and 
healthcare professionals.
PROCESSES 
Improve service delivery within a high quality, risk-based regulatory framework.
ORGANISATIONAL DEVELOPMENT 
Improve service delivery within a high quality, risk-based regulatory framework.
Influence legislation and policy development at European and international levels for 
the benefit of public and animal health.
HUMAN RESOURCES DEVELOPMENT 
Build future capabilities to meet evolving regulatory requirements, and scientific and 
technological advances.
FINANCIALS/VALUE FOR MONEY 
Build future capabilities to meet evolving regulatory requirements, and scientific and 
technological advances.
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